0001104659-19-001495.txt : 20190110 0001104659-19-001495.hdr.sgml : 20190110 20190110171431 ACCESSION NUMBER: 0001104659-19-001495 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20190104 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190110 DATE AS OF CHANGE: 20190110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Federal Street Acquisition Corp. CENTRAL INDEX KEY: 0001701821 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38153 FILM NUMBER: 19520901 BUSINESS ADDRESS: STREET 1: C/O THOMAS H LEE PARTNERS, L.P. STREET 2: 100 FEDERAL STREET, 35TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-227-1050 MAIL ADDRESS: STREET 1: C/O THOMAS H LEE PARTNERS, L.P. STREET 2: 100 FEDERAL STREET, 35TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 8-K 1 a19-2105_28k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 4, 2019

 


 

FEDERAL STREET ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

 


 

Delaware

 

001-38153

 

82-0908890

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

100 Federal Street, 35th Floor
 
Boston, Massachusetts 02110

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (617) 227-1050

 

Not Applicable

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

x          Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   o

 

 

 


 

Introductory Note

 

On January 4, 2019 (the “Closing Date”), Federal Street Acquisition Corp., a Delaware corporation (“FSAC”) consummated the previously announced business combination pursuant to that certain Amended and Restated Agreement and Plan of Merger, dated as of December 19, 2018 (“A&R Merger Agreement”),  by and among FSAC, Agiliti, Inc., a Delaware corporation ( “Agiliti”), Umpire SPAC Merger Sub, Inc., a Delaware corporation, Umpire Cash Merger Sub, Inc., a Delaware corporation, Agiliti Holdco, Inc. (previously known as UHS Holdco, Inc.), a Delaware corporation (“Agiliti Holdco”), solely in their capacities as Majority Stockholders, IPC/UHS, L.P. (“IPC/UHS”) and IPC/UHS Co-Investment Partners, L.P., each a Delaware limited partnership, solely in its capacity as the Stockholders’ Representative, IPC/UHS, and solely for the purposes stated therein, Umpire Equity Merger Sub, Inc., a Delaware corporation. The A&R Merger Agreement amended and restated the Agreement and Plan of Merger dated as of August 13, 2018. Pursuant to the A&R Merger Agreement, (i) FSAC became a wholly owned subsidiary of Agiliti and the holders of Class A common stock, par value $0.0001 per share, of FSAC (the “FSAC Class A Common Stock”) (including FSAC Class A Common Stock issued pursuant to the Backstop Agreement (as defined below) and issued upon conversion of the Class F common stock, par value $0.0001 per share, of FSAC) received shares of common stock, par value $0.0001 per share, of Agiliti (the “Agiliti Common Stock”); and (ii) Agiliti Holdco, Inc. became a wholly owned subsidiary of FSAC and the equityholders of Agiliti Holdco, Inc. received cash and/or shares of Agiliti Common Stock and/or fully-vested options to purchase shares of Agiliti Common Stock as merger consideration (the transactions contemplated by the A&R Merger Agreement are referred to herein as the “Business Combination”).

 

On December 19, 2018, in connection with the entry into the A&R Merger Agreement, FSAC entered into the Amended and Restated Subscription Agreement (the “Backstop Agreement”) with THL Agiliti LLC (the “THL Stockholder”), pursuant to which THL Stockholder agreed to purchase a number of shares of FSAC common stock at a price of $8.50 per share necessary to cause the minimum cash condition under the A&R Merger Agreement to be satisfied, subject to a cap of $750 million. On the Closing Date, pursuant to the Backstop Agreement, THL Stockholder purchased 86,795,398 shares of FSAC Class A Common Stock for an aggregate of $737.8 million, which shares were exchanged for shares of Agiliti Common Stock on a one-for-one basis at the closing of the Business Combination.

 

Item 1.01. Entry into a Material Definitive Agreement.

 

2018 Omnibus Incentive Plan

 

On the Closing Date, the Agiliti, Inc. 2018 Omnibus Incentive Plan (the “2018 Omnibus Incentive Plan”) became effective. The 2018 Omnibus Incentive Plan was approved by FSAC’s stockholders at the special meeting held on January 3, 2019 to approve the Business Combination (the “Special Meeting”). The purpose of the 2018 Omnibus Incentive Plan is to provide incentives that will attract, retain and motivate high performing officers, directors, employees and consultants of Agiliti. The 2018 Omnibus Incentive Plan provides for grants of stock options, stock appreciation rights, restricted stock, restricted stock units, bonus stock, dividend equivalents and other stock-based awards and other substitute awards, annual incentive awards and performance awards. Directors, officers and other employees of Agiliti and its subsidiaries, as well as others performing consulting or advisory services for Agiliti and its affiliates, will be eligible for grants under the 2018 Omnibus Incentive Plan. Agiliti has reserved a total of 10,356,000 shares of Agiliti Common Stock for issuance pursuant to the 2018 Omnibus Incentive Plan, subject to certain adjustments set forth therein.

 

The foregoing description of the 2018 Omnibus Incentive Plan does not purport to be complete and is qualified in its entirety by the terms and conditions of the 2018 Omnibus Incentive Plan, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

 

On the Closing Date, Agiliti entered into an advisory services agreement (the “Advisory Services Agreement”) with Agiliti Holdco, Agiliti Health and THL Managers VIII, LLC (the “Advisor”). Pursuant to the Advisory Services Agreement, the Advisor will provide management, consulting and other advisory services to the companies. In consideration for these services, the companies will pay to the Advisor (i) a non-refundable periodic retainer fee in an aggregate amount per fiscal quarter equal to the greater of (a) $375,000 or (b) 1% of the consolidated Adjusted EBITDA (as defined in the Advisory Services Agreement) for the immediately preceding fiscal quarter or such other amount as may be mutually agreed, with the first such payment to be made on April 15, 2019, (ii) fees in amounts to be mutually agreed in connection with any financing or refinancing, dividend, recapitalization, acquisition, disposition and spin-off or split-off transaction, (iii) in the case of an initial public offering (“IPO”), in addition to the fees under clauses (i) and (ii), an amount equal to the net present value of the higher periodic fee that would have been payable from the date of such IPO until the scheduled termination date of the Advisory Services Agreement, and (iv) fees for other management, consulting and other advisory services to be discussed in good faith among the parties. The companies will also pay expenses incurred by the Advisor, its consultants and certain other parties affiliated with Advisor.

 

The initial term of the Advisory Agreement ends on January 4, 2027, and is automatically extended for successive periods of one (1) year. The Advisory Services Agreement may be terminated by the Advisor at any time and by Agiliti on or prior to March 31, 2019 if the execution and delivery of the Advisory Services Agreement is not ratified by Agiliti at a meeting of its board of directors or a committee thereof prior to such date. The Advisory Services Agreement also terminates automatically immediately prior to an IPO or a transaction involving a change of control (as defined in the Advisory Services Agreement).

 

The foregoing description of the Advisory Services Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Advisory Services Agreement, which is attached hereto as Exhibit 10.13 and is incorporated herein by reference.

 

Assignment and Assumption Agreement

 

On the Closing Date, Agiliti, FSAC and Continental Stock Transfer & Trust Company (the “Warrant Agent”) entered into an Assignment and Assumption Agreement (the “Assignment and Assumption Agreement”) pursuant to which Agiliti agreed to accept and assume all of FSAC’s rights, interests and obligations in and under the warrants to purchase FSAC Class A Common Stock and under that certain Warrant Agreement, by and between

 

2


 

FSAC and the Warrant Agent, dated as of July 18, 2017. Following the Business Combination and the entry into the Assignment and Assumption Agreement, each FSAC warrant became exercisable for one share of Agiliti Common Stock in accordance with the terms of the agreement governing such warrants, and are referred to herein as the “Agiliti Warrants.”

 

The foregoing description of the Assignment and Assumption Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Assignment and Assumption Agreement, which is attached hereto as Exhibit 4.4 and is incorporated herein by reference.

 

Amendment to Investment Management Trust Agreement

 

In connection with the closing of the Business Combination, FSAC and Continental Stock Transfer & Trust Company entered into an amendment (the “IMTA Amendment”) to the Investment Management Trust Agreement, dated as of July 18, 2017. The IMTA Amendment allowed FSAC to pay revised deferred underwriting fees owned to the underwriters in FSAC’s initial public offering from funds outside of the trust account instead of from funds held therein to the extent there were insufficient funds existing in the trust account as of the closing of the Business Combination. In accordance with the IMTA Amendment, FSAC used funds from the trust account, together with other funds, to pay the revised deferred underwriting fees.

 

The foregoing description of the IMTA Amendment does not purport to be complete and is qualified in its entirety by the terms and conditions of the IMTA Amendment, which is attached hereto as Exhibit 10.12 and is incorporated herein by reference.

 

Item 1.02. Termination of a Material Definitive Agreement.

 

On the Closing Date, Agiliti, THL Stockholder, Thomas J. Leonard and certain other holders entered into a Registration Rights Agreement with respect to the Agiliti Common Stock and Agiliti Warrants held by such holders following the Business Combination. Upon effectiveness thereof, the Registration Rights Agreement, dated as of July 17, 2018 (the “FSAC RRA”), by and among FSAC and the holders party thereto was terminated. The FSAC RRA was entered into at the closing of FSAC’s initial public offering.

 

Item 2.01. Completion of Acquisition or Disposition of Assets.

 

The information set forth in the “Introductory Note” above is incorporated into this Item 2.01 by reference. On January 3, 2019, the Business Combination was approved by the stockholders of FSAC at the Special Meeting. The Business Combination was consummated on January 4, 2019.

 

Consideration to FSAC’s Stockholders and Warrant Holders in the Business Combination

 

In connection with the Business Combination, holders of 45,692,407 shares of FSAC Class A Common Stock exercised their right to redeem those shares for cash at a price of $10.16571689 per share, for an aggregate of approximately $464.5 million, which was paid to such holders on the Closing Date.

 

Upon completion of the Business Combination, the public stockholders of FSAC who did not exercise redemption rights received an aggregate of 307,593 shares of Agiliti Common Stock, with each public stockholder receiving one share of Agiliti Common Stock in exchange for each share of FSAC Class A Common Stock held on the Closing Date. In addition, each warrant to purchase FSAC Class A Common Stock issued and outstanding on the Closing Date became an Agiliti Warrant exercisable for shares of Agiliti Common Stock, and rights, interests and obligations in and under the FSAC warrants were assigned to and assumed by Agiliti.

 

In connection with the Business Combination, on January 4, 2019, FSAC issued 86,795,398 shares of FSAC Class A Common Stock to THL Stockholder immediately prior to the closing of the Business Combination pursuant to the Backstop Agreement. Such shares were exchanged on a one-for-one basis for shares of Agiliti Common Stock.

 

In addition, 11,500,000 shares of FSAC Class F common stock held by FS Sponsor, LLC and other former holders of Class F common stock of FSAC converted into shares of FSAC Class A Common Stock immediately

 

3


 

prior to the Business Combination and into shares of Agiliti Common Stock at the closing of the Business Combination.

 

Consideration Payable to Agiliti Holdco Equity Holders in the Business Combination

 

The consideration paid to holders of equity interests in Agiliti Holdco in connection with the Business Combination consisted of: (i) approximately $688.6 million in cash, subject to adjustment in accordance with the terms of the A&R Merger Agreement and (ii) 336,081 shares of Agiliti Common Stock, which were issued to Mr. Leonard. In addition, 25% of the outstanding options to purchase Agiliti Holdco common stock became exercisable in accordance with their terms for an aggregate of 2,975,618 shares of Agiliti Common Stock.

 

The material terms and conditions of the A&R Merger Agreement are described in the section entitled “Supplemental Information to Proposal No. 1 — Approval of the Business Combination” beginning on page 35 of Agiliti’s Supplement to the Definitive Proxy Statement/Prospectus (“Proxy Statement/Prospectus Supplement”) filed with the Securities and Exchange Commission (the “SEC”) on December 20, 2018 and in the section entitled “Proposal No. 1 — Approval of the Business Combination” beginning on page 81 of the Definitive Proxy Statement/Prospectus (“Proxy Statement/Prospectus”) filed with the SEC on October 10, 2018, which are incorporated herein by reference.

 

Agiliti Securities Outstanding Following the Business Combination

 

Immediately after the Business Combination, there were 98,939,072 shares of Agiliti Common Stock, Agiliti Warrants to purchase 37,950,000 shares of Agiliti Common Stock and options to purchase 2,975,618 shares of Agiliti Common Stock issued and outstanding. Upon the closing, FSAC’s common stock, warrants and units ceased trading on the NASDAQ stock exchange. Following the Business Combination, the Agiliti Common Stock and Agiliti Warrants will not trade on a national stock exchange due to the level of redemptions by FSAC stockholders.  Agiliti is evaluating working with market makers to obtain quotation of the Agiliti Warrants on the over-the-counter market.  However, there can be no assurances regarding if or when the Agiliti Warrants will be quoted.

 

FORM 10 INFORMATION

 

Forward-Looking Statements

 

Some of the information contained in this Current Report on Form 8-K, or incorporated herein by reference, contains forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When contained in this Current Report on Form 8-K, and incorporated herein by reference, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Agiliti’s management’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. These forward-looking statements are based on information available as of the date of this Current Report on Form 8-K, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and Agiliti does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

 

As a result of a number of known and unknown risks and uncertainties, Agiliti’s actual results or performance may be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to:

 

·                  Agiliti’s history of net losses;

 

·                  the need for substantial cash to operate and expand Agiliti’s business as planned;

 

·                  Agiliti’s expected substantial outstanding debt following the Business Combination;

 

·                  a decrease in the number of patients Agiliti’s customers serve;

 

4


 

·                  Agiliti’s inability to effect change in the manner in which healthcare providers traditionally procure medical equipment;

 

·                  the absence of long-term commitments with customers;

 

·                  Agiliti’s inability to renew contracts with group purchasing organizations and integrated delivery networks;

 

·                  changes in reimbursement rates and policies by third-party payors;

 

·                  the impact of healthcare reform initiatives;

 

·                  the impact of significant regulation of the healthcare industry and the need to comply with those regulations;

 

·                  the effect of prolonged negative changes in domestic and global economic conditions;

 

·                  difficulties or delays in Agiliti’s continued expansion into certain of Agiliti’s businesses/geographic markets and developments of new businesses/geographic markets;

 

·                  additional credit risks in increasing business with home care providers and nursing homes, impacts of equipment product recalls or obsolescence; and

 

·                  increases in vendor costs that cannot be passed through to Agiliti’s customers; and

 

·                  other risks and uncertainties indicated in this proxy statement/prospectus, including those set forth under the section entitled “Risk Factors.”

 

Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results may vary in material respects from those expressed or implied by these forward-looking statements. You should not place undue reliance on these forward-looking statements.

 

Business

 

The information set forth in the section entitled “Information about UHS” beginning on page 165 of the Proxy Statement/Prospectus is incorporated herein by reference.

 

Risk Factors

 

The Agiliti Common Stock and the Agiliti Warrants are not listed on a national securities exchange.

 

Due to the level of redemptions by FSAC stockholders, Agiliti was unable to comply with the NASDAQ listing requirements relating to the number of round lot holders, and therefore, following the Business Combination, the Agiliti Common Stock and the Agiliti Warrants are not listed on a national securities exchange. Because of the lack of listing, Agiliti and its stockholders and warrant holders could face significant material adverse consequences including:

 

·      a limited availability of market quotations for Agiliti’s securities;

·      reduced liquidity for Agiliti’s securities;

·      a determination that Agiliti common stock is a “penny stock,” which will require brokers trading in Agiliti common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for Agiliti’s securities;

·      a limited amount of news and analyst coverage; and

·      a decreased ability to issue additional securities or obtain additional financing in the future.

 

Agiliti is not subject to compliance with rules requiring the adoption of certain corporate governance measures and as a result Agiliti’s stockholders have limited protections against interested director transactions, conflicts of interest and similar matters.

 

The listing rules of the New York Stock Exchange and the NASDAQ Stock Market require the implementation of various measures relating to corporate governance. These measures are designed to enhance the integrity of corporate management and the securities markets and apply to securities which are listed on those exchanges. Because Agiliti is not listed on the NASDAQ Stock Market or the New York Stock Exchange, Agiliti is not presently required to comply with many of the corporate governance provisions and has not adopted some of these measures. The absence of such standards of corporate governance may leave Agiliti’s stockholders and warrantholders without protections against interested director transactions, conflicts of interest and similar matters.

 

The information set forth in the section entitled “Risk Factors” beginning on page 36 of the Proxy Statement/Prospectus and the section entitled “Update to Risk Factors” beginning on page 31 of the Proxy Statement/Prospectus Supplement is incorporated herein by reference.

 

Selected Consolidated Historical Financial and Other Information

 

The following table sets forth selected consolidated historical financial information derived from Agiliti Health’s (i) unaudited financial statements included in Agiliti Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 as of September 30, 2018 and for the nine month periods ended September 30, 2018 and September 30, 2017 and (ii) audited financial statements as of and for the years ended December 31, 2017, 2016, 2015, 2014 and 2013. The historical consolidated financial information of Agiliti Health as of September 30, 2017 was derived from unaudited financial statements included in Agiliti Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017. The selected consolidated historical financial statements of Agiliti Health, a wholly-owned subsidiary of Agiliti Holdco, and its subsidiaries are included below, as opposed to those of Agiliti. Agiliti is a holding company without any operations or employees, and no liabilities or material assets beyond its investment in Agiliti Holdco, the direct parent entity of Agiliti Health. Further, prior to the Closing Date, Agiliti had no material operations, assets, or liabilities.

 

The following summary financial information should be read in conjunction with the sections entitled “UHS’s Management’s Discussion and Analysis of Financial Condition and Results of Operations” beginning on page 205 of the Proxy Statement/Prospectus, “Appendix D: Management’s Discussion and Analysis of Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) and Subsidiaries for the Three and Nine Months Ended September 30, 2018 and September 30, 2017” beginning on page D-1 of the Proxy Statement/Prospectus

 

5


 

Supplement and the financial statements of Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) and Subsidiaries included in the Proxy Statement/Prospectus beginning on page F-31 and in Appendix C in the Proxy Statement/Prospectus Supplement beginning on page C-1.

 

 

 

Nine Months Ended
September 30,

 

Year Ended December 31,

 

(in thousands)

 

2018

 

2017

 

2017

 

2016

 

2015

 

2014

 

2013

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

Consolidated Statements of Operations Data:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$

421,175

 

$

382,633

 

$

514,783

 

$

479,501

 

$

448,681

 

$

436,664

 

$

428,440

 

Cost of revenue

 

273,322

 

255,497

 

343,028

 

322,649

 

303,889

 

309,903

 

301,202

 

Gross margin

 

147,853

 

127,136

 

171,755

 

156,852

 

144,792

 

126,761

 

127,238

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative(1)

 

102,138

 

93,172

 

125,910

 

119,389

 

121,583

 

114,194

 

111,857

 

Restructuring

 

 

 

 

 

2,321

 

3,059

 

236

 

(Gain) on settlement

 

(26,291

)

 

 

(3,074

)

(5,718

)

 

 

Intangible asset impairment charge

 

 

 

 

 

 

34,900

 

 

Total operating expenses

 

75,847

 

93,172

 

125,910

 

116,315

 

118,186

 

152,153

 

112,093

 

Operating income

 

72,006

 

33,964

 

45,845

 

40,537

 

26,606

 

(25,392

)

15,145

 

Loss on extinguishment of debt

 

 

 

 

 

 

 

1,853

 

Interest expense(1)

 

40,128

 

40,366

 

53,762

 

53,043

 

54,066

 

53,687

 

55,807

 

Income (loss) before income taxes and noncontrolling interest

 

31,878

 

(6,402

)

(7,917

)

(12,506

)

(27,460

)

(79,079

)

(42,515

)

(Benefit) provision for income taxes

 

767

 

888

 

(17,159

)

946

 

756

 

(13,065

)

(166

)

Net income attributable to noncontrolling interest

 

241

 

295

 

414

 

308

 

432

 

503

 

688

 

Net income (loss) attributable to Agiliti Health and subsidiaries

 

$

30,870

 

$

(7,585

)

$

8,828

 

$

(13,760

)

$

(28,648

)

$

(66,517

)

$

(43,037

)

Other Financial Data:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash provided by operating activities

 

$

54,836

 

$

33,734

 

$

70,619

 

$

54,722

 

$

72,284

 

$

60,572

 

$

57,574

 

Net cash used in investing activities

 

(37,352

)

(38,974

)

(55,124

)

(69,654

)

(52,606

)

(55,464

)

(56,433

)

Net cash (used in) provided by financing activities

 

(17,484

)

5,240

 

(15,495

)

14,932

 

(19,678

)

(5,108

)

(1,141

)

Other Operating Data (as of period end) (unaudited):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Medical equipment (approximate number of owned outsourcing units)

 

249,000

 

242,000

 

235,000

 

242,000

 

246,000

 

254,000

 

269,000

 

District service centers

 

86

 

86

 

87

 

88

 

88

 

88

 

89

 

Centers of excellence

 

5

 

5

 

5

 

5

 

5

 

5

 

6

 

Depreciation and amortization of intangibles

 

$

58,715

 

$

60,497

 

$

80,244

 

$

84,266

 

$

91,901

 

$

100,088

 

$

98,796

 

Consolidated Balance Sheet:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Working capital(2)

 

$

27,677

 

$

35,835

 

$

6,245

 

$

1,650

 

$

(8,855

)

$

782

 

$

(87

)

Total assets(3)(4)

 

826,138

 

794,833

 

805,445

 

818,123

 

797,575

 

821,038

 

899,738

 

Total debt(4)

 

697,417

 

724,887

 

703,108

 

707,317

 

687,458

 

698,585

 

696,735

 

(Deficit) equity

 

(5,260

)

(62,146

)

(44,378

)

(59,485

)

(49,158

)

(48,747

)

23,020

 

 


(1)         Agiliti Health adopted ASU No. 2017-07 Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost in 2018 and retrospectively applied ASU 2017-07 to all periods presented.

 

(2)         Represents total current assets (excluding cash and cash equivalents) less total current liabilities (excluding current portion of long-term debt).

 

(3)         Agiliti Health adopted ASU No. 2015-17 Balance Sheet Classification of Deferred Taxes in 2015 and retrospectively applying the ASU 2015-17 to all periods presented.

 

(4)         Agiliti Health adopted ASU No. 2015-03 Simplifying the Presentation of Debt Issuance Costs in 2016 and retrospectively applying the ASU 2015-03 to all periods presented.

 

Unaudited Pro Forma Condensed Combined Financial Information

 

The information set forth in Exhibit 99.1 to this Current Report on Form 8-K, which includes the unaudited pro forma condensed combined financial information of Agiliti is incorporated herein by reference.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations and Quantitative and Qualitative Disclosures About Market Risk

 

The information set forth in the section entitled “UHS’s Management’s Discussion and Analysis of Financial Condition and Results of Operations” beginning on page 205 of the Proxy Statement/Prospectus and in the section entitled “Appendix D: Management’s Discussion and Analysis of Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) and Subsidiaries for the Three and Nine Months Ended September 30, 2018 and September

 

6


 

30, 2017” beginning on page D-1 of the Proxy Statement/Prospectus Supplement is incorporated herein by reference.

 

Properties

 

The information set forth in the section entitled “Information about UHS — Properties” on page 177 of the Proxy Statement/Prospectus is incorporated herein by reference.

 

Security Ownership of Certain Beneficial Owners and Management

 

Following the Business Combination, FSAC is a wholly-owned subsidiary of Agiliti.

 

The following table sets forth information as of the Closing Date regarding the beneficial ownership of the Agiliti Common Stock by:

 

·                  each person known to be the beneficial owner of more than 5% of Agiliti’s outstanding ordinary shares;

·                  each director and each of Agiliti’s named executive officers; and

·                  all current executive officers and directors as a group.

 

The information below is based on an aggregate of 98,939,072 shares of Agiliti Common Stock issued and outstanding as of the Closing Date. Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if she, he or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days.

 

Unless otherwise indicated, we believe that all persons named in the table below have sole voting and investment power with respect to all shares of common stock beneficially owned by the individuals below:

 

Name of Beneficial Owners(1)

 

Number of Shares
Beneficially
Owned

 

Approximate
Percentage of
Outstanding
Common Stock

 

5% Stockholders:

 

 

 

 

 

THL Agiliti LLC (2)

 

113,145,398

 

99.3

%

Executive Officers and Directors:

 

 

 

 

 

Scott M. Sperling (2)

 

113,145,398

 

99.3

%

Joshua M. Nelson (2)

 

113,145,398

 

99.3

%

Megan M. Preiner (2)

 

113,145,398

 

99.3

%

Michael A. Bell

 

25,000

 

*

 

Gary L. Gottlieb

 

25,000

 

*

 

Barry Schochett (3)

 

27,653

 

*

 

John L. Workman (3)

 

27,653

 

*

 

Thomas J. Leonard (4)

 

1,495,772

 

1.5

%

James B. Pekarek (3)

 

304,346

 

*

 

Kevin E. Ketzel (3)

 

345,448

 

*

 

Bettyann Bird (3)

 

167,316

 

*

 

Robert L. Creviston (3)

 

123,970

 

*

 

All directors and executive officers as a group (14 individuals)

 

115,813,274

 

99.7

%

 


*                                         Less than 1 percent.

 

(1)                                 Unless otherwise indicated, the business address of each of the entities, directors and executives in this table is c/o Agiliti Health, Inc., 6625 West 78th Street, Suite 300, Minneapolis, Minnesota 55439.

 

(2)                                 Includes 14,950,000 of Agiliti Warrants, which are exercisable for an equal number of shares of Agiliti Common Stock. Voting and investment determinations with respect to the Agiliti Common Stock held by

 

7


 

THL Stockholder are made by unanimous consent of its members. The members of THL Agiliti are FS Sponsor, LLC, Thomas H. Lee Equity Fund VIII, L.P., Thomas H. Lee Parallel Fund VIII, L.P., THL Executive Fund VIII, L.P., THL Fund VIII Coinvestment Partners, L.P., and THL Equity Fund VIII Investors (Agiliti), L.P. Voting and investment determinations with respect to the Agiliti Warrants held by THL Stockholder are made in the sole discretion of FS Sponsor, LLC. Voting and investment determinations with respect to the securities beneficially owned by FS Sponsor, LLC, including the Agiliti Warrants, are made by a management committee.  Each of the entities and individuals named above disclaims beneficial ownership of the securities of Agiliti held of record by THL Stockholder, except to the extent of his, her or its pecuniary interest therein. The address of the entities and individuals named above is c/o Thomas H. Lee Partners, L.P., 100 Federal Street, 35th Floor, Boston, MA 02110.

 

(3)                                 Represents shares of Agiliti Common Stock issuable upon the exercise of fully-vested options.

 

(4)                                 Includes 1,159,691 shares of Agiliti common Stock issuable upon the exercise of fully-vested options.

 

Directors and Executive Officers

 

Information with respect to FSAC’s directors and executive officers immediately after the closing of the Business Combination is set forth in Item 5.02 of this Current Report on Form 8-K and is incorporated herein by reference.

 

Information with respect to Agiliti’s directors and executive officers immediately after the closing is set forth in the section entitled “Management and Board of Directors After the Business Combination” beginning on page 55 in the Proxy Statement/Prospectus Supplement and is incorporated herein by reference.

 

On January 4, 2019, each of Messrs. Leonard, Bell, Gottlieb, Nelson, Schochet, Sperling and Workman and Ms. Preiner were appointed to serve as directors of the post-combination company effective immediately following the consummation of the Business Combination. Mr. Workman was appointed as Chairman of the board of directors. The size of the board is eight members. Biographical information for these individuals is set forth in the section entitled “Management and Board of Directors After the Business Combination” beginning on page 55 of the Proxy Statement/Prospectus Supplement and is incorporated herein by reference.

 

The Board appointed Messrs. Gottlieb, Schochet and Workman to serve on the Audit Committee, with Mr. Workman serving as its Chairman. The Board appointed Messrs. Workman, Bell and Nelson to serve on the Compensation Committee, with Mr. Bell serving as its Chairman. The Board appointed Messrs. Gotliebb, Sperling and Nelson and Ms. Preiner to serve on the Nominating and Governance Committee, with Mr. Nelson serving as its Chairman. Information with respect to Agiliti’s Audit Committee, Compensation Committee and Nominating and Governance Committee is set forth in the section entitled “Management and Board of Directors After the Business Combination — Committees of the Board of Directors” beginning on page 58 of the Proxy Statement/Prospectus Supplement and is incorporated herein by reference.

 

In accordance with the amended and restated certificate of incorporation of Agiliti, Agiliti’s board of directors is divided into three classes, each comprising as nearly as possible one-third of the directors and serving three-year terms with only one class of directors being elected in each year. Messrs. Schochet and Nelson were assigned to Class I, Messrs. Leonard and Gottlieb and Ms. Preiner were assigned to Class II, and Messrs. Workman, Bell and Sperling were assigned to Class III. Each Class I director will have a term that expires at Agiliti’s annual meeting of stockholders in 2019, each Class II director will have a term that expires at Agiliti’s annual meeting of stockholders in 2020 and each Class III director will have a term that expires at Agiliti’s annual meeting of stockholders in 2021, or in each case until their respective successors are duly elected and qualified, or until their earlier resignation, removal or death.

 

In connection with the consummation of the Business Combination, on January 4, 2019, Thomas J. Leonard was appointed to serve as Agiliti’s Chief Executive Officer, Mr. James B. Pekarek was appointed to serve as Executive Vice President and Chief Financial Officer, Mr. Kevin E. Ketzel was appointed to serve as President, Ms. Bettyann Bird was appointed to serve as Senior Vice President, Marketing, Mr. Robert L. Creviston was appointed to serve as Chief Human Resources Officer, Mr. Scott A. Christensen was appointed to serve as Vice

 

8


 

President, Controller and Chief Accounting Officer, and Ms. Lee Neumann was appointed to serve as Senior Vice President, General Counsel and Corporate Secretary. Biographical information for these individuals is set forth in the section entitled “Management and Board of Directors After the Business Combination” beginning on page 55 of the Proxy Statement/Prospectus Supplement and is incorporated by reference herein.

 

In connection with the closing, on January 4, 2019, immediately prior to the consummation of the Business Combination, Mr. Kent R. Weldon ceased to be a director of Agiliti and each executive officer of Agiliti immediately prior to the closing ceased to be an executive officer.

 

Executive Compensation

 

The information set forth in Exhibit 99.2 to this Current Report on Form 8-K which includes the executive compensation information of Agiliti is incorporated herein by reference.

 

Director Compensation

 

The board of directors of Agiliti has not approved a director compensation program to date.

 

Certain Relationships and Related Transactions

 

The information set forth in the sections entitled “Certain Relationships and Related Person Transactions Related Party Transactions Following the Business Combination” and “Proposal No. 1 Approval of the Business Combination The Tax Receivables Agreement” beginning on page 255 and page 96 of the Proxy Statement/Prospectus, respectively, are incorporated herein by reference. The information set forth in the sections entitled “Supplemental Information to Proposal No. 1 Approval of the Business Combination Description of the Director Nomination Agreement with THL Stockholder”, “Supplemental Information to Proposal No. 1 Approval of the Business Combination Description of the Tax Receivable Agreement” and “Supplemental Information to Proposal No. 1 Approval of the Business Combination Description of the Registration Rights Agreement” on pages 37 and 38 of the Proxy Statement/Prospectus are incorporated herein by reference.

 

Additionally, the information set forth in the sections entitled “Assignment and Assumption Agreement” and “Advisory Services Agreement” in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. The information set forth under “Introductory Note” in this Current Report on Form 8-K is incorporated herein by reference.

 

Director Independence

 

At the closing of the Business Combination, the board of directors of Agiliti adopted NASDAQ listing standards to assess director independence. All of Agiliti’s directors are independent pursuant to the NASDAQ listing rules, except Mr. Leonard, Agiliti’s Chief Executive Officer.

 

Legal Proceedings

 

The information set forth in the section entitled “Information about UHS — Legal Proceedings” on page 177 of the Proxy Statement/Prospectus is incorporated herein by reference.

 

Market Price of and Dividends on the Registrant’s Common Equity and Related Stockholder Matters

 

The information set forth in the section entitled “Price Range of Securities and Dividends—FSAC” on page 257 of the Proxy Statement/Prospectus is incorporated herein by reference.

 

Market Information and Holders of Agiliti

 

The Agiliti Common Stock and Agiliti Warrants will not be listed on a national stock exchange. Historically there has not been, and currently there is no established public market for the Agiliti Common Stock or the Agiliti Warrants. Agiliti has agreed to register an aggregate of 115,384,844 shares of Agiliti Common Stock, including Agiliti Common Stock underlying Agiliti Warrants and Options.

 

9


 

As of January 4, 2019, there were 2,975,618 outstanding options to purchase Agiliti Common Stock, 37,950,000 Agiliti Warrants and no securities convertible into Agiliti Common Stock. Agiliti has reserved a total of 10,356,000 shares of Agiliti Common Stock for issuance pursuant to the 2018 Omnibus Incentive Plan, subject to certain adjustments set forth therein.

 

As of January 4, 2019, following the consummation of the Business Combination, there were seven holders of Agiliti Common Stock and two holders of Agiliti Warrants.

 

Dividends of Agiliti

 

We have not paid any cash dividends on the Agiliti Common Stock. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of the Business Combination. The payment of any cash dividends subsequent to the Business Combination will be within the discretion of Agiliti’s board of directors. However, we do not anticipate paying any dividends on the Agiliti Common Stock for the foreseeable future.

 

Recent Sales of Unregistered Securities

 

In connection with the closing of the Business Combination, FSAC issued 86,795,398 shares of FSAC Class A Common Stock to THL Stockholder in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). These shares were converted into shares of Agiliti Common Stock on a one-for-one basis at the closing of the Business Combination.

 

Description of Registrant’s Securities

 

Following the Business Combination, FSAC is a wholly-owned subsidiary of Agiliti. Pursuant to FSAC’s amended and restated certificate of incorporation, there are 1,000 shares of common stock, par value $0.0001 per share authorized, all of which are outstanding and held by Agiliti following the Business Combination.

 

The information set forth in the section entitled “Description of Agiliti’s Securities” beginning on page 245 of the Proxy Statement/Prospectus is incorporated herein by reference.

 

Indemnification of Directors and Officers

 

The information set forth in “Part II — Indemnification of Directors and Officers” of the Proxy Statement/Prospectus and in the section entitled “Indemnification Agreements” in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

 

Financial Statements, Supplementary Data and Exhibits

 

The information set forth under Item 9.01 of this Current Report on Form 8-K is incorporated herein by reference. The financial statements of Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) and Subsidiaries included in the Proxy Statement/Prospectus beginning on page F-31 and in Appendix C in the Proxy Statement/Prospectus Supplement beginning on page C-1, are incorporated herein by reference.

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On the Closing Date, all of FSAC’s outstanding units separated into their component parts of one share of FSAC Class A Common Stock and one half of one warrant to purchase one share of FSAC Class A Common Stock and shares of FSAC Class A common stock, FSAC’s warrants and FSAC’s units ceased trading on the NASDAQ stock exchange.

 

10


 

Item 3.03 Material Modification to Rights of Security Holders

 

On the Closing Date, in connection with the consummation of the Business Combination, FSAC’s Certificate of Incorporation and Bylaws were amended and restated. Following the Business Combination, FSAC is a wholly-owned subsidiary of Agiliti. Pursuant to FSAC’s amended and restated certificate of incorporation, there are 1,000 shares of common stock, par value $0.0001 per share authorized, all of which are outstanding and held by Agiliti following the Business Combination.

 

The foregoing description of the Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws of FSAC does not purport to be complete and is qualified in its entirety by the terms of the Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, which are attached hereto as Exhibits 3.1 and 3.2, respectively, and are incorporated herein by reference.

 

The information in the section entitled “Assignment and Assumption Agreement” in Item 1.01 in this Current Report on Form 8-K is incorporated herein by reference.

 

Item 4.01. Change in Registrant’s Certifying Accountant.

 

On January 4, 2019, the board of directors of Agiliti approved the engagement of KPMG LLP (“KPMG”) as Agiliti’s independent registered public accounting firm to audit Agiliti’s consolidated financial statements for the year ending December 31, 2019.  KPMG served as the independent registered public accounting firm of Agiliti Health prior to the Business Combination.  Accordingly, Marcum LLP (“Marcum”), the  independent registered public accounting firm of FSAC prior to the Business Combination, was informed of its dismissal as the independent registered public accounting firm effective on January 4, 2019.

 

Marcum’s report on FSAC’s financial statements as of December 31, 2017 and the related statements of operations, changes in stockholders’ equity and cash flows for the year ended December 31, 2017, did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles.

 

During the period from March 21, 2017 to December 31, 2017, and the subsequent period through January 4, 2019, there were no: (i) disagreements with Marcum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements if not resolved to their satisfaction would have caused them to make reference to the subject matter of the disagreement in connection with its report or (ii) reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.

 

During the period from March 21, 2017 to December 31, 2017, and subsequent period through January 4, 2019, FSAC has not consulted with KPMG regarding the application of accounting principles to a specified transaction, either contemplated or proposed, or the type of audit opinion that might be rendered on the financial statements of FSAC.

 

A letter from Marcum is attached as Exhibit 16.1 to this Form 8-K.

 

Item 5.01. Changes in Control of Registrant.

 

The information set forth under “Introductory Note” and Item 2.01 in this Current Report on Form 8-K is incorporated herein by reference.

 

Following the Business Combination, FSAC is a wholly-owned subsidiary of Agiliti. Following the Business Combination, THL Stockholder holds approximately 99.2% of Agiliti Common Stock (excluding shares of common stock issuable upon exercise of warrants). The total consideration to acquire Agiliti Holdco was approximately $1.44 billion. Such aggregate consideration consisted of cash and/or shares of Agiliti Common Stock and/or fully-vested options to purchase shares of Agiliti Common Stock. The sources of funds for the Business Combination include $660 million from a seven year senior secured delayed draw term loan facility entered into on the Closing Date, approximately $34 million from a five year senior secured revolving credit facility in an aggregate principal amount of $150,000,000 entered into on the Closing Date, approximately $19.6 million of existing capital leases rollover, approximately $21.8 million of equity rollover by existing holders, $737.8 million from the THL Stockholder pursuant to the Backstop Agreement and approximately $4.5 million from FSAC’s trust account.

 

11


 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 4, 2019, Mr. Sperling ceased to be the Executive Chairman and Mr. Weldon ceased to be the Vice Chairman and director of FSAC. Additionally on January 4, 2019, Messrs. Michael A. Bell, Gary L. Gottlieb, Henry A. McKinnell and Paul M. Montrone ceased to be directors of FSAC and Messrs. Arthur G. McAleer and Charles P. Holden and Ms. Shari H. Wolkon ceased to be the President, Chief Financial Officer and General Counsel and Secretary of FSAC, respectively.

 

On January 4, 2019, the directors of Agiliti were appointed to serve in identical capacities of FSAC. Messrs. Leonard, Pekarek and McCabe and Ms. Neuman were appointed to serve as Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer, respectively.  Biographical information with respect to such directors and executive officers is set forth in the section entitled “Management and Board of Directors After the Business Combination” beginning on page 55 of the Proxy Statement/Prospectus Supplement and under “Directors and Executive Officers” in Item 2.01 of this Current Report on Form 8-K and is incorporated herein by reference.

 

The information set forth in the section entitled “Proposal No. 4 — The Incentive Plan Proposal” beginning on page 136 of the Proxy Statement/Prospectus in the section entitled “Supplemental Information to Proposal No. 4 — The Incentive Plan Proposal” on page 49 of the Proxy Statement/Prospectus Supplement and under “2018 Omnibus Incentive Plan” in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

 

On January 4, 2019, concurrently with the consummation of the Business Combination and in accordance with the terms of the A&R Merger Agreement, Agiliti assumed the 2007 Stock Option Plan and the 2018 Executive Management Stock Option Plan of Agiliti Holdco. These plans govern the options to purchase Agiliti Common Stock that were rolled over from Agiliti Holdco upon the closing of the Business Combination. Also on January 4, 2019, Agiliti assumed the Agiliti Health Executive Severance Plan. The information set forth in the section entitled “Information About UHS — Executive Compensation Discussion and Analysis — Potential Payments Under Our Executive Severance Pay Plan” on page 194 of the Proxy Statement/Prospectus and in Exhibit 99.2 to this Current Report on Form 8-K which includes the executive compensation information of Agiliti is incorporated herein by reference.

 

Item 5.06. Change in Shell Company Status.

 

As a result of the Business Combination, FSAC ceased being a shell company. The material terms of the Business Combination are described in the section entitled “Supplemental Information to Proposal No. 1 — Approval of the Business Combination” beginning on page 35 of the Proxy Statement/Prospectus Supplement, in the section entitled “Proposal No. 1 — Approval of the Business Combination” beginning on page 81 of the Proxy Statement/Prospectus, in the information set forth under “Introductory Note” and in the information set forth under Item 2.01 in this Current Report on Form 8-K, each of which is incorporated herein by reference.

 

Item 7.01. Regulation FD Disclosure

 

On January 4, 2019, FSAC issued a press release announcing the consummation of the Business Combination. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.3 and is incorporated herein by reference.

 

In accordance with General Instruction B.2 of Form 8-K, the information under this Item 7.01 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

12


 

Item 9.01. Financial Statement and Exhibits.

 

(a)                                 Financial statements of businesses acquired

 

The financial statements of Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) and Subsidiaries included in the Proxy Statement/Prospectus beginning on page F-31 and in Appendix C in the Proxy Statement/Prospectus Supplement beginning on page C-1, are incorporated herein by reference.

 

The financial statements of FSAC included in the Proxy Statement/Prospectus beginning on page F-1 and in FSAC’s Quarterly Report on Form 10-Q for the quarters ended September 30, 2018 and 2017 beginning on page 1, are incorporated herein by reference.

 

(b)                                 Pro Forma Financial Information

 

The information set forth in Exhibit 99.1 to this Current Report on Form 8-K, which includes the unaudited pro forma condensed combined financial information of Agiliti for the year ended December 31, 2017 and for and as of the nine months ended September 30, 2018, is incorporated herein by reference.

 

(d)                       Exhibits.

 

Exhibit No.

 

Document

 

 

 

2.1(a)

 

Agreement and Plan of Merger, dated as of August 13, 2018, by and among Federal Street Acquisition Corp., Agiliti, Inc., Umpire SPAC Merger Sub, Inc., Umpire Equity Merger Sub, Inc., Umpire Cash Merger Sub, Inc., UHS Holdco, Inc., solely in its capacity as a Majority Stockholder, IPC/UHS Co-Investment Partners, L.P. and solely in its capacity as a Majority Stockholder and the Stockholders’ Representative, IPC/UHS, L.P. (incorporated by reference to Exhibit 2.1 to FSAC’s Current Report on Form 8-K/A filed August 14, 2018)

 

 

 

2.2(a)

 

Amended and Restated Merger Agreement, by and among Federal Street Acquisition Corp., Agiliti, Inc., Umpire SPAC Merger Sub, Inc., Umpire Equity Merger Sub, Inc., Umpire Cash Merger Sub, Inc., Agiliti Holdco, Inc., solely in their capacities as Majority Stockholders, IPC/UHS, L.P. and IPC/UHS Co Investment Partners, L.P., and solely in its capacity as the Stockholders’ Representative, IPC/UHS, L.P., and, solely for the purposes stated therein, Umpire Equity Merger Sub, Inc. (incorporated by reference to Exhibit 2.2(a) to FSAC’s Current Report on Form 8-K filed December 19, 2018)

 

 

 

3.1

 

Amended and Restated Certificate of Incorporation of Federal Street Acquisition Corp.

 

 

 

3.2

 

Amended and Restated Bylaws of Federal Street Acquisition Corp.

 

 

 

4.1

 

Specimen Warrant Certificate of Federal Street Acquisition Corp. (incorporated by reference to Exhibit 4.3 to FSAC’s Registration Statement on Form S-1 filed June 21, 2017).

 

 

 

4.2

 

Warrant Agreement, dated July 18, 2017, between Federal Street Acquisition Corp. and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 of FSAC’s Current Report on Form 8-K filed July 24, 2017).

 

 

 

4.3

 

Assignment and Assumption Agreement, dated as of January 4, 2019, between Continental Stock Transfer & Trust Company, Agiliti, Inc. and Federal Street Acquisition Corp.

 

13


 

10.1†

 

Agiliti Inc.’s 2018 Omnibus Incentive Plan.

 

 

 

10.2†

 

Form of Director and Officer Indemnification Agreement, by and between Agiliti, Inc. and its directors and executive officers.

 

 

 

10.3†

 

Agiliti Holdco, Inc. (f/k/a UHS Holdco, Inc.) Amended and Restated 2007 Stock Option Plan, dated as of November 4, 2014 (incorporated by reference to Exhibit 10.2 to Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) Quarterly Report on Form 10-Q filed November 6, 2014).

 

 

 

10.4†

 

Form of notice to option holders regarding amendments to outstanding options (incorporated by reference to Exhibit 10.3 to Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) Quarterly Report on Form 10-Q filed on November 6, 2014).

 

 

 

10.5†

 

Form of Option Agreement Evidencing a Grant of an Option Under the 2007 Stock Option Plan, dated as of May 8, 2015, between Agiliti Health, Inc. (f/k/a Universal Health Services, Inc.) and Thomas Leonard (incorporated by reference to Exhibit 10.3 to Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) Quarterly Report on Form 10-Q filed on May 13, 2015).

 

 

 

10.6†

 

Amendment One to Option Agreement, dated March 14, 2016, between UHS Holdco and Thomas Leonard (incorporated by reference to Exhibit 10.25 to Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) Form 10-K filed on March 15, 2016).

 

 

 

10.7†

 

Agiliti Holdco, Inc. (f/k/a UHS Holdco, Inc.) 2018 Executive Management Stock Option Plan (incorporated by reference to Exhibit 10.1 to Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) Form 10-Q filed on May 14, 2018).

 

 

 

10.8†

 

Form of Agiliti Holdco, Inc. (f/k/a UHS Holdco, Inc.) Executive Management Stock Option Agreement (incorporated by reference to Exhibit 10.2 to Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) Form 10-Q filed on May 14, 2018).

 

 

 

10.9†

 

Amendment No. 1 to Agiliti Holdco, Inc. (f/k/a UHS Holdco, Inc.) Executive Management Stock Option Plan dated August 9, 2018 (incorporated by reference to Exhibit 10.2 to Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) Form 10-Q filed on August 13, 2018).

 

 

 

10.10†

 

Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) Executive Severance Pay Plan, dated November 2, 2016 (incorporated by reference to Exhibit 10.1 to Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.) Quarterly Report on Form 10-Q filed on November 7, 2016).

 

 

 

10.11

 

Amended and Restated Subscription Agreement, dated December 19, 2018, by and between THL Agiliti LLC and Federal Street Acquisition Corp. (incorporated by reference to Exhibit 10.1 to FSAC’s Current Report on Form 8-K filed December 19, 2018).

 

 

 

10.12

 

Amendment to Investment Management Trust Agreement, dated as of July 18, 2017, between Federal Street Acquisition Corp. and Continental Stock Transfer & Trust Company

 

 

 

10.13

 

Advisory Services Agreement, dated as of January 4, 2019, by and among Agiliti, Inc., Agiliti Holdco, Inc., Agiliti Health, Inc. and THL Managers VIII, LLC.

 

14


 

16.1

 

Letter from Marcum LLP to the Securities and Exchange Commission dated January 10, 2019.

 

 

 

99.1

 

Unaudited pro forma condensed combined financial information of Agiliti, Inc. for the year ended December 31, 2017 and for and as of the nine months ended September 30, 2018.

 

 

 

99.2

 

Executive Compensation of Agiliti, Inc.

 

 

 

99.3

 

Press Release dated January 4, 2019.

 


(a)                 Certain schedules and exhibits to this Exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.

 

                         Indicates a management contract or compensatory plan.

 

15


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: January 10, 2019

 

 

FEDERAL STREET ACQUISITION CORP.

 

 

 

By:

/s/ James Pekarek

 

Name:

James Pekarek

 

Title:

Chief Financial Officer

 

16


EX-3.1 2 a19-2105_2ex3d1.htm EX-3.1

Exhibit 3.1

 

SECOND AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
FEDERAL STREET ACQUISITION CORP.

 

January 4, 2019

 

Federal Street Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS:

 

1.             The name of the Corporation is “Federal Street Acquisition Corp.” The original certificate of incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on March 21, 2017 (the “Original Certificate”).  The Original Certificate was amended and restated in its entirety on July 18, 2017 (the “Restated Certificate”).

 

2.             This Second Amended and Restated Certificate of Incorporation (the “Second Amended and Restated Certificate”), which both restates and amends the provisions of the Restated Certificate, was duly adopted in accordance with Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware, as amended from time to time.

 

3.             The text of the Original Certificate is hereby restated and amended in its entirety to read as follows:

 

ARTICLE ONE

 

The name of the corporation is Federal Street Acquisition Corp. (hereinafter called the “Corporation”).

 

ARTICLE TWO

 

The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, Wilmington, County of New Castle, State of Delaware, 19808, and the name of the Corporation’s registered agent at such address is Corporation Service Company.

 

ARTICLE THREE

 

The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.

 

ARTICLE FOUR

 

The total number of shares of stock which the Corporation has authority to issue is 1,000 shares of common stock, with a par value of $0.0001 per share.

 

ARTICLE FIVE

 

The Corporation is to have perpetual existence.

 


 

ARTICLE SIX

 

In furtherance and not in limitation of the powers conferred by statute, the board of directors of the Corporation is expressly authorized to make, alter or repeal the by-laws of the Corporation.

 

ARTICLE SEVEN

 

Meetings of stockholders may be held within or without the State of Delaware, as the by-laws of the Corporation may provide.  The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the board of directors or in the by-laws of the Corporation.  Election of directors need not be by written ballot unless the by-laws of the Corporation so provide.

 

ARTICLE EIGHT

 

To the fullest extent permitted by the General Corporation Law of the State of Delaware as the same exists or may hereafter be amended, a director of this Corporation shall not be liable to the Corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director.  Any repeal or modification of this ARTICLE EIGHT shall not adversely affect any right or protection of a director of the Corporation existing at the time of such repeal or modification.

 

ARTICLE NINE

 

The Corporation expressly elects not to be governed by Section 203 of the General Corporation Law of the State of Delaware.

 

ARTICLE TEN

 

The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Second Amended and Restated Certificate in the manner now or hereafter prescribed herein and by the laws of the State of Delaware, and all rights conferred upon stockholders herein are granted subject to this reservation.

 

ARTICLE ELEVEN

 

To the maximum extent permitted from time to time under the law of the State of Delaware, the Corporation renounces any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, business opportunities that are from time to time presented to its officers, directors or stockholders, other than those officers, directors or stockholders who are employees of the Corporation.  No amendment or repeal of this ARTICLE ELEVEN shall apply to or have any effect on the liability or alleged liability of any officer, director or stockholder of the Corporation for or with respect to any opportunities of which such officer, director, or stockholder becomes aware prior to such amendment or repeal.

 

*     *     *     *     *

 

2


 

IN WITNESS WHEREOF, Federal Street Acquisition Corp. has caused this Second Amended and Restated Certificate to be duly executed and acknowledged in its name and on its behalf by an authorized officer as of the date first set forth above.

 

 

FEDERAL STREET ACQUISITION CORP.

 

 

 

 

 

 

By:

/s/ Thomas J. Leonard

 

Name:

Thomas J. Leonard

 

Title:

Chief Executive Officer

 


EX-3.2 3 a19-2105_2ex3d2.htm EX-3.2

Exhibit 3.2

 

AMENDED AND RESTATED

 

BYLAWS
OF
FEDERAL STREET ACQUISITION CORP.
A Delaware Corporation

 

(Adopted as of January 4, 2019)

 

ARTICLE I.

 

OFFICES

 

Section 1.      Registered Office.  The registered office of the corporation within the State of Delaware shall be located at either (a) the principal place of business of the corporation in the State of Delaware or (b) the office of the corporation or individual acting as the corporation’s registered agent in Delaware.

 

Section 2.      The name of the corporation’s registered agent at such address shall be Corporation Service Company.  The registered office and/or registered agent of the corporation may be changed from time to time by action of the board of directors.

 

Section 3.      Other Offices.  The corporation may also have offices at such other places, both within and without the State of Delaware, as the board of directors may from time to time determine or the business of the corporation may require.

 

ARTICLE II.

 

MEETINGS OF STOCKHOLDERS

 

Section 1.      Annual Meetings.  An annual meeting of the stockholders shall be held each year within one hundred twenty (120) days after the close of the immediately preceding fiscal year of the corporation for the purpose of electing directors and conducting such other proper business as may come before the meeting.  The date, time and place, if any, and/or the means of remote communication, if any, of the annual meeting shall be determined by the board of directors of the corporation.  No annual meeting of stockholders need be held if not required by the corporation’s certificate of incorporation or by the General Corporation Law of the State of Delaware.

 

Section 2.      Special Meetings.  Special meetings of stockholders may be called for any purpose (including, without limitation, the filling of board vacancies and newly created directorships) and may be held at such time and place, within or without the State of Delaware, and/or by means of remote communication, as shall be stated in a written notice of meeting or in a duly executed waiver of notice thereof.  Such meetings may be called at any time by a majority of the members of the board of directors and shall be called by the president upon the written request of holders of shares entitled to cast not less than fifty percent (50%) of the votes at the meeting, which written request shall state the purpose or purposes of the meeting and shall be delivered to the president.  The date, time and place, if any, and/or the means of remote

 


 

communication, if any, of any special meeting of stockholders shall be determined by the board of directors of the corporation.

 

Section 3.      Place of Meetings.  The board of directors may designate any place, either within or without the State of Delaware, as the place of meeting for any annual meeting or for any special meeting called by the board of directors and may also designate any means of remote communication with respect to such meeting.  If no designation is made, or if a special meeting be otherwise called, the place of meeting shall be the principal executive office of the corporation.

 

Section 4.      Notice.  Whenever stockholders are required or permitted to take any action at a meeting, written or printed notice stating the place, if any, date and hour of the meeting, the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of special meetings, the purpose or purposes, of such meeting, shall be given to each stockholder entitled to vote at such meeting not less than ten (10) nor more than sixty (60) days before the date of the meeting.  All such notices shall be delivered, either personally, by mail, or by a form of electronic transmission consented to by the stockholder to whom the notice is given, by or at the direction of the board of directors, the president or the secretary, and if mailed, such notice shall be deemed to be delivered when deposited in the United States mail, postage prepaid, addressed to the stockholder at his, her or its address as the same appears on the records of the corporation.  If given by electronic transmission, such notice shall be deemed to be delivered (a) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice; (b) if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice; (c) if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of (1) such posting, and (2) the giving of such separate notice, and (d) if by any other form of electronic transmission, when directed to the stockholder.  Any such consent to a method of delivery of notice shall be revocable by the stockholder by written notice to the corporation.  Any such consent to a method of delivery of notice shall be deemed revoked if (x) the corporation is unable to deliver by electronic transmission two (2) consecutive notices given by the corporation in accordance with such consent and (y) such inability becomes known to the secretary or an assistant secretary of the corporation or to the transfer agent.  Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened.

 

Section 5.      Stockholders List.  The officer who has charge of the stock ledger of the corporation shall make, at least ten (10) days before every meeting of the stockholders, a complete list of the stockholders entitled to vote at such meeting arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder.  Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, for a period of at least ten (10) days prior to the meeting: (1) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, and/or (2) during ordinary business hours, at the principal place of business of the corporation.  In the event that the corporation determines to make the list available on an electronic network, the corporation may take reasonable steps to

 

2


 

ensure that such information is available only to stockholders of the corporation.  If the meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the entire time the meeting is in progress, and may be inspected by any stockholder who is present.  If the meeting is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder on a reasonably accessible electronic network during the entire time the meeting is in progress, and the information required to access such list shall be provided with the notice of the meeting.

 

Section 6.      Quorum.  The holders of a majority of the votes represented by the issued and outstanding shares of capital stock entitled to vote, present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders, except as otherwise provided by statute or by the corporation’s certificate of incorporation.  If a quorum is not present, the holders of a majority of the shares present in person or represented by proxy at the meeting, and entitled to vote at the meeting, may adjourn the meeting to another time and/or place, if any.  When a specified item of business requires a vote by a class or series (if the corporation shall then have outstanding shares of more than one class or series) voting as a class, the holders of a majority of the shares of such class or series shall constitute a quorum (as to such class or series) for the transaction of such item of business.

 

Section 7.      Adjourned Meetings.  When a meeting is adjourned to another time and place, if any, notice need not be given of the adjourned meeting if the time and place, if any, thereof and the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken.  At the adjourned meeting, the corporation may transact any business which might have been transacted at the original meeting.  If the adjournment is for more than thirty (30) days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.

 

Section 8.      Vote Required.  When a quorum is present, the affirmative vote of the majority of votes represented by shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the stockholders, unless the question is one upon which by express provisions of an applicable law or of the corporation’s certificate of incorporation a different vote is required, in which case such express provision shall govern and control the decision of such question.  Where a separate vote by class is required, the affirmative vote of the majority of shares of such class present in person or represented by proxy at the meeting shall be the act of such class.

 

Section 9.      Voting Rights.  Except as otherwise provided by the General Corporation Law of the State of Delaware or by the corporation’s certificate of incorporation or any amendments thereto and subject to Section 3 of Article VI hereof, every stockholder shall at every meeting of the stockholders be entitled to one (1) vote in person or by proxy for each share of common stock held by such stockholder.

 

Section 10.    Proxies.  Each stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to corporate action in writing without a meeting may authorize another person or persons to act for such stockholder by proxy, but no such proxy shall be voted or acted

 

3


 

upon after three (3) years from its date, unless the proxy provides for a longer period.  A duly executed proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power.  A proxy may be made irrevocable regardless of whether the interest with which it is coupled is an interest in the stock itself or an interest in the corporation generally.  Any proxy is suspended when the person executing the proxy is present at a meeting of stockholders and elects to vote, except that when such proxy is coupled with an interest and the fact of the interest appears on the face of the proxy, the agent named in the proxy shall have all voting and other rights referred to in the proxy, notwithstanding the presence of the person executing the proxy.  At each meeting of the stockholders, and before any voting commences, all proxies filed at or before the meeting shall be submitted to and examined by the secretary or a person designated by the secretary, and no shares may be represented or voted under a proxy that has been found to be invalid or irregular.

 

Section 11.    Action by Written Consent.  Any action required to be taken at any annual or special meeting of stockholders of the corporation, or any action which may be taken at any annual or special meeting of such stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken and bearing the dates of signature of the stockholders who signed the consent or consents, shall be signed by the holders of issued and outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the corporation by delivery to its registered office in the state of Delaware, or the corporation’s principal place of business, or an officer or agent of the corporation having custody of the book or books in which proceedings of meetings of the stockholders are recorded.  Delivery made to the corporation’s registered office shall be by hand or by certified or registered mail, or by reputable overnight courier service, or by facsimile or electronic mail, with confirmation of receipt.  All consents properly delivered in accordance with this section shall be deemed to be recorded when so delivered.  No written consent shall be effective to take the corporate action referred to therein unless, within sixty (60) days after the earliest dated consent delivered to the corporation as required by this section, written consents signed by the holders of a sufficient number of shares to take such corporate action are so recorded.  Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing.  Any action taken pursuant to such written consent or consents of the stockholders shall have the same force and effect as if taken by the stockholders at a meeting thereof.  Any copy, facsimile or other reliable reproduction of consent in writing may be substituted or used in lieu of the original writing for any and all purposes for which the original writing could be used; provided that such copy, facsimile or other reproduction shall be a complete reproduction of the entire original writing.

 

Section 12.    Action by Facsimile, Electronic Mail or Other Electronic Transmission Consent.  A facsimile, electronic mail or other electronic transmission by a stockholder (or by any person authorized to act on such person’s behalf) of a written consent to an action to be taken (including the delivery of such a document in the .pdf, .tif, .gif, .peg or similar format attached to an electronic mail message) shall be deemed to be written, signed, dated and delivered to the corporation for the purposes of this Article; provided that any such facsimile, electronic mail or other electronic transmission sets forth or is delivered with information from which the corporation can determine (A) that the facsimile, electronic mail or other electronic transmission

 

4


 

was transmitted by the stockholder or by a person authorized to act for the stockholder and (B) the date on which such stockholder or authorized person transmitted such facsimile, electronic mail or other electronic transmission.  The date on which such facsimile, electronic mail or other electronic transmission is transmitted shall be deemed to be the date on which such consent or proxy was signed, unless otherwise provided in such consent.  Any such facsimile, electronic mail or other electronic transmission of a consent or proxy shall be treated in all respects as an original executed consent and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.  At the request of the board of directors or the Secretary of the corporation, each stockholder or other authorized person who delivered a consent by facsimile, electronic mail or other electronic transmission shall re-execute the original form thereof and deliver such original to the corporation at its registered office in the State of Delaware, its principal place of business or to an officer or agent of the corporation having custody of the book in which proceedings of meetings of stockholders are recorded.

 

ARTICLE III.

 

DIRECTORS

 

Section 1.      General Powers.  The business and affairs of the corporation shall be managed by or under the direction of the board of directors.

 

Section 2.      Number, Election and Term of Office.  The number of directors which shall constitute the first board of directors shall be eight (8).  Thereafter, the number of directors shall be established from time to time by resolution of the board of directors.  The directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote in the election of directors.  The directors shall be elected in this manner at the annual meeting of the stockholders, except as otherwise provided in Section 4 of this Article III.  Each director elected shall hold office until a successor is duly elected and qualified or until his or her earlier death, resignation or removal as hereinafter provided.

 

Section 3.      Removal and Resignation.  Any director or the entire board of directors may be removed at any time, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors.  Whenever the holders of any class or series are entitled to elect one or more directors by the provisions of the corporation’s certificate of incorporation, the provisions of this section shall apply, in respect to the removal without cause of a director or directors so elected, to the vote of the holders of the outstanding shares of that class or series and not to the vote of the outstanding shares as a whole.  Any director may resign at any time upon notice given in writing or by electronic transmission to the corporation.

 

Section 4.      Vacancies.  Except as otherwise provided in the corporation’s certificate of incorporation, board vacancies and newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, even if less than a quorum, or by a sole remaining director.  Each director so chosen shall hold office until a successor is duly elected and qualified or until his or her earlier death, resignation or removal as herein provided.

 

5


 

Section 5.      Annual Meetings.  The annual meeting of each newly elected board of directors shall be held without notice (other than notice under these bylaws) immediately after, and at the same place, if any, as the annual meeting of stockholders.

 

Section 6.      Other Meetings and Notice.  Regular meetings, other than the annual meeting, of the board of directors may be held without notice at such time and at such place, if any, as shall from time to time be determined by resolution of the board of directors and promptly communicated to all directors then in office.  Special meetings of the board of directors may be called by or at the request of at least two of the directors on at least 24 hours notice to each director, either personally, by telephone, by mail, and/or by electronic transmission.  In like manner and on like notice, the president must call a special meeting on the written request of at least a majority of the directors then in office promptly after receipt of such request.

 

Section 7.      Quorum, Required Vote and Adjournment.  Directors then in office holding a majority of the votes (or such greater number required by applicable law) of all directors then in office shall constitute a quorum for the transaction of business.  The vote of directors holding a majority of votes present at a meeting at which a quorum is present shall be the act of the board of directors.  If a quorum shall not be present at any meeting of the board of directors, the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present.  Each director shall be entitled to one vote on exactly the matter presented to the board for approval.

 

Section 8.      Committees.  The board of directors may, by resolution passed by a majority of the directors then in office, designate one or more committees, each committee to consist of one or more of the directors of the corporation, which to the extent provided in such resolution or these bylaws shall have and may exercise the powers of the board of directors in the management and affairs of the corporation, except as otherwise limited by law.  The board of directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee.  Such committee or committees shall have such name or names as may be determined from time to time by resolution adopted by the board of directors.  Each committee shall keep regular minutes of its meetings and report the same to the board of directors when required.

 

Section 9.      Committee Rules.  Each committee of the board of directors may fix its own rules of procedure and shall hold its meetings as provided by such rules, except as may otherwise be provided by a resolution of the board of directors designating such committee.  Unless otherwise provided in such a resolution, the presence of at least a majority of the members of the committee then in office shall be necessary to constitute a quorum.  In the event that a member and that member’s alternate, if alternates are designated by the board of directors as provided in Section 8 of this Article III, of such committee is or are absent or disqualified, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the board of directors to act at the meeting in place of any such absent or disqualified member.

 

Section 10.    Communications Equipment.  Members of the board of directors or any committee thereof may participate in and act at any meeting of such board or committee by means of conference telephone or other communications equipment by means of which all

 

6


 

persons participating in the meeting can hear each other, and participation in the meeting pursuant to this section shall constitute presence in person at the meeting.

 

Section 11.    Waiver of Notice and Presumption of Assent.  Any member of the board of directors or any committee thereof who is present at a meeting shall be conclusively presumed to have waived notice of such meeting, except when such member attends for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened.  Such member shall be conclusively presumed to have assented to any action taken unless his or her dissent shall be entered in the minutes of the meeting or unless his or her written dissent to such action shall be filed with the person acting as the secretary of the meeting before the adjournment thereof or shall be forwarded by registered mail to the secretary of the corporation immediately after the adjournment of the meeting.  Such right to dissent shall not apply to any member who voted in favor of such action.

 

Section 12.    Action by Written Consent.  Unless otherwise restricted by the corporation’s certificate of incorporation, any action required or permitted to be taken at any meeting of the board of directors, or of any committee thereof, may be taken without a meeting if all members of the board or committee, as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the board of directors or committee.  Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

 

ARTICLE IV.

 

OFFICERS

 

Section 1.      Number.  The officers of the corporation shall be elected by the board of directors and may consist of a president and chief executive officer, one or more vice-presidents, a chief financial officer, a secretary, a treasurer, and such other officers and assistant officers as may be deemed necessary or desirable by the board of directors.  Any number of offices may be held by the same person.  In its discretion, the board of directors may choose not to fill any office for any period as it may deem advisable.

 

Section 2.      Election and Term of Office.  The officers of the corporation shall be elected annually by the board of directors at the first meeting of the board of directors held after each annual meeting of stockholders or as soon thereafter as conveniently may be.  Vacancies may be filled or new offices created and filled at any meeting of the board of directors.  Each officer shall hold office until a successor is duly elected and qualified or until his or her earlier death, resignation or removal as hereinafter provided.

 

Section 3.      Removal.  Any officer or agent elected by the board of directors may be removed by the board of directors whenever in its judgment the best interests of the corporation would be served thereby, but such removal shall be without prejudice to the contract rights, if any, of the person so removed.

 

7


 

Section 4.      Vacancies.  Any vacancy occurring in any office because of death, resignation, removal, disqualification or otherwise, may be filled by the board of directors for the unexpired portion of the term by the board of directors then in office.

 

Section 5.      Compensation.  Compensation of all officers shall be fixed by the board of directors, and no officer shall be prevented from receiving such compensation by virtue of his or her also being a director of the corporation.

 

Section 6.      Chief Executive Officer.  The chief executive officer shall be the chief executive officer of the corporation.  In the absence of the chairman of the board, the chief executive officer shall preside at all meetings of the stockholders and board of directors at which he or she is present.  Subject to the powers of the board of directors, the chief executive officer shall have general charge of the business, affairs and property of the corporation, and control over its officers, agents and employees, and shall see that all orders and resolutions of the board of directors are carried into effect.  The chief executive officer shall execute bonds, mortgages and other contracts, except where required or permitted by law to be otherwise signed and executed and except where the signing and execution thereof shall be expressly delegated by the board of directors to some other officer or agent of the corporation.  The chief executive officer shall have such other powers and perform such other duties as may be prescribed by the board of directors or as may be provided in these bylaws.

 

Section 7.      President.  The president shall, under the direction of the chief executive officer, engage in the general and active management of the business of the corporation.  In the absence of the chairman of the board and the chief executive officer, the president shall preside at all meetings of the stockholders and board of directors at which he or she is present.  Subject to the powers of the board of directors and the direction of the chief executive officer, the president shall have general charge of the business, affairs and property of the corporation, and control over its officers, agents and employees, and shall see that all orders and resolutions of the board of directors and the chief executive officer are carried into effect.  The president, in the absence of the chief executive officer, shall execute bonds, mortgages and other contracts, except where required or permitted by law to be otherwise signed and executed and except where the signing and execution thereof shall be expressly delegated by the board of directors to some other officer or agent of the corporation.  The president shall have such other powers and perform such other duties as may be prescribed by the board of directors or as may be provided in these bylaws.

 

Section 8.      Chief Financial Officer.  The chief financial officer of the corporation shall, under the direction of the chief executive officer, be responsible for all financial and accounting matters and for the direction of the offices of treasurer and controller.  The chief financial officer shall have such other powers and perform such other duties as may be prescribed by the president or the board of directors or as may be provided in these bylaws, including, without limitation, all powers of the treasurer set forth in Section 11 of this Article IV.

 

Section 9.      Vice-presidents.  The vice-president, or if there shall be more than one, the vice-presidents in the order determined by the board of directors, shall, in the absence or disability of the president, act with all of the powers and be subject to all the restrictions of the

 

8


 

president.  The vice-presidents shall also perform such other duties and have such other powers as the board of directors, the president or these bylaws may, from time to time, prescribe.

 

Section 10.    The Secretary and Assistant Secretaries.  The secretary shall attend all meetings of the board of directors, all meetings of the committees thereof and all meetings of the stockholders and record all the proceedings of the meetings in a book or books to be kept for that purpose.  Under the president’s supervision, the secretary shall give, or cause to be given, all notices required to be given by these bylaws or bylaw, and shall have such powers and perform such duties as the board of directors, the president or these bylaws may, from time to time, prescribe, and shall have custody of the corporate seal of the corporation, if any.  The secretary, or an assistant secretary, shall have authority to affix the corporate seal to any instrument requiring it and when so affixed, it may be attested by his or her signature or by the signature of such assistant secretary.  The board of directors may give general authority to any other officer to affix the seal of the corporation and to attest the affixing by his or her signature.  The assistant secretary, or if there be more than one, the assistant secretaries in the order determined by the board of directors, shall, in the absence or disability of the secretary, perform the duties and exercise the powers of the secretary and shall perform such other duties and have such other powers as the board of directors, the president, or secretary may, from time to time, prescribe.

 

Section 11.    The Treasurer and Assistant Treasurer.  The treasurer shall have the custody of the corporate funds and securities; shall keep full and accurate accounts of receipts and disbursements in books belonging to the corporation; shall deposit all monies and other valuable effects in the name and to the credit of the corporation as may be ordered by the board of directors; shall cause the funds of the corporation to be disbursed when such disbursements have been duly authorized, taking proper vouchers for such disbursements; shall render to the president and the board of directors, at its regular meeting or when the board of directors so requires, an account of the corporation; and shall have such powers and perform such duties as the board of directors, the president or these bylaws may, from time to time, prescribe.  If required by the board of directors, the treasurer shall give the corporation a bond (which shall be rendered every six (6) years) in such sums and with such surety or sureties as shall be satisfactory to the board of directors for the faithful performance of the duties of the office of treasurer and for the restoration to the corporation, in case of death, resignation, retirement, or removal from office, of all books, papers, vouchers, money, and other property of whatever kind in the possession or under the control of the treasurer belonging to the corporation.  The assistant treasurer, or if there shall be more than one, the assistant treasurers in the order determined by the board of directors, shall in the absence or disability of the treasurer, perform the duties and exercise the powers of the treasurer.  The assistant treasurers shall perform such other duties and have such other powers as the board of directors, the president or treasurer may, from time to time, prescribe.

 

Section 12.    Other Officers, Assistant Officers and Agents.  Officers, assistant officers and agents, if any, other than those whose duties are provided for in these bylaws, shall have such authority and perform such duties as may, from time to time, be prescribed by resolution of the board of directors.

 

Section 13.    Absence or Disability of Officers.  In the case of the absence or disability of any officer of the corporation and of any person hereby authorized to act in such officer’s place

 

9


 

during such officer’s absence or disability, the board of directors may by resolution delegate the powers and duties of such officer to any other officer or to any director, or to any other person whom it may select.

 

ARTICLE V.

 

INDEMNIFICATION OF OFFICERS, DIRECTORS AND OTHERS

 

Section 1.      General.  The corporation shall indemnify and hold harmless, unless prohibited from doing so by the General Corporation Law of the State of Delaware, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the corporation to provide broader indemnification rights than said law permitted the corporation to provide prior to such amendment), any person who was or is a party or is threatened to be made a party to or is involved in any threatened, pending or completed action, suit or proceeding, whether brought by or in the right of the corporation or any of its subsidiaries and whether civil, criminal, administrative or investigative (hereinafter a “proceeding”), or any appeal of such proceeding, by reason of or arising out of the fact that he or she, or any other person for whom he or she is the legal representative, is or was a director or officer of the corporation, or is or was serving at the request of the corporation as a director or officer of another corporation or of a partnership, limited liability company, joint venture, trust, association or other enterprise, against all expenses, liabilities and losses (including attorneys’ fees, costs and charges, and related disbursements, judgments, fines, excise taxes or penalties under the Employee Retirement Income Security Act of 1974, as amended from time to time (“ERISA”), penalties and amounts paid or to be paid in settlement) actually and reasonably incurred or suffered by him or her in connection with such proceeding if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding to which he or she is a party or threatened to be made a party, had no reasonable cause to believe his or her conduct was unlawful.  The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his or her conduct was unlawful.  Each employee and agent of the corporation and each person who serves or may have served at the request of the corporation as an employee or agent of another corporation, or as an employee or agent of any partnership, joint venture, limited liability company, trust, association or other enterprise may, in the discretion of the board of directors, be indemnified by the corporation to the same extent as provided herein with respect to directors and officers of the corporation.  The provisions of this Section 1 of Article V shall apply to any member of any committee appointed by the board of directors of the corporation as fully as though such person shall have been an officer or director of the corporation.  The right to indemnification conferred in this Article V shall be a contract right and, subject to Sections 2 and 3 of this Article V, shall include the right to be paid by the corporation the expenses incurred in defending any such proceeding in advance of its final disposition.

 

Section 2.      Procedure.  Any indemnification of a director or officer of the corporation provided for under Section 1 of this Article V or advance of expenses (including attorneys’ fees,

 

10


 

costs and charges) provided for under Section 3 of this Article V shall be made promptly, and in any event within forty-five (45) days (or, in the case of an advance of expenses, twenty (20) days, provided that the undertaking contemplated by Section 3 of this Article V has been delivered to the corporation), upon the written request of the director or officer.  If a determination by the corporation that the director or officer is entitled to indemnification pursuant to this Article V is required, and the corporation fails to respond within sixty (60) days to a written request for indemnity, the corporation shall be deemed to have approved the request.  If the corporation wrongfully denies a written request for indemnification or advancing of expenses, in whole or in part, or if payment in full pursuant to such request is not properly made within forty-five (45) days (or, in the case of an advance of expenses, twenty (20) days, provided that the undertaking contemplated by Section 3 of this Article V has been delivered to the corporation), the right to indemnification or advances as granted by this Article V shall be enforceable by the director or officer in any court of competent jurisdiction.  Such person’s costs and expenses incurred in connection with successfully establishing his or her right to indemnification, in whole or in part, in any such action shall also be indemnified by the corporation.  It shall be a defense to any such action for indemnification or the advance of expenses (other than an action brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the required undertaking, if any, has been tendered to the corporation) that the claimant has not met the standards of conduct which make it permissible under the General Corporation Law of the State of Delaware for the corporation to indemnify the claimant for the amount claimed, but the burden of such defense shall be on the corporation.  Neither the failure of the corporation (including its board of directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth in the General Corporation Law of the State of Delaware, nor an actual determination by the corporation (including its board of directors, independent legal counsel, or its stockholder) that the claimant has not met such applicable standard of conduct, shall create a presumption that the claimant has not met the applicable standard of conduct.

 

Section 3.      Advances for Expenses.  Expenses incurred by any person described in Section 1 of this Article V in defending a proceeding shall be paid by the corporation in advance of the final disposition of such proceeding upon receipt of an undertaking by or on behalf of the director or officer to repay such amount if it shall be ultimately determined that he or she is not entitled to be indemnified by the corporation.

 

Section 4.      Rights Not Exclusive.  The rights to indemnification and advancement of expenses provided by, or granted pursuant to, the other subsections of this Article V shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may now or hereafter be entitled under any law, bylaw, provision of the corporation’s certificate of incorporation, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding such office.

 

Section 5.      Exception to Right of Indemnification or Advancement of Expenses.  Notwithstanding any other subsections of this Article V and except as may otherwise be agreed by the corporation, no person shall be entitled to indemnification or advancement of expenses by

 

11


 

the corporation with respect to proceeding brought by such person (other than a proceeding brought by such person (a) by way of defense or counterclaim, (b) to enforce such person’s rights under the corporation’s certificate of incorporation or under these bylaws, or (c) to enforce any other rights of such person to indemnification or advancement of expenses by the corporation under any contract or under statute or applicable law, including any rights under Section 145 of the DGCL), unless the bringing of such proceeding shall have been approved by the board of directors of the corporation.

 

Section 6.      Insurance.  The corporation shall have power to purchase and maintain insurance on its own behalf and on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, limited liability company, trust, association or other enterprise against any expense, liability or loss asserted against him or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify him or her against such expense, liability or loss under the provisions of this Article V.

 

Section 7.      Service for Subsidiaries.  Any person serving, or who has served, as a director or officer of another corporation or of a partnership, joint venture, limited liability company, trust, association or other enterprise, at least 50% of whose equity interests or assets are owned, directly or indirectly, by the corporation (a “subsidiary” for this Article V) shall be conclusively presumed to be, or to have been, serving in such capacity at the request of the corporation.

 

Section 8.      Reliance.  Persons who after the date of the adoption of the provisions of this Article V become or remain directors or officers of the corporation or who, while a director or officer of the corporation, become or remain a director or officer of a subsidiary, shall be conclusively presumed to have relied on the rights to indemnity, advance of expenses and other rights contained in this Article V in entering into or continuing such service.  The rights to indemnification and to the advance of expenses conferred in this Article V shall apply to claims made against an indemnitee arising out of acts or omissions which occurred or occur both prior and subsequent to the adoption hereof.

 

Section 9.      Contract Rights.  The provisions of this Article V shall be deemed to be a vested contract right between the corporation and each director and officer who serves in any such capacity at any time while this Article V and the relevant provisions of the General Corporation Law of the State of Delaware or other applicable law are in effect.  Such contract right shall vest for each director and officer at the time such person is elected or appointed to such position, and no repeal or modification of this Article V or any such law shall affect any such vested rights or obligations of any current or former director or officer with respect to any actual or threatened action, suit or proceeding arising out of, or relating to, any actions, transactions or facts occurring prior to the final adoption of such repeal or modification.

 

Section 10.    Definitions.  For the purposes of this Article V, (a) references to “the corporation” include, in addition to the resulting corporation, all constituent corporations (including any constituent of a constituent) absorbed in a consolidation or merger as well as the resulting or surviving corporation so that any person who is or was a director or officer of such a constituent corporation or is or was serving at the request of such constituent corporation as a

 

12


 

director or officer of another corporation, partnership, joint venture, limited liability company, trust, association or other enterprise shall stand in the same position under the provisions of this Article V with respect to the resulting or surviving corporation as he or she would if he or she had served the resulting or surviving corporation in the same capacity; (b) references to “other enterprises” include employee benefit plans; (c) references to “fines” include any excise taxes assessed on a person with respect to any employee benefit plan; (d) references to “serving at the request of the corporation” shall include any service as a director or officer of the corporation which imposes duties on, or involves services by, such director or officer with respect to an employee benefit plan, its participants or beneficiaries; and (e) a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the corporation.”

 

Section 11.    Survival of Rights.  The indemnification and advancement of expenses provided by or granted pursuant to this Article V shall continue as to a person who has ceased to be a director or officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.

 

Section 12.    Savings Clause.  If this Article V or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the corporation shall nevertheless indemnify and advance expenses to each person entitled to indemnification under Section 1 of this Article V as to all expense, liability and loss (including attorneys’ fees and related disbursements, judgments, fines, ERISA excise taxes and penalties, penalties and amounts paid or to be paid in settlement) actually and reasonably incurred or suffered by such person and for which indemnification or advancement of expenses is available to such person pursuant to this Article V to the fullest extent permitted by any applicable portion of this Article V that shall not have been invalidated and to the fullest extent permitted by applicable law.

 

Section 13.    Jurisdiction.  The Court of Chancery of the State of Delaware shall have exclusive jurisdiction to hear and determine all actions for indemnification or advancement of expenses brought with respect to this Article V, and the Court of Chancery of the State of Delaware may summarily determine the corporation’s obligation to advance expenses (including attorneys’ fees, costs and charges) under this Article V.

 

ARTICLE VI.

 

CERTIFICATES OF STOCK

 

Section 1.      Certificates of Shares.  The shares of the corporation shall be represented by certificates, provided that the board of directors of the corporation may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the corporation. Notwithstanding the adoption of such a resolution by the board of directors, every holder of stock represented by certificates and upon request every holder of uncertificated shares shall be entitled to have a certificate signed by, or in the name of the corporation by the Chief Executive Officer, the President, or Vice President, and by the Secretary or Treasurer of the corporation representing the number of shares registered in

 

13


 

certificate form. Any or all the signatures on the certificate may be a facsimile. In case any officer or officers who have signed, or whose facsimile, electronic mail or other electronic signature or signatures have been used on, any such certificate or certificates shall cease to be such officer or officers of the corporation whether because of death, resignation or otherwise before such certificate or certificates have been delivered by the corporation, such certificate or certificates may nevertheless be issued and delivered as though the person or persons who signed such certificate or certificates or whose facsimile, electronic mail or other electronic signature or signatures have been used thereon had not ceased to be such officer or officers of the corporation.

 

Section 2.      Transfer of Shares. Transfers of shares of the corporation shall be made only on the books of the corporation by the holder of record thereof or by his or her legal representative, who shall furnish proper evidence of authority to transfer, or by his or her attorney thereunto authorized by power of attorney duly executed and filed with the Secretary of the corporation, and on surrender for cancellation of certificate for such shares. No transfer of stock shall be valid as against the corporation for any purposes until it shall have been entered in the stock records of the corporation by an entry showing from and to whom transferred.

 

Section 3.      Lost Certificates.  The board of directors may direct a new certificate or certificates to be issued in place of any certificate or certificates previously issued by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed.  When authorizing such issue of a new certificate or certificates, the board of directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of such lost, stolen, or destroyed certificate or certificates, or his or her legal representative, to give the corporation a bond sufficient to indemnify the corporation against any claim that may be made against the corporation on account of the loss, theft or destruction of any such certificate or the issuance of such new certificate.

 

Section 4.      Fixing a Record Date for Stockholder Meetings.  In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the board of directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the board of directors, and which record date shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting.  If no record date is fixed by the board of directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be the close of business on the next day preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held.  A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided that the board of directors may fix a new record date for the adjourned meeting.

 

Section 5.      Fixing a Record Date for Action by Written Consent.  In order that the corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting, the board of directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the board of directors, and which date shall not be more than ten days after the date upon which the resolution

 

14


 

fixing the record date is adopted by the board of directors.  If no record date has been fixed by the board of directors, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when no prior action by the board of directors is required by statute, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the corporation by delivery to its registered office in the State of Delaware, its principal place of business, or an officer or agent of the corporation having custody of the book in which proceedings of meetings of stockholders are recorded.  Delivery made to the corporation’s registered office shall be by hand or by certified or registered mail, return receipt requested or by facsimile, electronic mail or other electronic transmission, with confirmation of receipt.  If no record date has been fixed by the board of directors and prior action by the board of directors is required by statute, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be at the close of business on the day on which the board of directors adopts the resolution taking such prior action.

 

Section 6.      Fixing a Record Date for Other Purposes.  In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment or any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purposes of any other lawful action, the board of directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty days prior to such action.  If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the board of directors adopts the resolution relating thereto.

 

Section 7.              Registered Stockholders.  Before due presentment for registration of transfer of a certificate representing shares of the corporation or of an instruction requesting registration of transfer of uncertificated shares, the corporation may treat the registered owner as the person exclusively entitled to inspect for any proper purpose the stock ledger and the other books and records of the corporation, vote such shares, receive dividends or notifications with respect to such shares and otherwise exercise all the rights and powers of the owner of such shares, except that a person who is the beneficial owner of such shares (if held in a voting trust or by a nominee on behalf of such person) may, upon providing documentary evidence of beneficial ownership of such shares and satisfying such other conditions as are provided under applicable law, may also so inspect the books and records of the corporation.

 

Section 8.      Subscriptions for Stock.  Unless otherwise provided for in the subscription agreement, subscriptions for shares shall be paid in full at such time, or in such installments and at such times, as shall be determined by the board of directors.  Any call made by the board of directors for payment on subscriptions shall be uniform as to all shares of the same class or as to all shares of the same series.  In case of default in the payment of any installment or call when such payment is due, the corporation may proceed to collect the amount due in the same manner as any debt due the corporation.

 

15


 

ARTICLE VII.

 

GENERAL PROVISIONS

 

Section 1.      Dividends.  Subject to any applicable provisions of the corporation’s certificate of incorporation, dividends payable upon the capital stock of the corporation may be declared by the board of directors at any regular or special meeting, pursuant to law.  Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the corporation’s certificate of incorporation.  Before payment of any dividend, there may be set aside out of any funds of the corporation available for dividends such sum or sums as the directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the corporation, or any other purpose and the directors may modify or abolish any such reserve in the manner in which it was created.

 

Section 2.      Checks, Drafts or Orders.  All checks, drafts, or other orders for the payment of money by or to the corporation and all notes and other evidences of indebtedness issued in the name of the corporation shall be signed by such officer or officers, agent or agents of the corporation, and in such manner, as shall be determined by resolution of the board of directors or a duly authorized committee thereof.

 

Section 3.      Contracts.  The board of directors may authorize any officer or officers, or any agent or agents, of the corporation to enter into any contract or to execute and deliver any instrument in the name of and on behalf of the corporation, and such authority may be general or confined to specific instances.

 

Section 4.      Loans.  The corporation may lend money to, or guarantee any obligation of, or otherwise assist any officer or other employee of the corporation or of its subsidiary, including any officer or employee who is a director of the corporation or its subsidiary, whenever, in the judgment of the directors, such loan, guaranty or assistance may reasonably be expected to benefit the corporation.  The loan, guaranty or other assistance may be with or without interest, and may be unsecured, or secured in such manner as the board of directors shall approve, including, without limitation, a pledge of shares of stock of the corporation.  Nothing in this section contained shall be deemed to deny, limit or restrict the powers of guaranty or warranty of the corporation at common law or under any statute.

 

Section 5.      Fiscal Year.  The fiscal year of the corporation shall be fixed by resolution of the board of directors.

 

Section 6.      Corporate Seal.  The board of directors may provide a corporate seal which shall be in the form of a circle and shall have inscribed thereon the name of the corporation and the words “Corporate Seal, Delaware”.  The seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.

 

Section 7.      Voting Securities Owned By Corporation.  Voting securities in any other corporation or other entity (such as a limited liability company, limited partnership or trust) held by the corporation shall be voted as directed by the board of directors, unless the board of

 

16


 

directors specifically confers authority to vote with respect thereto, which authority may be general or confined to specific instances, upon some other person or officer.  Any person authorized to vote securities shall have the power to appoint proxies, with general power of substitution.

 

Section 8.      Inspection of Books and Records.  Any stockholder of record, in person or by attorney or other agent, shall, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose the corporation’s stock ledger, a list of its stockholders, and its other books and records, and to make copies or extracts therefrom.  A proper purpose shall mean any purpose reasonably related to such person’s interest as a stockholder.  In every instance where an attorney or other agent shall be the person who seeks the right to inspection, the demand under oath shall be accompanied by a power of attorney or such other writing which authorizes the attorney or other agent to so act on behalf of the stockholder.  The demand under oath shall be directed to the corporation at its registered office in the State of Delaware or at its principal place of business.

 

Section 9.      Exclusive Jurisdiction.  The Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director or officer of the corporation to the corporation or the corporation’s stockholders, (iii) any action asserting a claim against the corporation arising pursuant to any provision of the General Corporation Law of the State of Delaware or the corporation’s certificate of incorporation or bylaws or (iv) any action asserting a claim against the corporation governed by the internal affairs doctrine.

 

Section 10.    Section Headings.  Section headings in these bylaws are for convenience of reference only and shall not be given any substantive effect in limiting or otherwise construing any provision herein.

 

Section 11.    Inconsistent Provisions.  In the event that any provision of these bylaws is or becomes inconsistent with any provision of the corporation’s certificate of incorporation, the General Corporation Law of the State of Delaware or any other applicable law, the provision of these bylaws shall not be given any effect to the extent of such inconsistency but shall otherwise be given full force and effect.

 

ARTICLE VIII.

 

AMENDMENTS

 

These bylaws may be amended, altered, or repealed and new bylaws adopted at any meeting of the board of directors at which a quorum is present by a vote of a majority of the directors.  The fact that the power to adopt, amend, alter, or repeal the bylaws has been conferred upon the board of directors shall not divest the stockholders of the same powers.

 

17


EX-4.3 4 a19-2105_2ex4d3.htm EX-4.3

Exhibit 4.3

 

Execution Version

 

ASSIGNMENT AND ASSUMPTION AGREEMENT

 

THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (the “Agreement”) is entered into and effective as of January 4, 2019, by and among Federal Street Acquisition Corp., a Delaware corporation (“FSAC”), Agiliti, Inc., a Delaware corporation (“Agiliti”), and Continental Stock Transfer & Trust Company, a New York corporation (“Continental”).

 

WHEREAS, FSAC and Continental have previously entered into a warrant agreement, dated as of July 18, 2017 (the “Warrant Agreement”), governing the terms of FSAC’s 37,950,000 outstanding warrants to purchase shares of common stock of FSAC (the “Warrants”);

 

WHEREAS, FSAC has entered into an Amended and Restated Agreement and Plan of Merger, dated as of December 19, 2018 (the “Merger Agreement”), by and among FSAC, Agiliti, Umpire SPAC Merger Sub, Inc., a Delaware corporation, Umpire Cash Merger Sub, Inc., a Delaware corporation, Agiliti Holdco, Inc., a Delaware corporation (“Agiliti Holdco”), solely in its capacity as the Majority Stockholder and the Stockholders’ Representative, IPC/UHS, L.P. and solely for Sections 1.6 and 9.12 of the Merger Agreement, Umpire Equity Merger Sub, Inc., a Delaware corporation, pursuant to which (i) FSAC will become a wholly owned subsidiary of Agiliti and the holders of FSAC’s Class A common stock (including Class A common stock issued upon conversion of FSAC’s Class F common stock) will receive shares of common stock of Agiliti; and (ii) Agiliti Holdco, will become a wholly owned subsidiary of FSAC, the equityholders of Agiliti Holdco will receive cash and certain executive officers of Agiliti Holdco will receive cash and shares of common stock, par value $0.0001 per share (the “Common Stock”), of Agiliti and/or fully-vested options to purchase shares of common stock of Agiliti as merger consideration (the transactions contemplated by the Merger Agreement are referred to herein as the “Business Combination”);

 

WHEREAS, pursuant to Section 2.5(b) of the Merger Agreement, upon the consummation of the Business Combination, each Warrant (or portion thereof) issued and outstanding immediately prior thereto shall become exercisable for shares of Common Stock (or an equivalent portion thereof), and the rights and obligations of FSAC under the Warrant Agreement shall be assigned to and assumed by Agiliti; and

 

WHEREAS, as a result of the foregoing, the parties hereto wish for FSAC to assign to Agiliti all of FSAC’s rights, interests and obligations in and under the Warrant Agreement and for Agiliti to accept such assignment and assume all of FSAC’s obligations thereunder, in each case, effective upon the consummation of the Business Combination;

 

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, the parties hereby agree as follows:

 

1.                                      Assignment and Assumption of Warrant Agreement. FSAC hereby assigns, and Agiliti hereby agrees to accept and assume, effective as of the consummation of the Business Combination, all of FSAC’s rights, interests and obligations in, and under the Warrant Agreement and Warrants. Unless the context otherwise requires, from and after the consummation of the Business Combination, any references in the Warrant Agreement or the

 


 

Warrants to: (i) the “Company” shall mean Agiliti; (ii) “Common Stock” or “shares” shall mean the Common Stock; and (iii) the “Board” or any committee thereof shall mean the board of directors of Agiliti or any committee thereof.

 

2.                                      Replacement Instruments. Following the consummation of the Business Combination, upon request by any holder of a Warrant, Agiliti shall issue a new instrument for such Warrant reflecting the adjustment to the terms and conditions described herein.

 

3.                                      Amendment to Warrant Agreement. To the extent required by this Agreement, the Warrant Agreement is hereby deemed amended pursuant to Section 9.8 thereof to reflect the subject matter contained herein, effective as of the consummation of the Business Combination.

 

4.                                      Governing Law. The validity, interpretation, and performance of this Agreement shall be governed in all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction.

 

5.                                      Counterpart. This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument. Execution and delivery of this Agreement by electronic mail or exchange of facsimile of .pdf copies bearing the facsimile signature of a party hereto shall constitute a valid and binding execution and delivery of this Agreement by such party.

 

6.                                      Successors and Assigns. All the covenants and provisions of this Agreement shall bind and inure to the benefit of each party’s respective successors and assigns.

 

[Signature Page Follows]

 


 

IN WITNESS WHEREOF, the parties hereto have signed this Agreement as of the date and year first written above.

 

 

FEDERAL STREET ACQUISITION CORP.

 

 

 

 

By:

/s/ James Pekarek

 

 

Name:

James Pekarek

 

 

Title:

Chief Financial Officer

 

 

 

 

AGILITI, INC.

 

 

 

 

By:

/s/ Lee M. Neumann

 

 

Name:

Lee Neumann

 

 

Title:

Senior Vice President, General Counsel and Corporate Secretary

 


 

 

CONTINENTAL STOCK TRANSFER & TRUST COMPANY

 

 

 

 

By:

/s/ Isaac J. Kagan

 

 

Name: Isaac J. Kagan

 

 

Title: Vice President

 


EX-10.1 5 a19-2105_2ex10d1.htm EX-10.1

Exhibit 10.1

 

AGILITI, INC.

 


 

2018 OMNIBUS INCENTIVE PLAN

 


 

ARTICLE I
PURPOSE

 

The purpose of this Agiliti, Inc. 2018 Omnibus Incentive Plan is to enhance the profitability and value of the Company for the benefit of its stockholders by enabling the Company to offer Eligible Individuals cash and stock-based incentives in order to attract, retain and reward such individuals and strengthen the mutuality of interests between such individuals and the Company’s stockholders.  The Plan is effective as of the date set forth in Article XV.

 

ARTICLE II
DEFINITIONS

 

For purposes of the Plan, the following terms shall have the following meanings:

 

2.1                               Affiliate means each of the following:  (a) any Subsidiary; (b) any Parent; (c) any corporation, trade or business (including, without limitation, a partnership or limited liability company) which is directly or indirectly controlled 50% or more (whether by ownership of stock, assets or an equivalent ownership interest or voting interest) by the Company or one of its Affiliates; (d) any trade or business (including, without limitation, a partnership or limited liability company) which directly or indirectly controls 50% or more (whether by ownership of stock, assets or an equivalent ownership interest or voting interest) of the Company; and (e) any other entity in which the Company or any of its Affiliates has a material equity interest and which is designated as an “Affiliate” by resolution of the Committee; provided that, unless otherwise determined by the Committee, the Common Stock subject to any Award constitutes “service recipient stock” for purposes of Section 409A of the Code or otherwise does not subject the Award to Section 409A of the Code.

 

2.2                               Award means any award under the Plan of any Stock Option, Stock Appreciation Right, Restricted Stock Award, Performance Award, Other Stock-Based Award or Other Cash-Based Award.  All Awards shall be granted by, confirmed by, and subject to the terms of, a written agreement between the Company and the Participant.

 

2.3                               Award Agreement means the written or electronic agreement setting forth the terms and conditions applicable to an Award.

 

2.4                               Board means the Board of Directors of the Company.

 

2.5                               Cause means, unless otherwise determined by the Committee in the applicable Award Agreement,(i) the commission by Participant of, or the indictment of Participant for (or pleading guilty or nolo contendere to), a felony or a crime involving moral turpitude, (ii)

 


 

Participant’s repeated failure or refusal to faithfully and diligently perform the usual and customary duties of his employment or to act in accordance with any lawful direction or order of the Board, which failure or refusal is not cured within thirty (30) days after written notice thereof is given to Participant, (iii) Participant’s material breach of fiduciary duty, (iv) Participant’s theft, fraud, or dishonesty with regard to the Company or any of its Affiliates or in connection with Participant’s duties, (v) Participant’s material violation of the Company’s code of conduct or similar written policies, (vi) Participant’s willful misconduct unrelated to the Company or any of its Affiliates having, or likely to have, a material negative impact on the Company or any of its Affiliates (economically or its reputation), (vii) an act of gross negligence or willful misconduct by the Participant that relates to the affairs of the Company or any of its Affiliates, or (viii) material breach by Participant of any provisions of the Award Agreement.  With respect to a Participant’s Termination of Directorship, “cause” means an act or failure to act that constitutes cause for removal of a director under applicable Delaware law.

 

2.6                               Change in Control has the meaning set forth in 11.2.

 

2.7                               Change in Control Price has the meaning set forth in Section 11.1.

 

2.8                               Codemeans the Internal Revenue Code of 1986, as amended.  Any reference to any section of the Code shall also be a reference to any successor provision and any treasury regulation promulgated thereunder.

 

2.9                               Committee means any committee of the Board duly authorized by the Board to administer the Plan.  If no committee is duly authorized by the Board to administer the Plan, the term “Committee” shall be deemed to refer to the Board for all purposes under the Plan.

 

2.10                        Common Stock means the common stock, $0.001 par value per share, of the Company.

 

2.11                        Company means Agiliti, Inc., a Delaware corporation and its successors by operation of law.

 

2.12                        Consultant means any natural person who is an advisor or consultant to the Company or its Affiliates.

 

2.13                        Disability means, unless otherwise determined by the Committee in the applicable Award Agreement, with respect to a Participant’s Termination, a permanent and total disability as defined in Section 22(e)(3) of the Code.    Notwithstanding the foregoing, for Awards that are subject to Section 409A of the Code, Disability shall mean that a Participant is disabled under Section 409A(a)(2)(C)(i) or (ii) of the Code.

 

2.14                        Effective Date means the effective date of the Plan as defined in Article XV.

 

2.15                        Eligible Employees means each employee of the Company or an Affiliate.

 

2.16                        Eligible Individual means an Eligible Employee, Non-Employee Director or Consultant who is designated by the Committee in its discretion as eligible to receive Awards subject to the conditions set forth herein.

 

A-2


 

2.17                        Exchange Act means the Securities Exchange Act of 1934, as amended.  Reference to a specific section of the Exchange Act or regulation thereunder shall include such section or regulation, any valid regulation or interpretation promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.

 

2.18                        Fair Market Value means, for purposes of the Plan, unless otherwise required by any applicable provision of the Code or any regulations issued thereunder, as of any date, as determined in a manner established by the Committee in good faith that it considers appropriate taking into account the requirements of Section 409A of the Code.

 

2.19                        Family Member means “family member” as defined in Section A.1.(a)(5) of the general instructions of Form S-8.

 

2.20                        Incentive Stock Option means any Stock Option awarded to an Eligible Employee of the Company, its Subsidiaries and its Parents (if any) under the Plan intended to be and designated as an “Incentive Stock Option” within the meaning of Section 422 of the Code.

 

2.21                        Non-Employee Director means a director or a member of the Board of the Company or any Affiliate who is not an active employee of the Company or any Affiliate.

 

2.22                        Non-Qualified Stock Option means any Stock Option awarded under the Plan that is not an Incentive Stock Option.

 

2.23                        Non-Tandem Stock Appreciation Right shall mean the right to receive an amount in cash and/or stock equal to the difference between (x) the Fair Market Value of a share of Common Stock on the date such right is exercised, and (y) the aggregate exercise price of such right, otherwise than on surrender of a Stock Option.

 

2.24                        Other Cash-Based Award means an Award granted pursuant to Section 10.3 of the Plan and payable in cash at such time or times and subject to such terms and conditions as determined by the Committee in its sole discretion.

 

2.25                        Other Stock-Based Award means an Award under Article X of the Plan that is valued in whole or in part by reference to, or is payable in or otherwise based on, Common Stock, including, without limitation, an Award valued by reference to an Affiliate.

 

2.26                        Parent means any parent corporation of the Company within the meaning of Section 424(e) of the Code.

 

2.27                        Participantmeans an Eligible Individual to whom an Award has been granted pursuant to the Plan.

 

2.28                        Performance Award means an Award granted to a Participant pursuant to Article IX hereof contingent upon achieving certain performance goals.

 

A-3


 

2.29                        Performance Period means the designated period during which the performance goals must be satisfied with respect to the Award to which the performance goals relate.

 

2.30                        Person” has the meaning shall ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and 14(d) thereof, including a “group” as defined in Section 13(d) thereof.

 

2.31                        Plan means this Agiliti, Inc. 2018 Omnibus Incentive Plan, as amended from time to time.

 

2.32                        Proceedinghas the meaning set forth in Section 14.9.

 

2.33                        Reference Stock Option has the meaning set forth in Section 7.1.

 

2.34                        Registration Date means the date on which the Company sells its Common Stock in a bona fide, firm commitment underwriting pursuant to a registration statement under the Securities Act.

 

2.35                        Reorganization has the meaning set forth in Section 4.2(b)(ii).

 

2.36                        Restricted Stock means an Award of shares of Common Stock under the Plan that is subject to restrictions under Article VIII.

 

2.37                        Restriction Period has the meaning set forth in Section 8.3(a) with respect to Restricted Stock.

 

2.38                        Rule 16b-3 means Rule 16b-3 under Section 16(b) of the Exchange Act as then in effect or any successor provision.

 

2.39                        Section 409A of the Code means the nonqualified deferred compensation rules under Section 409A of the Code and any applicable treasury regulations and other official guidance thereunder.

 

2.40                        Securities Act means the Securities Act of 1933, as amended and all rules and regulations promulgated thereunder.  Reference to a specific section of the Securities Act or regulation thereunder shall include such section or regulation, any valid regulation or interpretation promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.

 

2.41                        Stock Appreciation Right shall mean the right pursuant to an Award granted under Article VII.

 

2.42                        Stock Option or Option means any option to purchase shares of Common Stock granted to Eligible Individuals granted pursuant to Article VI.

 

2.43                        Subsidiary means any subsidiary corporation of the Company within the meaning of Section 424(f) of the Code.

 

A-4


 

2.44                        Tandem Stock Appreciation Right shall mean the right to surrender to the Company all (or a portion) of a Stock Option in exchange for an amount in cash and/or stock equal to the difference between (i) the Fair Market Value on the date such Stock Option (or such portion thereof) is surrendered, of the Common Stock covered by such Stock Option (or such portion thereof), and (ii) the aggregate exercise price of such Stock Option (or such portion thereof).

 

2.45                        Ten Percent Stockholdermeans a person owning stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company, its Subsidiaries or its Parent.

 

2.46                        Terminationmeans a Termination of Consultancy, Termination of Directorship or Termination of Employment, as applicable.

 

2.47                        Termination of Consultancy means:  (a) that the Consultant is no longer acting as a consultant to the Company or an Affiliate; or (b) when an entity which is retaining a Participant as a Consultant ceases to be an Affiliate unless the Participant otherwise is, or thereupon becomes, a Consultant to the Company or another Affiliate at the time the entity ceases to be an Affiliate.  In the event that a Consultant becomes an Eligible Employee or a Non-Employee Director upon the termination of such Consultant’s consultancy, unless otherwise determined by the Committee, in its sole discretion, no Termination of Consultancy shall be deemed to occur until such time as such Consultant is no longer a Consultant, an Eligible Employee or a Non-Employee Director.  Notwithstanding the foregoing, the Committee may otherwise define Termination of Consultancy in the Award Agreement or, if no rights of a Participant are reduced, may otherwise define Termination of Consultancy thereafter, provided that any such change to the definition of the term “Termination of Consultancy” does not subject the applicable Award to Section 409A of the Code.

 

2.48                        Termination of Directorship means that the Non-Employee Director has ceased to be a director of the Company; except that if a Non-Employee Director becomes an Eligible Employee or a Consultant upon the termination of such Non-Employee Director’s directorship, such Non-Employee Director’s ceasing to be a director of the Company shall not be treated as a Termination of Directorship unless and until the Participant has a Termination of Employment or Termination of Consultancy, as the case may be.

 

2.49                        Termination of Employment means:  (a) a termination of employment (for reasons other than a military or personal leave of absence granted by the Company) of a Participant from the Company and its Affiliates; or (b) when an entity which is employing a Participant ceases to be an Affiliate, unless the Participant otherwise is, or thereupon becomes, employed by the Company or another Affiliate at the time the entity ceases to be an Affiliate.  In the event that an Eligible Employee becomes a Consultant or a Non-Employee Director upon the termination of such Eligible Employee’s employment, unless otherwise determined by the Committee, in its sole discretion, no Termination of Employment shall be deemed to occur until such time as such Eligible Employee is no longer an Eligible Employee, a Consultant or a Non-Employee Director.  Notwithstanding the foregoing, the Committee may otherwise define Termination of Employment in the Award Agreement or, if no rights of a Participant are reduced, may otherwise define Termination of Employment thereafter, provided that any such change to

 

A-5


 

the definition of the term “Termination of Employment” does not subject the applicable Award to Section 409A of the Code.

 

2.50                        Transfer means: (a) when used as a noun, any direct or indirect transfer, sale, assignment, pledge, hypothecation, encumbrance or other disposition (including the issuance of equity in any entity), whether for value or no value and whether voluntary or involuntary (including by operation of law), and (b) when used as a verb, to directly or indirectly transfer, sell, assign, pledge, encumber, charge, hypothecate or otherwise dispose of (including the issuance of equity in any entity) whether for value or for no value and whether voluntarily or involuntarily (including by operation of law).  “Transferred” and “Transferable” shall have a correlative meaning.

 

ARTICLE III
ADMINISTRATION

 

3.1                               The Committee.  The Plan shall be administered and interpreted by the Committee.

 

3.2                               Grants of Awards.  The Committee shall have full authority to grant, pursuant to the terms of the Plan, to Eligible Individuals:  (i) Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock Awards, (iv) Performance Awards; (v) Other Stock-Based Awards; and (vi) Other Cash-Based Awards.  In particular, the Committee shall have the authority:

 

(a)         to select the Eligible Individuals to whom Awards may from time to time be granted hereunder;

 

(b)         to determine whether and to what extent Awards, or any combination thereof, are to be granted hereunder to one or more Eligible Individuals;

 

(c)          to determine the number of shares of Common Stock to be covered by each Award granted hereunder;

 

(d)         to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder (including, but not limited to, the exercise or purchase price (if any), any restriction or limitation, any vesting schedule or acceleration thereof, or any forfeiture restrictions or waiver thereof, regarding any Award and the shares of Common Stock relating thereto, based on such factors, if any, as the Committee shall determine, in its sole discretion);

 

(e)          to determine the amount of cash to be covered by each Award granted hereunder;

 

(f)           to determine whether, to what extent and under what circumstances grants of Options and other Awards under the Plan are to operate on a tandem basis and/or in conjunction with or apart from other awards made by the Company outside of the Plan;

 

(g)          to determine whether and under what circumstances a Stock Option may be settled in cash, Common Stock and/or Restricted Stock under Section 6.4(d);

 

A-6


 

(h)         to determine whether a Stock Option is an Incentive Stock Option or Non-Qualified Stock Option;

 

(i)             to determine whether to require a Participant, as a condition of the granting of any Award, to not sell or otherwise dispose of shares acquired pursuant to the exercise of an Award for a period of time as determined by the Committee, in its sole discretion, following the date of the acquisition of such Award;

 

(j)            to modify, extend or renew an Award, subject to Article XII and Section 6.4(l), provided, however, that such action does not subject the Award to Section 409A of the Code without the consent of the Participant; and

 

(k)         solely to the extent permitted by applicable law, to determine whether, to what extent and under what circumstances to provide loans (which may be on a recourse basis and shall bear interest at the rate the Committee shall provide) to Participants in order to exercise Options under the Plan.

 

3.3                               Guidelines.  Subject to Article XII hereof, the Committee shall have the authority to adopt, alter and repeal such administrative rules, guidelines and practices governing the Plan and perform all acts, including the delegation of its responsibilities (to the extent permitted by applicable law and applicable stock exchange rules), as it shall, from time to time, deem advisable; to construe and interpret the terms and provisions of the Plan and any Award issued under the Plan (and any agreements relating thereto); and to otherwise supervise the administration of the Plan.  The Committee may correct any defect, supply any omission or reconcile any inconsistency in the Plan or in any agreement relating thereto in the manner and to the extent it shall deem necessary to effectuate the purpose and intent of the Plan.  The Committee may adopt special guidelines and provisions for persons who are residing in or employed in, or subject to, the taxes of, any domestic or foreign jurisdictions to comply with applicable tax and securities laws of such domestic or foreign jurisdictions.  Notwithstanding the foregoing, no action of the Committee under this Section 3.3 shall impair the rights of any Participant without the Participant’s consent.  To the extent applicable, the Plan is intended to comply with the applicable requirements of Rule 16b-3.

 

3.4                               Decisions Final.  Any decision, interpretation or other action made or taken in good faith by or at the direction of the Company, the Board or the Committee (or any of its members) arising out of or in connection with the Plan shall be within the absolute discretion of all and each of them, as the case may be, and shall be final, binding and conclusive on the Company and all employees and Participants and their respective heirs, executors, administrators, successors and assigns.

 

3.5                               Procedures.  If the Committee is appointed, the Board shall designate one of the members of the Committee as chairman and the Committee shall hold meetings, subject to the By-Laws of the Company, at such times and places as it shall deem advisable, including, without limitation, by telephone conference or by written consent to the extent permitted by applicable law.  A majority of the Committee members shall constitute a quorum.  All determinations of the Committee shall be made by a majority of its members.  Any decision or determination reduced to writing and signed by all of the Committee members in accordance with the By-Laws of the

 

A-7


 

Company, shall be fully effective as if it had been made by a vote at a meeting duly called and held.  The Committee shall keep minutes of its meetings and shall make such rules and regulations for the conduct of its business as it shall deem advisable.

 

3.6                               Designation of Consultants/Liability.

 

(a)         The Committee may designate employees of the Company and professional advisors to assist the Committee in the administration of the Plan and (to the extent permitted by applicable law and applicable exchange rules) may grant authority to officers to grant Awards and/or execute agreements or other documents on behalf of the Committee.

 

(b)         The Committee may employ such legal counsel, consultants and agents as it may deem desirable for the administration of the Plan and may rely upon any opinion received from any such counsel or consultant and any computation received from any such consultant or agent.  Expenses incurred by the Committee or the Board in the engagement of any such counsel, consultant or agent shall be paid by the Company.  The Committee, its members and any person designated pursuant to sub-section (a) above shall not be liable for any action or determination made in good faith with respect to the Plan.  To the maximum extent permitted by applicable law, no officer of the Company or member or former member of the Committee or of the Board shall be liable for any action or determination made in good faith with respect to the Plan or any Award granted under it.

 

3.7                               Indemnification.  To the maximum extent permitted by applicable law and the Certificate of Incorporation and By-Laws of the Company and to the extent not covered by insurance directly insuring such person, each officer or employee of the Company or any Affiliate and member or former member of the Committee or the Board shall be indemnified and held harmless by the Company against any cost or expense (including reasonable fees of counsel reasonably acceptable to the Committee) or liability (including any sum paid in settlement of a claim with the approval of the Committee), and advanced amounts necessary to pay the foregoing at the earliest time and to the fullest extent permitted, arising out of any act or omission to act in connection with the administration of the Plan, except to the extent arising out of such officer’s, employee’s, member’s or former member’s own fraud or bad faith.  Such indemnification shall be in addition to any right of indemnification the employees, officers, directors or members or former officers, directors or members may have under applicable law or under the Certificate of Incorporation or By-Laws of the Company or any Affiliate.  Notwithstanding anything else herein, this indemnification will not apply to the actions or determinations made by an individual with regard to Awards granted to such individual under the Plan.

 

ARTICLE IV
SHARE LIMITATION

 

4.1                               Shares.  The aggregate number of shares of Common Stock that may be issued or used for reference purposes or with respect to which Awards may be granted under the Plan shall not exceed 10,356,000 shares (subject to any increase or decrease pursuant to Section 4.2) (the “Share Reserve”), which may be either authorized and unissued Common Stock or Common Stock held in or acquired for the treasury of the Company or both.  The maximum number of shares of Common Stock with respect to which Incentive Stock Options may be granted under the

 

A-8


 

Plan shall be equal to the Share Reserve.  With respect to Stock Appreciation Rights settled in Common Stock, upon settlement, only the number of shares of Common Stock delivered to a Participant (based on the difference between the Fair Market Value of the shares of Common Stock subject to such Stock Appreciation Right on the date such Stock Appreciation Right is exercised and the exercise price of each Stock Appreciation Right on the date such Stock Appreciation Rights was awarded) shall count against the aggregate and individual share limitations set forth under this Article IV.  If any Option, Stock Appreciation Right or Other Stock-Based Awards granted under the Plan expires, terminates or is canceled for any reason without having been exercised in full, the number of shares of Common Stock underlying any unexercised Award shall again be available for the purpose of Awards under the Plan.  If any shares of Restricted Stock, Performance Awards or Other Stock-Based Awards denominated in shares of Common Stock awarded under the Plan to a Participant are forfeited for any reason, the number of forfeited shares of Restricted Stock, Performance Awards or Other Stock-Based Awards denominated in shares of Common Stock shall again be available for purposes of Awards under the Plan.  If a Tandem Stock Appreciation Right or a Limited Stock Appreciation Right is granted in tandem with an Option, such grant shall only apply once against the maximum number of shares of Common Stock which may be issued under the Plan.  Any Award under the Plan settled in cash shall not be counted against the foregoing maximum share limitations.  Notwithstanding any other provision of the Plan to the contrary, the aggregate grant date fair value (computed as of the date of grant in accordance with applicable financial accounting rules) of all Awards granted to any Non-Employee Director during any single calendar year (excluding Awards made at the election of the Director in lieu of all or a portion of annual and committee cash retainers pursuant to Section 6.3) shall not exceed $500,000.

 

4.2                               Changes.

 

(a)         The existence of the Plan and the Awards granted hereunder shall not affect in any way the right or power of the Board or the stockholders of the Company to make or authorize (i) any adjustment, recapitalization, reorganization or other change in the Company’s capital structure or its business, (ii) any merger or consolidation of the Company or any Affiliate, (iii) any issuance of bonds, debentures, preferred or prior preference stock ahead of or affecting the Common Stock, (iv) the dissolution or liquidation of the Company or any Affiliate, (v) any sale or transfer of all or part of the assets or business of the Company or any Affiliate or (vi) any other corporate act or proceeding.

 

(b)         Subject to the provisions of Section 11.1:

 

(i)             If the Company at any time subdivides (by any split, recapitalization or otherwise) the outstanding Common Stock into a greater number of shares of Common Stock, or combines (by reverse split, combination or otherwise) its outstanding Common Stock into a lesser number of shares of Common Stock, then the respective exercise prices for outstanding Awards that provide for a Participant elected exercise and the number of shares of Common Stock covered by outstanding Awards, as well as the Share Reserve, shall be appropriately adjusted by the Committee to prevent dilution or enlargement of the rights granted to, or available for, Participants under the Plan.

 

A-9


 

(ii)          Excepting transactions covered by Section 4.2(b)(i), if the Company effects any merger, consolidation, statutory exchange, spin-off, reorganization, sale or transfer of all or substantially all the Company’s assets or business, or other corporate transaction or event in such a manner that the Company’s outstanding shares of Common Stock are converted into the right to receive (or the holders of Common Stock are entitled to receive in exchange therefor), either immediately or upon liquidation of the Company, securities or other property of the Company or other entity (each, a Reorganization), then, subject to the provisions of Section 11.1, (A) the aggregate number or kind of securities that thereafter may be issued under the Plan, (B) the number or kind of securities or other property (including cash) to be issued pursuant to Awards granted under the Plan (including as a result of the assumption of the Plan and the obligations hereunder by a successor entity, as applicable), or (C) the purchase price thereof, shall be appropriately adjusted by the Committee to prevent dilution or enlargement of the rights granted to, or available for, Participants under the Plan.

 

(iii)       If there shall occur any change in the capital structure of the Company other than those covered by Section 4.2(b)(i) or 4.2(b)(ii), including by reason of any extraordinary dividend (whether cash or equity), any conversion, any adjustment, any issuance of any class of securities convertible or exercisable into, or exercisable for, any class of equity securities of the Company, then the Committee shall adjust any Award and make such other adjustments to the Plan to prevent dilution or enlargement of the rights granted to, or available for, Participants under the Plan.

 

(iv)      Any such adjustment determined by the Committee pursuant to this Section 4.2(b) shall be final, binding and conclusive on the Company and all Participants and their respective heirs, executors, administrators, successors and permitted assigns.  Any adjustment to, or assumption or substitution of, an Award under this Section 4.2(b) shall be intended to comply with the requirements of Section 409A of the Code and Treasury Regulation §1.424-1 (and any amendments thereto), to the extent applicable.  Except as expressly provided in this Section 4.2 or in the applicable Award Agreement, a Participant shall have no additional rights under the Plan by reason of any transaction or event described in this Section 4.2.

 

(v)         Fractional shares of Common Stock resulting from any adjustment in Awards pursuant to Section 4.2(a) or this Section 4.2(b) shall be aggregated until, and eliminated at, the time of exercise or payment by rounding-down for fractions less than one-half and rounding-up for fractions equal to or greater than one-half.  No cash settlements shall be required with respect to fractional shares eliminated by rounding.  Notice of any adjustment shall be given by the Committee to each Participant whose Award has been adjusted and such adjustment (whether or not such notice is given) shall be effective and binding for all purposes of the Plan.

 

4.3                               Non-Employee Director Compensation.  Notwithstanding any provision of the Plan to the contrary, the aggregate value of all compensation paid or granted to any individual for service as a Non-Employee Director with respect to any calendar year, including Awards granted under this Plan and cash fees paid by the Company to such Non-Employee Director outside of the Plan, shall not exceed six hundred thousand dollars ($600,000), calculating the value of any Awards granted during such calendar year based on the grant date fair value of such Awards for financial reporting purposes.

 

A-10


 

ARTICLE V
ELIGIBILITY

 

5.1                               General Eligibility.  All current and prospective Eligible Individuals are eligible to be granted Awards.  Eligibility for the grant of Awards and actual participation in the Plan shall be determined by the Committee in its sole discretion.  The Committee shall have full discretion to treat different Participants under the Plan differently in any circumstance, and will not be required to treat all Participants in a uniform manner.

 

5.2                               Incentive Stock Options.  Notwithstanding the foregoing, only Eligible Employees of the Company, its Subsidiaries and its Parent (if any) are eligible to be granted Incentive Stock Options under the Plan.  Eligibility for the grant of an Incentive Stock Option and actual participation in the Plan shall be determined by the Committee in its sole discretion.

 

5.3                               General Requirement.  The vesting and exercise of Awards granted to a prospective Eligible Individual are conditioned upon such individual actually becoming an Eligible Employee, Consultant or Non-Employee Director, respectively.

 

ARTICLE VI
STOCK OPTIONS

 

6.1                               Options.  Stock Options may be granted alone or in addition to other Awards granted under the Plan.  Each Stock Option granted under the Plan shall be of one of two types: (a) an Incentive Stock Option or (b) a Non-Qualified Stock Option.

 

6.2                               Grants.  The Committee shall have the authority to grant to any Eligible Employee one or more Incentive Stock Options, Non-Qualified Stock Options, or both types of Stock Options.  The Committee shall have the authority to grant any Consultant or Non-Employee Director one or more Non-Qualified Stock Options.  To the extent that any Stock Option does not qualify as an Incentive Stock Option (whether because of its provisions or the time or manner of its exercise or otherwise), such Stock Option or the portion thereof which does not so qualify shall constitute a separate Non-Qualified Stock Option.

 

6.3                               Incentive Stock Options.  Notwithstanding anything in the Plan to the contrary, no term of the Plan relating to Incentive Stock Options shall be interpreted, amended or altered, nor shall any discretion or authority granted under the Plan be so exercised, so as to disqualify the Plan under Section 422 of the Code, or, without the consent of the Participants affected, to disqualify any Incentive Stock Option under such Section 422.

 

6.4                               Terms of Options.  Options granted under the Plan shall be subject to the following terms and conditions and shall be in such form and contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee shall deem desirable:

 

(a)         Exercise Price.  The exercise price per share of Common Stock subject to a Stock Option shall be determined by the Committee at the time of grant, provided that the per share exercise price of a Stock Option shall not be less than 100% (or, in the case of an Incentive Stock Option granted to a Ten Percent Stockholder, 110%) of the Fair Market Value of the Common Stock at the time of grant.

 

A-11


 

(b)         Stock Option Term.  The term of each Stock Option shall be fixed by the Committee, provided that no Stock Option shall be exercisable more than 10 years after the date the Option is granted; and provided further that the term of an Incentive Stock Option granted to a Ten Percent Stockholder shall not exceed five years.

 

(c)          Exercisability.  Unless otherwise provided by the Committee in accordance with the provisions of this Section 6.4, Stock Options granted under the Plan shall be exercisable at such time or times and subject to such terms and conditions as shall be determined by the Committee at the time of grant.  If the Committee provides, in its discretion, that any Stock Option is exercisable subject to certain limitations (including, without limitation, that such Stock Option is exercisable only in installments or within certain time periods), the Committee may waive such limitations on the exercisability at any time at or after the time of grant in whole or in part (including, without limitation, waiver of the installment exercise provisions or acceleration of the time at which such Stock Option may be exercised), based on such factors, if any, as the Committee shall determine, in its sole discretion.

 

(d)         Method of Exercise.  Subject to whatever installment exercise and waiting period provisions apply under Section 6.4(c), to the extent vested, Stock Options may be exercised in whole or in part at any time during the Option term, by giving written notice of exercise to the Company specifying the number of shares of Common Stock to be purchased.  Such notice shall be accompanied by payment in full of the purchase price as follows:  (i) in cash or by check, bank draft or money order payable to the order of the Company; (ii) solely to the extent permitted by applicable law, if the Common Stock is traded on a national securities exchange, and the Committee authorizes, through a procedure whereby the Participant delivers irrevocable instructions to a broker reasonably acceptable to the Committee to deliver promptly to the Company an amount equal to the purchase price; or (iii) on such other terms and conditions as may be acceptable to the Committee (including, without limitation, with the consent of the Committee, having the Company withhold shares of Common Stock issuable upon exercise of the Stock Option, or by payment in full or in part in the form of Common Stock owned by the Participant, based on the Fair Market Value of the Common Stock on the payment date as determined by the Committee).  No shares of Common Stock shall be issued until payment therefor, as provided herein, has been made or provided for.

 

(e)          Non-Transferability of Options.  No Stock Option shall be Transferable by the Participant other than by will or by the laws of descent and distribution, and all Stock Options shall be exercisable, during the Participant’s lifetime, only by the Participant.  Notwithstanding the foregoing, the Committee may determine, in its sole discretion, at the time of grant or thereafter that a Non-Qualified Stock Option that is otherwise not Transferable pursuant to this Section is Transferable to a Family Member in whole or in part and in such circumstances, and under such conditions, as specified by the Committee, provided that “for-value” Transfers shall not be permitted.  A Non-Qualified Stock Option that is Transferred to a Family Member pursuant to the preceding sentence (i) may not be subsequently Transferred other than by will or by the laws of descent and distribution and (ii) remains subject to the terms of the Plan and the applicable Award Agreement.  Any shares of Common Stock acquired upon the exercise of a Non-Qualified Stock Option by a permissible transferee of a Non-Qualified Stock Option or a permissible transferee pursuant to a Transfer after the exercise of the Non-Qualified Stock Option shall be subject to the terms of the Plan and the applicable Award Agreement.

 

A-12


 

(f)           Termination by Death or Disability.  Unless otherwise determined by the Committee at the time of grant, or if no rights of the Participant are reduced, thereafter, if a Participant’s Termination is by reason of death or Disability, all Stock Options that are held by such Participant that are vested and exercisable at the time of the Participant’s Termination may be exercised by the Participant (or in the case of the Participant’s death, by the legal representative of the Participant’s estate) at any time within a period of ninety (90) days from the date of such Termination, but in no event beyond the expiration of the stated term of such Stock Options.

 

(g)          Involuntary Termination Without Cause.  Unless otherwise determined by the Committee at the time of grant, or if no rights of the Participant are reduced, thereafter, if a Participant’s Termination is by involuntary termination by the Company without Cause, all Stock Options that are held by such Participant that are vested and exercisable at the time of the Participant’s Termination may be exercised by the Participant at any time within a period of ninety (90) days from the date of such Termination, but in no event beyond the expiration of the stated term of such Stock Options.

 

(h)         Voluntary Resignation.  Unless otherwise determined by the Committee at the time of grant, or if no rights of the Participant are reduced, thereafter, if a Participant’s Termination is voluntary (other than a voluntary termination described in Section 6.4(i)(y) hereof), all Stock Options that are held by such Participant that are vested and exercisable at the time of the Participant’s Termination may be exercised by the Participant at any time within a period of ninety (90) days from the date of such Termination, but in no event beyond the expiration of the stated term of such Stock Options.

 

(i)             Termination for Cause.  Unless otherwise determined by the Committee at the time of grant, or if no rights of the Participant are reduced, thereafter, if a Participant’s Termination (x) is for Cause or (y) is a voluntary Termination (as provided in Section 6.4(h)) after the occurrence of an event that would be grounds for a Termination for Cause, all Stock Options, whether vested or not vested, that are held by such Participant shall thereupon terminate and expire as of the date of such Termination.

 

(j)            Unvested Stock Options.  Unless otherwise determined by the Committee at the time of grant, or if no rights of the Participant are reduced, thereafter, Stock Options that are not vested as of the date of a Participant’s Termination for any reason shall terminate and expire as of the date of such Termination.

 

(k)         Incentive Stock Option Limitations.  To the extent that the aggregate Fair Market Value (determined as of the time of grant) of the Common Stock with respect to which Incentive Stock Options are exercisable for the first time by an Eligible Employee during any calendar year under the Plan and/or any other stock option plan of the Company, any Subsidiary or any Parent exceeds $100,000, such Options shall be treated as Non-Qualified Stock Options.  In addition, if an Eligible Employee does not remain employed by the Company, any Subsidiary or any Parent at all times from the time an Incentive Stock Option is granted until three months prior to the date of exercise thereof (or such other period as required by applicable law), such Stock Option shall be treated as a Non-Qualified Stock Option.  Should any provision of the Plan not be necessary in order for the Stock Options to qualify as Incentive Stock Options, or should any

 

A-13


 

additional provisions be required, the Committee may amend the Plan accordingly, without the necessity of obtaining the approval of the stockholders of the Company.

 

(l)             Form, Modification, Extension and Renewal of Stock Options.  Subject to the terms and conditions and within the limitations of the Plan, Stock Options shall be evidenced by such form of agreement or grant as is approved by the Committee, and the Committee may (i) modify, extend or renew outstanding Stock Options granted under the Plan (provided that the rights of a Participant are not reduced without such Participant’s consent and provided further that such action does not subject the Stock Options to Section 409A of the Code without the consent of the Participant), and (ii) accept the surrender of outstanding Stock Options (to the extent not theretofore exercised) and authorize the granting of new Stock Options in substitution therefor (to the extent not theretofore exercised).  Notwithstanding the foregoing, an outstanding Option may not be modified to reduce the exercise price thereof nor may a new Option at a lower price be substituted for a surrendered Option (other than adjustments or substitutions in accordance with Section 4.2), unless such action is approved by the stockholders of the Company.  Moreover, no payment in cash for an Option that has an exercise price less than the Fair Market Value shall be permitted.

 

(m)     Deferred Delivery of Common Stock.  The Committee may in its discretion permit Participants to defer delivery of Common Stock acquired pursuant to a Participant’s exercise of an Option in accordance with the terms and conditions established by the Committee in the applicable Award Agreement, which shall be intended to comply with the requirements of Section 409A of the Code.

 

(n)         Early Exercise.  The Committee may provide that a Stock Option include a provision whereby the Participant may elect at any time before the Participant’s Termination to exercise the Stock Option as to any part or all of the shares of Common Stock subject to the Stock Option prior to the full vesting of the Stock Option and such shares shall be subject to the provisions of Article VIII and be treated as Restricted Stock.  Unvested shares of Common Stock so purchased may be subject to a repurchase option in favor of the Company or to any other restriction the Committee determines to be appropriate.

 

(o)         Other Terms and Conditions.  The Committee may include a provision in an Award Agreement providing for the automatic exercise of a Non-Qualified Stock Option on a cashless basis on the last day of the term of such Option if the Participant has failed to exercise the Non-Qualified Stock Option as of such date, with respect to which the Fair Market Value of the shares of Common Stock underlying the Non-Qualified Stock Option exceeds the exercise price of such Non-Qualified Stock Option on the date of expiration of such Option, subject to Section 14.4.  Stock Options may contain such other provisions, which shall not be inconsistent with any of the terms of the Plan, as the Committee shall deem appropriate.

 

ARTICLE VII
STOCK APPRECIATION RIGHTS

 

7.1                               Tandem Stock Appreciation Rights.  Stock Appreciation Rights may be granted in conjunction with all or part of any Stock Option (a “Reference Stock Option”) granted under the Plan (“Tandem Stock Appreciation Rights”).  In the case of a Non-Qualified Stock Option,

 

A-14


 

such rights may be granted either at or after the time of the grant of such Reference Stock Option.  In the case of an Incentive Stock Option, such rights may be granted only at the time of the grant of such Reference Stock Option.

 

7.2                               Terms and Conditions of Tandem Stock Appreciation Rights.  Tandem Stock Appreciation Rights granted hereunder shall be subject to such terms and conditions, not inconsistent with the provisions of the Plan, as shall be determined from time to time by the Committee, and the following:

 

(a)         Exercise Price.  The exercise price per share of Common Stock subject to a Tandem Stock Appreciation Right shall be determined by the Committee at the time of grant, provided that the per share exercise price of a Tandem Stock Appreciation Right shall not be less than 100% of the Fair Market Value of the Common Stock at the time of grant.

 

(b)         Term.  A Tandem Stock Appreciation Right or applicable portion thereof granted with respect to a Reference Stock Option shall terminate and no longer be exercisable upon the termination or exercise of the Reference Stock Option, except that, unless otherwise determined by the Committee, in its sole discretion, at the time of grant, a Tandem Stock Appreciation Right granted with respect to less than the full number of shares covered by the Reference Stock Option shall not be reduced until, and then only to the extent that the exercise or termination of the Reference Stock Option causes, the number of shares covered by the Tandem Stock Appreciation Right to exceed the number of shares remaining available and unexercised under the Reference Stock Option.

 

(c)          Exercisability.  Tandem Stock Appreciation Rights shall be exercisable only at such time or times and to the extent that the Reference Stock Options to which they relate shall be exercisable in accordance with the provisions of Article VI, and shall be subject to the provisions of Section 6.4(c).

 

(d)         Method of Exercise.  A Tandem Stock Appreciation Right may be exercised by the Participant by surrendering the applicable portion of the Reference Stock Option.  Upon such exercise and surrender, the Participant shall be entitled to receive an amount determined in the manner prescribed in this Section 7.2.  Stock Options which have been so surrendered, in whole or in part, shall no longer be exercisable to the extent that the related Tandem Stock Appreciation Rights have been exercised.

 

(e)          Payment.  Upon the exercise of a Tandem Stock Appreciation Right, a Participant shall be entitled to receive up to, but no more than, an amount in cash and/or Common Stock (as chosen by the Committee in its sole discretion) equal in value to the excess of the Fair Market Value of one share of Common Stock over the Option exercise price per share specified in the Reference Stock Option agreement multiplied by the number of shares of Common Stock in respect of which the Tandem Stock Appreciation Right shall have been exercised, with the Committee having the right to determine the form of payment.

 

(f)           Deemed Exercise of Reference Stock Option.  Upon the exercise of a Tandem Stock Appreciation Right, the Reference Stock Option or part thereof to which such Stock Appreciation Right is related shall be deemed to have been exercised for the purpose of the

 

A-15


 

limitation set forth in Article IV of the Plan on the number of shares of Common Stock to be issued under the Plan.

 

(g)          Non-Transferability. Tandem Stock Appreciation Rights shall be Transferable only when and to the extent that the underlying Stock Option would be Transferable under Section 6.4(e) of the Plan.

 

7.3                               Non-Tandem Stock Appreciation Rights.  Non-Tandem Stock Appreciation Rights may also be granted without reference to any Stock Options granted under the Plan.

 

7.4                               Terms and Conditions of Non-Tandem Stock Appreciation Rights.  Non-Tandem Stock Appreciation Rights granted hereunder shall be subject to such terms and conditions, not inconsistent with the provisions of the Plan, as shall be determined from time to time by the Committee, and the following:

 

(a)         Exercise Price.  The exercise price per share of Common Stock subject to a Non-Tandem Stock Appreciation Right shall be determined by the Committee at the time of grant, provided that the per share exercise price of a Non-Tandem Stock Appreciation Right shall not be less than 100% of the Fair Market Value of the Common Stock at the time of grant.

 

(b)         Term.  The term of each Non-Tandem Stock Appreciation Right shall be fixed by the Committee, but shall not be greater than 10 years after the date the right is granted.

 

(c)          Exercisability.  Unless otherwise provided by the Committee in accordance with the provisions of this Section 7.4, Non-Tandem Stock Appreciation Rights granted under the Plan shall be exercisable at such time or times and subject to such terms and conditions as shall be determined by the Committee at the time of grant.  If the Committee provides, in its discretion, that any such right is exercisable subject to certain limitations (including, without limitation, that it is exercisable only in installments or within certain time periods), the Committee may waive such limitations on the exercisability at any time at or after grant in whole or in part (including, without limitation, waiver of the installment exercise provisions or acceleration of the time at which such right may be exercised), based on such factors, if any, as the Committee shall determine, in its sole discretion.

 

(d)         Method of Exercise.  Subject to whatever installment exercise and waiting period provisions apply under Section 7.4(c), Non-Tandem Stock Appreciation Rights may be exercised in whole or in part at any time in accordance with the applicable Award Agreement, by giving written notice of exercise to the Company specifying the number of Non-Tandem Stock Appreciation Rights to be exercised.

 

(e)          Payment.  Upon the exercise of a Non-Tandem Stock Appreciation Right a Participant shall be entitled to receive, for each right exercised, up to, but no more than, an amount in cash and/or Common Stock (as chosen by the Committee in its sole discretion) equal in value to the excess of the Fair Market Value of one share of Common Stock on the date that the right is exercised over the Fair Market Value of one share of Common Stock on the date that the right was awarded to the Participant.

 

A-16


 

(f)           Termination.  Unless otherwise determined by the Committee at grant or, if no rights of the Participant are reduced, thereafter, subject to the provisions of the applicable Award Agreement and the Plan, upon a Participant’s Termination for any reason, Non-Tandem Stock Appreciation Rights will remain exercisable following a Participant’s Termination on the same basis as Stock Options would be exercisable following a Participant’s Termination in accordance with the provisions of Sections 6.4(f) through 6.4(j).

 

(g)          Non-Transferability.  No Non-Tandem Stock Appreciation Rights shall be Transferable by the Participant other than by will or by the laws of descent and distribution, and all such rights shall be exercisable, during the Participant’s lifetime, only by the Participant.

 

7.5                               Limited Stock Appreciation Rights.  The Committee may, in its sole discretion, grant Tandem and Non-Tandem Stock Appreciation Rights either as a general Stock Appreciation Right or as a Limited Stock Appreciation Right.  Limited Stock Appreciation Rights may be exercised only upon the occurrence of a Change in Control or such other event as the Committee may, in its sole discretion, designate at the time of grant or thereafter.  Upon the exercise of Limited Stock Appreciation Rights, except as otherwise provided in an Award Agreement, the Participant shall receive in cash and/or Common Stock, as determined by the Committee, an amount equal to the amount (i) set forth in Section 7.2(e) with respect to Tandem Stock Appreciation Rights, or (ii) set forth in Section 7.4(e) with respect to Non-Tandem Stock Appreciation Rights.

 

7.6                               Other Terms and Conditions.  The Committee may include a provision in an Award Agreement providing for the automatic exercise of a Stock Appreciation Right on a cashless basis on the last day of the term of such Stock Appreciation Right if the Participant has failed to exercise the Stock Appreciation Right as of such date, with respect to which the Fair Market Value of the shares of Common Stock underlying the Stock Appreciation Right exceeds the exercise price of such Stock Appreciation Right on the date of expiration of such Stock Appreciation Right, subject to Section 14.4.  Stock Appreciation Rights may contain such other provisions, which shall not be inconsistent with any of the terms of the Plan, as the Committee shall deem appropriate.

 

ARTICLE VIII
RESTRICTED STOCK

 

8.1                               Awards of Restricted Stock.  Shares of Restricted Stock may be issued either alone or in addition to other Awards granted under the Plan.  The Committee shall determine the Eligible Individuals, to whom, and the time or times at which, grants of Restricted Stock shall be made, the number of shares to be awarded, the price (if any) to be paid by the Participant (subject to Section 8.2), the time or times within which such Awards may be subject to forfeiture, the vesting schedule and rights to acceleration thereof, and all other terms and conditions of the Awards.

 

The Committee may condition the grant or vesting of Restricted Stock upon the attainment of specified performance targets (including, the performance goals) or such other factor as the Committee may determine in its sole discretion.

 

A-17


 

8.2                               Awards and Certificates.  Eligible Individuals selected to receive Restricted Stock shall not have any right with respect to such Award, unless and until such Participant has delivered a fully executed copy of the agreement evidencing the Award to the Company, to the extent required by the Committee, and has otherwise complied with the applicable terms and conditions of such Award.  Further, such Award shall be subject to the following conditions:

 

(a)         Purchase Price.  The purchase price of Restricted Stock shall be fixed by the Committee.  Subject to Section 4.3, the purchase price for shares of Restricted Stock may be zero to the extent permitted by applicable law, and, to the extent not so permitted, such purchase price may not be less than par value.

 

(b)         Acceptance.  Awards of Restricted Stock must be accepted within a period of 60 days (or such shorter period as the Committee may specify at grant) after the grant date, by executing a Restricted Stock agreement and by paying whatever price (if any) the Committee has designated thereunder.

 

(c)          Legend.  Each Participant receiving Restricted Stock shall be issued a stock certificate in respect of such shares of Restricted Stock, unless the Committee elects to use another system, such as book entries by the transfer agent, as evidencing ownership of shares of Restricted Stock.  Such certificate shall be registered in the name of such Participant, and shall, in addition to such legends required by applicable securities laws, bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Award, substantially in the following form:

 

“The anticipation, alienation, attachment, sale, transfer, assignment, pledge, encumbrance or charge of the shares of stock represented hereby are subject to the terms and conditions (including forfeiture) of the Agiliti, Inc. (the “Company”) 2018 Omnibus Incentive Plan (the “Plan”) and an Agreement entered into between the registered owner and the Company dated           .  Copies of such Plan and Agreement are on file at the principal office of the Company.”

 

(d)         Custody.  If stock certificates are issued in respect of shares of Restricted Stock, the Committee may require that any stock certificates evidencing such shares be held in custody by the Company until the restrictions thereon shall have lapsed, and that, as a condition of any grant of Restricted Stock, the Participant shall have delivered a duly signed stock power or other instruments of assignment (including a power of attorney), each endorsed in blank with a guarantee of signature if deemed necessary or appropriate by the Company, which would permit transfer to the Company of all or a portion of the shares subject to the Restricted Stock Award in the event that such Award is forfeited in whole or part.

 

8.3                               Restrictions and Conditions.  The shares of Restricted Stock awarded pursuant to the Plan, as well as any dividend equivalent rights awarded in respect to shares of Restricted Stock, shall be subject to the following restrictions and conditions:

 

(a)         Restriction Period.  The Participant shall not be permitted to Transfer shares of Restricted Stock awarded under the Plan during the period or periods set by the Committee (the “Restriction Period”) commencing on the date of such Award, as set forth in the Restricted Stock

 

A-18


 

Award Agreement and such agreement shall set forth a vesting schedule and any event that would accelerate vesting of the shares of Restricted Stock.  Within these limits, based on service, attainment of performance goals and/or such other factors or criteria as the Committee may determine in its sole discretion, the Committee may condition the grant or provide for the lapse of such restrictions in installments in whole or in part, or may accelerate the vesting of all or any part of any Restricted Stock Award and/or waive the deferral limitations for all or any part of any Restricted Stock Award.

 

(b)         If the grant of shares of Restricted Stock or the lapse of restrictions is based on the attainment of performance goals, the Committee shall establish the objective performance goals and the applicable vesting percentage of the Restricted Stock applicable to each Participant or class of Participants in writing prior to the beginning of the applicable fiscal year or at such later date as otherwise determined by the Committee and while the outcome of the performance goals are substantially uncertain.  Such performance goals may incorporate provisions for disregarding (or adjusting for) changes in accounting methods, corporate transactions (including, without limitation, dispositions and acquisitions) and other similar type events or circumstances.

 

(c)          Rights as a Stockholder.  Except as provided in Section 8.3(a) and this Section 8.3(c) or as otherwise determined by the Committee in an Award Agreement, the Participant shall have, with respect to the shares of Restricted Stock, all of the rights of a holder of shares of Common Stock of the Company, including, without limitation, the right to receive dividends, the right to vote such shares and, subject to and conditioned upon the full vesting of shares of Restricted Stock, the right to tender such shares.  The Committee may, in its sole discretion, determine at the time of grant that the payment of dividends shall be deferred until, and conditioned upon, the expiration of the applicable Restriction Period.

 

(d)         Termination.  Unless otherwise determined by the Committee at grant or, if no rights of the Participant are reduced, thereafter, subject to the applicable provisions of the Award Agreement and the Plan, upon a Participant’s Termination for any reason during the relevant Restriction Period, all Restricted Stock still subject to restriction will be forfeited in accordance with the terms and conditions established by the Committee at grant or thereafter.

 

(e)          Lapse of Restrictions.  If and when the Restriction Period expires without a prior forfeiture of the Restricted Stock, the certificates for such shares shall be delivered to the Participant.  All legends shall be removed from said certificates at the time of delivery to the Participant, except as otherwise required by applicable law or other limitations imposed by the Committee.

 

ARTICLE IX
PERFORMANCE AWARDS

 

9.1                               Performance Awards.  The Committee may grant a Performance Award to a Participant payable upon the attainment of specific performance goals.  If the Performance Award is payable in shares of Restricted Stock, such shares shall be transferable to the Participant only upon attainment of the relevant performance goal in accordance with Article VIII.  If the Performance Award is payable in cash, it may be paid upon the attainment of the relevant performance goals either in cash or in shares of Restricted Stock (based on the then current Fair

 

A-19


 

Market Value of such shares), as determined by the Committee, in its sole and absolute discretion.  Each Performance Award shall be evidenced by an Award Agreement in such form that is not inconsistent with the Plan and that the Committee may from time to time approve.

 

9.2                               Terms and Conditions.  Performance Awards awarded pursuant to this Article IX shall be subject to the following terms and conditions:

 

(a)         Earning of Performance Award.  At the expiration of the applicable Performance Period, the Committee shall determine the extent to which the performance goals established pursuant to Section 9.2(c) are achieved and the percentage of each Performance Award that has been earned.

 

(b)         Non-Transferability.  Subject to the applicable provisions of the Award Agreement and the Plan, Performance Awards may not be Transferred during the Performance Period.

 

(c)          Performance Goals; Dividends.  Unless otherwise determined by the Committee at the time of grant, amounts equal to dividends declared during the Performance Period with respect to the number of shares of Common Stock covered by a Performance Award will not be paid to the Participant.  Any dividend equivalents may be accrued but are subject to the same restrictions of the underlying Performance Award.

 

(d)         Payment.  Following the Committee’s determination in accordance with Section 9.2(a), the Company shall settle Performance Awards, in such form (including, without limitation, in shares of Common Stock or in cash) as determined by the Committee, in an amount equal to such Participant’s earned Performance Awards.

 

(e)          Termination.  Subject to the applicable provisions of the Award Agreement and the Plan, upon a Participant’s Termination for any reason during the Performance Period for a given Performance Award, the Performance Award in question will vest or be forfeited in accordance with the terms and conditions established by the Committee at grant.

 

(f)           Accelerated Vesting.  Based on service, performance and/or such other factors or criteria, if any, as the Committee may determine, the Committee may, at or after grant, accelerate the vesting of all or any part of any Performance Award.

 

ARTICLE X
OTHER STOCK-BASED AND CASH-BASED AWARDS

 

10.1                        Other Stock-Based Awards.  The Committee is authorized to grant to Eligible Individuals Other Stock-Based Awards, including restricted stock units, that are payable in, valued in whole or in part by reference to, or otherwise based on or related to shares of Common Stock, including but not limited to, shares of Common Stock awarded purely as a bonus and not subject to restrictions or conditions, shares of Common Stock in payment of the amounts due under an incentive or performance plan sponsored or maintained by the Company or an Affiliate, stock equivalent units, restricted stock units, and Awards valued by reference to book value of shares of Common Stock.  Other Stock-Based Awards may be granted either alone or in addition to or in tandem with other Awards granted under the Plan.

 

A-20


 

Subject to the provisions of the Plan, the Committee shall have authority to determine the Eligible Individuals, to whom, and the time or times at which, such Awards shall be made, the number of shares of Common Stock to be awarded pursuant to such Awards, and all other conditions of the Awards.  The Committee may also provide for the grant of Common Stock under such Awards upon the completion of a specified Performance Period.

 

The Committee may condition the grant or vesting of Other Stock-Based Awards upon the attainment of specified performance goals as the Committee may determine, in its sole discretion.

 

10.2                        Terms and Conditions.  Other Stock-Based Awards made pursuant to this Article X shall be subject to the following terms and conditions:

 

(a)         Non-Transferability.  Subject to the applicable provisions of the Award Agreement and the Plan, shares of Common Stock subject to Awards made under this Article X may not be Transferred prior to the date on which the shares are issued, or, if later, the date on which any applicable restriction, performance or deferral period lapses.

 

(b)         Dividends.  Unless otherwise determined by the Committee at the time of Award, subject to the provisions of the Award Agreement and the Plan, the recipient of an Award under this Article X shall not be entitled to receive, currently or on a deferred basis, dividends or dividend equivalents in respect of the number of shares of Common Stock covered by the Award.

 

(c)          Vesting.  Any Award under this Article X and any Common Stock covered by any such Award shall vest or be forfeited to the extent so provided in the Award Agreement, as determined by the Committee, in its sole discretion.

 

(d)         Price.  Common Stock issued on a bonus basis under this Article X may be issued for no cash consideration.  Common Stock purchased pursuant to a purchase right awarded under this Article X shall be priced, as determined by the Committee in its sole discretion.

 

10.3                        Other Cash-Based Awards.  The Committee may from time to time grant Other Cash-Based Awards to Eligible Individuals in such amounts, on such terms and conditions, and for such consideration, including no consideration or such minimum consideration as may be required by applicable law, as it shall determine in its sole discretion.  Other Cash-Based Awards may be granted subject to the satisfaction of vesting conditions or may be awarded purely as a bonus and not subject to restrictions or conditions, and if subject to vesting conditions, the Committee may accelerate the vesting of such Awards at any time in its sole discretion.  The grant of an Other Cash-Based Award shall not require a segregation of any of the Company’s assets for satisfaction of the Company’s payment obligation thereunder.

 

ARTICLE XI
CHANGE IN CONTROL PROVISIONS

 

11.1                        Benefits.  In the event of a Change in Control of the Company (as defined below), and except as otherwise provided by the Committee in an Award Agreement, a Participant’s unvested Awards shall not vest automatically and a Participant’s Awards shall be treated in accordance with one or more of the following methods as determined by the Committee:

 

A-21


 

(a)         Awards, whether or not then vested, shall be continued, assumed, or have new rights substituted therefor, as determined by the Committee in a manner consistent with the requirements of Section 409A of the Code, and restrictions to which shares of Restricted Stock or any other Award granted prior to the Change in Control are subject shall not lapse upon a Change in Control and the Restricted Stock or other Award shall, where appropriate in the sole discretion of the Committee, receive the same distribution as other Common Stock on such terms as determined by the Committee; provided that the Committee may decide to award additional Restricted Stock or other Awards in lieu of any cash distribution.  Notwithstanding anything to the contrary herein, for purposes of Incentive Stock Options, any assumed or substituted Stock Option shall comply with the requirements of Treasury Regulation Section 1.424-1 (and any amendment thereto).  If the Awards are not continued or assumed, all of the unvested Awards (but only those that are not assumed, substituted, and/or continued) will vest.

 

(b)         The Committee, in its sole discretion, may provide for the purchase of any Awards by the Company or an Affiliate for an amount of cash equal to the excess (if any) of the Change in Control Price (as defined below) of the shares of Common Stock covered by such Awards, over the aggregate exercise price of such Awards.  For purposes hereof, “Change in Control Price” shall mean, in the sole discretion of the Committee, the highest price per share of Common Stock paid in any transaction related to a Change in Control of the Company.

 

(c)          The Committee may, in its sole discretion, terminate all outstanding and unexercised Stock Options, Stock Appreciation Rights, or any Other Stock-Based Award that provides for a Participant elected exercise, effective as of the date of the Change in Control, by delivering notice of termination to each Participant at least twenty (20) days prior to the date of consummation of the Change in Control, in which case during the period from the date on which such notice of termination is delivered to the consummation of the Change in Control, each such Participant shall have the right to exercise in full all of such Participant’s Awards that are then outstanding (without regard to any limitations on exercisability otherwise contained in the Award Agreements), but any such exercise shall be contingent on the occurrence of the Change in Control, and, provided that, if the Change in Control does not take place within a specified period after giving such notice for any reason whatsoever, the notice and exercise pursuant thereto shall be null and void.

 

(d)         Notwithstanding any other provision herein to the contrary, the Committee may, in its sole discretion, provide for accelerated vesting or lapse of restrictions, of an Award at any time.

 

(e)          Notwithstanding the foregoing, any escrow, holdback, earnout or similar provisions in the definitive documents relating to such Change in Control may apply to any payment to Participants to the same extent and in the same manner as such provisions apply to the holders of Common Stock. In addition, Participants will be required to execute any definitive transaction documents in connection with any Change in Control at the request of the Company or its Subsidiaries or Affiliates, or any of their collective successors.

 

11.2                        Change in Control.  Unless otherwise determined by the Committee in the applicable Award Agreement or other written agreement with a Participant approved by the

 

A-22


 

Committee, a “Change in Control” shall be deemed to occur if, in a single transaction or in a series of related transactions, one of any of the following events occur:

 

(a)         any Person has “beneficial ownership” (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of more than 50% of either (A) the then-outstanding shares of Stock (“Outstanding Company Common Stock”) or (B) the combined voting power of the then-outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”);

 

(b)         individuals who, as of the Effective Date, constitute the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for election by the Company’s shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board;

 

(c)          consummation of a reorganization, merger, statutory share exchange or consolidation or similar corporate transaction involving the Company or any entity controlled by the Company, or a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or stock of another entity by the Company or any entity controlled by the Company (each, a “Business Combination”), in each case, unless, following such Business Combination, (A) all or substantially all of the individuals and entities that were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation or entity resulting from such Business Combination (including, without limitation, a corporation or entity that, as a result of such transaction, owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person beneficially owns, directly or indirectly, more than 50% of, respectively, the then-outstanding shares of common stock of the corporation or equity of the entity resulting from such Business Combination or the combined voting power of the then-outstanding voting securities of such corporation or entity, and (C) at least a majority of the members of the board of directors or comparable governing body of the entity resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination; or

 

(d)         immediately prior to the complete liquidation or dissolution of the Company.

 

Notwithstanding the foregoing, with respect to any Award that is characterized as “nonqualified deferred compensation” within the meaning of Section 409A of the Code, an event shall not be

 

A-23


 

considered to be a Change in Control under the Plan for purposes of payment of such Award unless such event is also a “change in ownership,” a “change in effective control” or a “change in the ownership of a substantial portion of the assets” of the Company within the meaning of Section 409A of the Code.

 

ARTICLE XII
TERMINATION OR AMENDMENT OF PLAN

 

Notwithstanding any other provision of the Plan, the Board may at any time, and from time to time, amend, in whole or in part, any or all of the provisions of the Plan (including any amendment deemed necessary to ensure that the Company may comply with any regulatory requirement referred to in Article XIV or Section 409A of the Code), or suspend or terminate it entirely, retroactively or otherwise; provided, however, that, unless otherwise required by law or specifically provided herein, the rights of a Participant with respect to Awards granted prior to such amendment, suspension or termination, may not be impaired without the consent of such Participant and, provided further, that without the approval of the holders of the Company’s Common Stock entitled to vote in accordance with applicable law, no amendment may be made that would (i) increase the aggregate number of shares of Common Stock that may be issued under the Plan (except by operation of Section 4.2); (ii)  change the classification of individuals eligible to receive Awards under the Plan; (iii) decrease the minimum option price of any Stock Option or Stock Appreciation Right; (iv) extend the maximum option period under Section 6.4; (v) award any Stock Option or Stock Appreciation Right in replacement of a canceled Stock Option or Stock Appreciation Right with a higher exercise price than the replacement award; or (vi) require stockholder approval in order for the Plan to continue to comply with the applicable provisions of Section 422 of the Code.  In no event may the Plan be amended without the approval of the stockholders of the Company in accordance with the applicable laws of the State of Delaware to increase the aggregate number of shares of Common Stock that may be issued under the Plan, decrease the minimum exercise price of any Award, or to make any other amendment that would require stockholder approval under Financial Industry Regulatory Authority (FINRA) rules and regulations or the rules of any exchange or system on which the Company’s securities are listed or traded at the request of the Company.  Notwithstanding anything herein to the contrary, the Board may amend the Plan or any Award Agreement at any time without a Participant’s consent to comply with applicable law including Section 409A of the Code in a manner that does not impair the rights of any holder of any Award or if necessary, impairs the rights of any holder of any Award to the minimum extent necessary.  The Committee may amend the terms of any Award theretofore granted, prospectively or retroactively, but, no such amendment or other action by the Committee shall impair the rights of any holder without the holder’s consent.

 

ARTICLE XIII
UNFUNDED STATUS OF PLAN

 

The Plan is intended to constitute an “unfunded” plan for incentive and deferred compensation.  With respect to any payment as to which a Participant has a fixed and vested interest but which are not yet made to a Participant by the Company, nothing contained herein

 

A-24


 

shall give any such Participant any right that is greater than those of a general unsecured creditor of the Company.

 

ARTICLE XIV
GENERAL PROVISIONS

 

14.1                        Legend.  The Committee may require each person receiving shares of Common Stock pursuant to a Stock Option or other Award under the Plan to represent to and agree with the Company in writing that the Participant is acquiring the shares without a view to distribution thereof.  In addition to any legend required by the Plan, the certificates for such shares may include any legend that the Committee deems appropriate to reflect any restrictions on Transfer.  All certificates for shares of Common Stock delivered under the Plan shall be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations and other requirements of the Securities and Exchange Commission, any stock exchange upon which the Common Stock is then listed or any national securities exchange system upon whose system the Common Stock is then quoted, any applicable federal or state securities law, and any applicable corporate law, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.

 

14.2                        Other Plans.  Nothing contained in the Plan shall prevent the Board from adopting other or additional compensation arrangements, subject to stockholder approval if such approval is required, and such arrangements may be either generally applicable or applicable only in specific cases.

 

14.3                        No Right to Employment/Directorship/Consultancy.  Neither the Plan nor the grant of any Option or other Award hereunder shall give any Participant or other employee, Consultant or Non-Employee Director any right with respect to continuance of employment, consultancy or directorship by the Company or any Affiliate, nor shall there be a limitation in any way on the right of the Company or any Affiliate by which an employee is employed or a Consultant or Non-Employee Director is retained to terminate such employment, consultancy or directorship at any time.

 

14.4                        Withholding of Taxes.  The Company shall have the right to deduct from any payment to be made pursuant to the Plan, or to otherwise require, prior to the issuance or delivery of shares of Common Stock or the payment of any cash hereunder, payment by the Participant of, any federal, state or local taxes required by law to be withheld.  Upon the vesting of Restricted Stock (or other Award that is taxable upon vesting), or upon making an election under Section 83(b) of the Code, a Participant shall pay all required withholding to the Company.  Any minimum statutorily required withholding obligation with regard to any Participant may be satisfied, unless otherwise otherwise prohibited by the Committee, by reducing the number of shares of Common Stock otherwise deliverable or by delivering shares of Common Stock already owned, provided, however, that, at the Participant’s discretion, the number of shares of Common Stock otherwise deliverable to the Participant may be further reduced in an amount up to the maximum individual tax rate in the Participant’s particular jurisdiction, and only if the Company has a statutory obligation to withhold taxes on the Participant’s behalf, in such case only if such reduction would not result in adverse financial accounting treatment, as determined by the Company (and in particular in connection with the effectiveness of the amendments to FASB

 

A-25


 

Accounting Standards Codification Topic 718, Compensation — Stock Compensation, as amended by FASB Accounting Standards Update No. 2016-09, Improvements to Employee Share-Based Payment Accounting).  Any fraction of a share of Common Stock required to satisfy such tax obligations shall be disregarded and the amount due shall be paid instead in cash by the Participant.

 

14.5                        No Assignment of Benefits.  No Award or other benefit payable under the Plan shall, except as otherwise specifically provided by law or permitted by the Committee, be Transferable in any manner, and any attempt to Transfer any such benefit shall be void, and any such benefit shall not in any manner be liable for or subject to the debts, contracts, liabilities, engagements or torts of any person who shall be entitled to such benefit, nor shall it be subject to attachment or legal process for or against such person.

 

14.6                        Listing and Other Conditions.

 

(a)         Unless otherwise determined by the Committee, as long as the Common Stock is listed on a national securities exchange or system sponsored by a national securities association, the issuance of shares of Common Stock pursuant to an Award shall be conditioned upon such shares being listed on such exchange or system.  The Company shall have no obligation to issue such shares unless and until such shares are so listed, and the right to exercise any Option or other Award with respect to such shares shall be suspended until such listing has been effected.

 

(b)         If at any time counsel to the Company shall be of the opinion that any sale or delivery of shares of Common Stock pursuant to an Option or other Award is or may in the circumstances be unlawful or result in the imposition of excise taxes on the Company under the statutes, rules or regulations of any applicable jurisdiction, the Company shall have no obligation to make such sale or delivery, or to make any application or to effect or to maintain any qualification or registration under the Securities Act or otherwise, with respect to shares of Common Stock or Awards, and the right to exercise any Option or other Award shall be suspended until, in the opinion of said counsel, such sale or delivery shall be lawful or will not result in the imposition of excise taxes on the Company.

 

(c)          Upon termination of any period of suspension under this Section 14.6, any Award affected by such suspension which shall not then have expired or terminated shall be reinstated as to all shares available before such suspension and as to shares which would otherwise have become available during the period of such suspension, but no such suspension shall extend the term of any Award.

 

(d)         A Participant shall be required to supply the Company with certificates, representations and information that the Company requests and otherwise cooperate with the Company in obtaining any listing, registration, qualification, exemption, consent or approval the Company deems necessary or appropriate.

 

14.7                        Stockholders Agreement and Other Requirements.  Notwithstanding anything herein to the contrary, as a condition to the receipt of shares of Common Stock pursuant to an Award under the Plan, to the extent required by the Committee, the Participant shall execute and deliver a stockholder’s agreement or such other documentation that shall set forth certain

 

A-26


 

restrictions on transferability of the shares of Common Stock acquired upon exercise or purchase, and such other terms as the Board or Committee shall from time to time establish.  Such stockholder’s agreement or other documentation shall apply to the Common Stock acquired under the Plan and covered by such stockholder’s agreement or other documentation.  The Company may require, as a condition of exercise, the Participant to become a party to any other existing stockholder agreement (or other agreement).

 

14.8                        Governing Law.  The Plan and actions taken in connection herewith shall be governed and construed in accordance with the laws of the State of Delaware (regardless of the law that might otherwise govern under applicable Delaware principles of conflict of laws).

 

14.9                        Jurisdiction; Waiver of Jury Trial.  Any suit, action or proceeding with respect to the Plan or any Award Agreement, or any judgment entered by any court of competent jurisdiction in respect of any thereof, shall be resolved only in the courts of the State of Delaware or the United States District Court for the District of Delaware and the appellate courts having jurisdiction of appeals in such courts.  In that context, and without limiting the generality of the foregoing, the Company and each Participant shall irrevocably and unconditionally (a) submit in any proceeding relating to the Plan or any Award Agreement, or for the recognition and enforcement of any judgment in respect thereof (a “Proceeding”), to the exclusive jurisdiction of the courts of the State of Delaware, the court of the United States of America for the District of Delaware, and appellate courts having jurisdiction of appeals from any of the foregoing, and agree that all claims in respect of any such Proceeding shall be heard and determined in such Delaware State court or, to the extent permitted by law, in such federal court, (b) consent that any such Proceeding may and shall be brought in such courts and waives any objection that the Company and each Participant may now or thereafter have to the venue or jurisdiction of any such Proceeding in any such court or that such Proceeding was brought in an inconvenient court and agree not to plead or claim the same, (c) waive all right to trial by jury in any Proceeding (whether based on contract, tort or otherwise) arising out of or relating to the Plan or any Award Agreement, (d) agree that service of process in any such Proceeding may be effected by mailing a copy of such process by registered or certified mail (or any substantially similar form of mail), postage prepaid, to such party, in the case of a Participant, at the Participant’s address shown in the books and records of the Company or, in the case of the Company, at the Company’s principal offices, attention General Counsel, and (e) agree that nothing in the Plan shall affect the right to effect service of process in any other manner permitted by the laws of the State of Delaware.

 

14.10                 Construction.  Wherever any words are used in the Plan in the masculine gender they shall be construed as though they were also used in the feminine gender in all cases where they would so apply, and wherever words are used herein in the singular form they shall be construed as though they were also used in the plural form in all cases where they would so apply.

 

14.11                 Other Benefits.  No Award granted or paid out under the Plan shall be deemed compensation for purposes of computing benefits under any retirement plan of the Company or its Affiliates nor affect any benefit under any other benefit plan now or subsequently in effect under which the availability or amount of benefits is related to the level of compensation.

 

14.12                 Costs.  The Company shall bear all expenses associated with administering the Plan, including expenses of issuing Common Stock pursuant to Awards hereunder.

 

A-27


 

14.13                 No Right to Same Benefits.  The provisions of Awards need not be the same with respect to each Participant, and such Awards to individual Participants need not be the same in subsequent years.

 

14.14                 Death/Disability.  The Committee may in its discretion require the transferee of a Participant to supply it with written notice of the Participant’s death or Disability and to supply it with a copy of the will (in the case of the Participant’s death) or such other evidence as the Committee deems necessary to establish the validity of the transfer of an Award.  The Committee may also require that the agreement of the transferee to be bound by all of the terms and conditions of the Plan.

 

14.15                 Section 16(b) of the Exchange Act.  All elections and transactions under the Plan by persons subject to Section 16 of the Exchange Act involving shares of Common Stock are intended to comply with any applicable exemptive condition under Rule 16b-3.  The Committee may establish and adopt written administrative guidelines, designed to facilitate compliance with Section 16(b) of the Exchange Act, as it may deem necessary or proper for the administration and operation of the Plan and the transaction of business thereunder.

 

14.16                 Section 409A of the Code.  The Plan is intended to comply with the applicable requirements of Section 409A of the Code and shall be limited, construed and interpreted in accordance with such intent.  To the extent that any Award is subject to Section 409A of the Code, it shall be paid in a manner that will comply with Section 409A of the Code, including proposed, temporary or final regulations or any other guidance issued by the Secretary of the Treasury and the Internal Revenue Service with respect thereto.  Notwithstanding anything herein to the contrary, any provision in the Plan that is inconsistent with Section 409A of the Code shall be deemed to be amended to comply with Section 409A of the Code and to the extent such provision cannot be amended to comply therewith, such provision shall be null and void.  The Company shall have no liability to a Participant, or any other party, if an Award that is intended to be exempt from, or compliant with, Section 409A of the Code is not so exempt or compliant or for any action taken by the Committee or the Company and, in the event that any amount or benefit under the Plan becomes subject to penalties under Section 409A of the Code, responsibility for payment of such penalties shall rest solely with the affected Participants and not with the Company.  Notwithstanding any contrary provision in the Plan or Award Agreement, any payment(s) of “nonqualified deferred compensation” (within the meaning of Section 409A of the Code) that are otherwise required to be made under the Plan to a “specified employee” (as defined under Section 409A of the Code) as a result of such employee’s separation from service (other than a payment that is not subject to Section 409A of the Code) shall be delayed for the first six (6) months following such separation from service (or, if earlier, the date of death of the specified employee) and shall instead be paid (in a manner set forth in the Award Agreement) upon expiration of such delay period.

 

14.17                 Successor and Assigns.  The Plan shall be binding on all successors and permitted assigns of a Participant, including, without limitation, the estate of such Participant and the executor, administrator or trustee of such estate.

 

A-28


 

14.18                 Severability of Provisions.  If any provision of the Plan shall be held invalid or unenforceable, such invalidity or unenforceability shall not affect any other provisions hereof, and the Plan shall be construed and enforced as if such provisions had not been included.

 

14.19                 Payments to Minors, Etc.  Any benefit payable to or for the benefit of a minor, an incompetent person or other person incapable of receipt thereof shall be deemed paid when paid to such person’s guardian or to the party providing or reasonably appearing to provide for the care of such person, and such payment shall fully discharge the Committee, the Board, the Company, its Affiliates and their employees, agents and representatives with respect thereto.

 

14.20                 Special Rule Related to Securities Trading Policy.  The Company has established (or may from time to time establish) a securities trading policy (the ‘‘Policy’’) relative to disclosure and trading on inside information as described in the Policy. Under the Policy, certain Participants are or may be prohibited from trading Common Stock or other securities of the Company except during certain ‘‘window periods’’ as described in the Policy. If, under the terms of an Agreement, the last day on which a Stock Option or Stock Appreciation Right can be exercised falls on a date that is not, in the opinion of counsel to the Company, within a window period permitted by the Policy, the applicable exercise period shall automatically be extended by this Section 14.20 until the second business day of, in the opinion of counsel to the Company, a window period under the Policy, but in no event beyond the expiration date of the Stock Option or Stock Appreciation Right. The Committee shall interpret and apply the extension automatically provided by the preceding sentence to ensure when possible without extending the exercise period beyond the expiration date that in no event shall the term of any Stock Option or Stock Appreciation Right expire except during a window period.

 

14.21                 Headings and Captions.  The headings and captions herein are provided for reference and convenience only, shall not be considered part of the Plan, and shall not be employed in the construction of the Plan.

 

14.22                 Company Recoupment of Awards.  A Participant’s rights with respect to any Award hereunder shall in all events be subject to (i) any right that the Company may have under any Company recoupment policy or other agreement or arrangement with a Participant, or (ii) any right or obligation that the Company may have regarding the clawback of “incentive-based compensation” under Section 10D of the Exchange Act and any applicable rules and regulations promulgated thereunder from time to time by the U.S. Securities and Exchange Commission.

 

ARTICLE XV
EFFECTIVE DATE OF PLAN

 

The Plan shall become effective on January 4, 2019, which is the date of its adoption by the Board, subject to the approval of the Plan by the stockholders of the Company in accordance with the requirements of the laws of the State of Delaware.

 

A-29


 

ARTICLE XVI
TERM OF PLAN

 

No Award shall be granted pursuant to the Plan on or after the tenth anniversary of the earlier of the date that the Plan is adopted or the date of stockholder approval, but Awards granted prior to such tenth anniversary may extend beyond that date.

 

ARTICLE XVII
NAME OF PLAN

 

The Plan shall be known as the “Agiliti, Inc. 2018 Omnibus Incentive Plan.”

 

A-30


EX-10.2 6 a19-2105_2ex10d2.htm EX-10.2

Exhibit 10.2

 

Execution Version

 

FORM OF

INDEMNITY AGREEMENT

 

THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of [·], 2018, by and between AGILITI, INC., a Delaware corporation (the “Company”), and [·] (“Indemnitee”).

 

RECITALS

 

WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of such corporations;

 

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that, in order to attract and retain qualified individuals, the Company will maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities;

 

WHEREAS, directors, officers and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself;

 

WHEREAS, the Amended and Restated Certificate of Incorporation (the “Charter”) and Amended and Restated Bylaws (the “Bylaws”) of the Company require indemnification of the officers and directors of the Company.  Indemnitee may also be entitled to indemnification pursuant to applicable provisions of the Delaware General Corporation Law (“DGCL”).  The Charter, Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification, hold harmless, exoneration, advancement and reimbursement rights;

 

WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;

 

WHEREAS, the Board has determined that the increased difficulty in attracting and retaining qualified individuals to serve as directors and officers is detrimental to the best interests of the Company’s stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;

 

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, hold harmless, exonerate and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so protected against liabilities;

 

WHEREAS, this Agreement is a supplement to and in furtherance of the Charter and Bylaws of the Company and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder;

 

[WHEREAS, Indemnitee has certain rights to indemnification and/or insurance provided by Thomas H. Lee Partners, L.P. (“THL”) or affiliates of THL that Indemnitee and THL intend to be secondary to the primary obligation of the Company to indemnify Indemnitee as provided herein, with the Company’s acknowledgment of and agreement to the foregoing being a material condition to Indemnitee’s willingness to serve as a director or in any other capacity for the Company and its subsidiaries;](1)

 


(1)                                 Bracketed provisions apply only to THL directors.

 


 

WHEREAS, Indemnitee may not be willing to serve as an officer or director, advisor or in another capacity without adequate protection, and the Company desires Indemnitee to serve in such capacity.  Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he be so indemnified; and

 

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Indemnitee do hereby covenant and agree as follows:

 

TERMS AND CONDITIONS

 

1.                                      SERVICES TO THE COMPANY.  Indemnitee will serve or continue to serve as an officer, director, advisor, key employee or in any other capacity of the Company, as applicable, for so long as Indemnitee is duly elected, appointed or retained or until Indemnitee tenders his resignation.

 

2.                                      DEFINITIONS.  As used in this Agreement:

 

2.1.                            References to “agent” shall mean any person who is or was a director, officer or employee of the Company or a subsidiary of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, advisor, fiduciary or other official of another corporation, partnership, limited liability company, joint venture, trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of the Company.

 

2.2.                            The terms “Beneficial Owner” and “Beneficial Ownership” shall have the meanings set forth in Rule 13d-3 promulgated under the Exchange Act (as defined below) as in effect on the date hereof.

 

2.3.                            A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:

 

2.3.1.                  Acquisition of Stock by Third Party.  Any Person (as defined below) becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company’s then outstanding securities entitled to vote generally in the election of directors, unless (1) the change in the relative Beneficial Ownership of the Company’s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors, or (2) such acquisition was approved in advance by the Continuing Directors (as defined below) and such acquisition would not constitute a Change in Control under part 2.3.3 of this definition;

 

2.3.2.                  Change in Board of Directors.  Individuals who, as of the date hereof, constitute the Board, and any new director whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two thirds of the directors then still in office who were directors on the date hereof or whose election or nomination for election was previously so approved or who was otherwise nominated by THL or any of its affiliates (collectively, the “Continuing Directors”), cease for any reason to constitute at least a majority of the members of the Board;

 

2.3.3.                  Corporate Transactions.  The effective date of a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, involving the Company and one or more businesses (a “Business Combination”), in each case, unless, following such Business Combination:  (1) all or substantially all of the individuals and entities who were the Beneficial Owners of securities entitled to vote generally in the election of directors immediately prior to such Business Combination beneficially own, directly or indirectly, more than 51% of the combined voting power of the then outstanding securities of the Company entitled to vote generally in the election of directors resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more Subsidiaries) in substantially the same proportions as their ownership immediately prior to such Business Combination, of the securities entitled to vote generally in the election of directors; (2) no Person (excluding any corporation resulting from such Business Combination) becomes

 

2


 

the Beneficial Owner, directly or indirectly, of 15% or more of the combined voting power of the then outstanding securities entitled to vote generally in the election of directors of the surviving corporation except to the extent that such ownership existed prior to the Business Combination; and (3) at least a majority of the Board of Directors of the corporation resulting from such Business Combination were Continuing Directors at the time of the execution of the initial agreement, or of the action of the Board of Directors, providing for such Business Combination;

 

2.3.4.                  Liquidation.  The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement or series of agreements for the sale or disposition by the Company of all or substantially all of the Company’s assets (or, if such approval is not required, the decision by the Board to proceed with such a liquidation, sale, or disposition in one transaction or a series of related transactions); or

 

2.3.5.                  Other Events.  There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.

 

2.4.                            Corporate Status” describes the status of a person who is or was a director, officer, trustee, general partner, managing member, fiduciary, employee or agent of the Company or of any other Enterprise (as defined below) which such person is or was serving at the request of the Company.

 

2.5.                            Delaware Court” shall mean the Court of Chancery of the State of Delaware.

 

2.6.                            Disinterested Director” shall mean a director of the Company who is not and was not a party to the Proceeding (as defined below) in respect of which indemnification is sought by Indemnitee.

 

2.7.                            Enterprise” shall mean the Company and any other corporation, constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger to which the Company (or any of its wholly owned subsidiaries) is a party, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, general partner, managing member, fiduciary, employee or agent.

 

2.8.                            Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

 

2.9.                            Expenses” shall include all reasonable direct and indirect costs, fees and expenses of any type or nature whatsoever, including, without limitation, all attorneys’ fees and costs, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, fees of private investigators and professional advisors, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, fax transmission charges, secretarial services and all other disbursements, obligations or expenses in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settlement or appeal of, or otherwise participating in, a Proceeding (as defined below), including reasonable compensation for time spent by Indemnitee for which he or she is not otherwise compensated by the Company or any third party.  Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding (as defined below), including without limitation the principal, premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent.  Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.

 

2.10.                     Independent Counsel” shall mean a law firm or a member of a law firm with significant experience in matters of corporate law and neither presently is, nor in the past five years has been, retained to represent:  (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements); or (ii) any other party to the Proceeding (as defined below) giving rise to a claim for indemnification hereunder.  Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement.

 

3


 

2.11.                     References to “fines” shall include, but not be limited to, any excise tax assessed on Indemnitee with respect to any employee benefit plan; references to “serving at the request of the Company” shall include any service as a director, officer, employee, agent or fiduciary of the Company which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to an employee benefit plan, its participants or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

2.12.                     The term “Person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act as in effect on the date hereof; provided, however, that “Person” shall exclude:  (i) the Company; (ii) any Subsidiaries (as defined below) of the Company; (iii) any employment benefit plan of the Company or of a Subsidiary (as defined below) of the Company or of any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company; and (iv) any trustee or other fiduciary holding securities under an employee benefit plan of the Company or of a Subsidiary (as defined below) of the Company or of a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

 

2.13.                     The term “Proceeding” shall include any actual, threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened, pending or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil (including intentional or unintentional tort claims), criminal, administrative, or investigative or related nature, in which Indemnitee was, is, will or might be involved as a party or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action (or failure to act) taken by him or of any action (or failure to act) on his part while acting as a director or officer of the Company, or by reason of the fact that he is or was serving at the request of the Company as a director, officer, trustee, general partner, managing member, fiduciary, employee or agent of any other Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement, or advancement of expenses can be provided under this Agreement.

 

2.14.                     The term “Subsidiary,” with respect to any Person, shall mean any corporation or other entity of which a majority of the voting power of the voting equity securities or equity interest is owned, directly or indirectly, by that Person.

 

3.                                      INDEMNITY IN THIRD-PARTY PROCEEDINGS.

 

To the fullest extent permitted by applicable law, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this Section 3 if Indemnitee was, is, or is threatened to be made, a party to or a participant (as a witness or otherwise) in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor.  Pursuant to this Section 3, Indemnitee shall be indemnified, held harmless and exonerated against all Expenses, judgments, liabilities, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually incurred by Indemnitee or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding, had no reasonable cause to believe that his conduct was unlawful.

 

4.                                      INDEMNITY IN PROCEEDINGS BY OR IN THE RIGHT OF THE COMPANY.

 

To the fullest extent permitted by applicable law, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this Section 4 if Indemnitee was, is, or is threatened to be made, a party to or a participant (as a witness or otherwise) in any Proceeding by or in the right of the Company to procure a judgment in its favor.  To the fullest extent permitted by applicable law, pursuant to this Section 4, Indemnitee shall be indemnified, held harmless and exonerated against all Expenses, judgments, liabilities, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually incurred by him

 

4


 

or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company.  No indemnification, hold harmless or exoneration for Expenses, judgments, liabilities, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that any court in which the Proceeding was brought or the Delaware Court shall determine upon application that Indemnitee is entitled to indemnification, to be held harmless or to exoneration.

 

5.                                      INDEMNIFICATION FOR EXPENSES OF A PARTY WHO IS WHOLLY OR PARTLY SUCCESSFUL.

 

Notwithstanding any other provisions of this Agreement, to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall, to the fullest extent permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee against all Expenses actually incurred by Indemnitee in connection therewith.  If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall, to the fullest extent permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee against all Expenses actually incurred by Indemnitee or on Indemnitee’s behalf in connection with each successfully resolved claim, issue or matter.  If Indemnitee is not wholly successful in such Proceeding, the Company also shall, to the fullest extent permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee against all Expenses incurred in connection with a claim, issue or matter related to any claim, issue, or matter on which Indemnitee was successful.  For purposes of this Section 5 and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

 

6.                                      INDEMNIFICATION FOR EXPENSES OF A WITNESS.

 

Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a witness in any Proceeding to which Indemnitee is not a party, he shall, to the fullest extent permitted by applicable law, be indemnified, held harmless and exonerated against all Expenses actually incurred by Indemnitee or on Indemnitee’s behalf in connection therewith.

 

7.                                      ADDITIONAL INDEMNIFICATION, HOLD HARMLESS AND EXONERATION RIGHTS.

 

7.1.                            Notwithstanding any limitation in Sections 3, 4, or 5, the Company shall, to the fullest extent permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually incurred by Indemnitee in connection with the Proceeding.  No indemnification, hold harmless or exoneration rights shall be available under this Section 7.1 on account of Indemnitee’s conduct which constitutes a breach of Indemnitee’s duty of loyalty to the Company or its stockholders or is an act or omission not in good faith or which involves intentional misconduct or a knowing violation of the law.

 

7.2.                            Notwithstanding any limitation in Sections 3, 4, 5 or 7.1, the Company shall, to the fullest extent permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually incurred by Indemnitee in connection with the Proceeding.

 

5


 

8.                                      CONTRIBUTION IN THE EVENT OF JOINT LIABILITY.

 

8.1.                            To the fullest extent permissible under applicable law, if the indemnification, hold harmless and/or exoneration rights provided for in this Agreement are unavailable to Indemnitee in whole or in part for any reason whatsoever, the Company, in lieu of indemnifying, holding harmless or exonerating Indemnitee, shall pay, in the first instance, the entire amount incurred by Indemnitee, whether for judgments, liabilities, fines, penalties, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding without requiring Indemnitee to contribute to such payment, and the Company hereby waives and relinquishes any right of contribution it may have at any time against Indemnitee.

 

8.2.                            The Company shall not enter into any settlement of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee.

 

8.3.                            The Company hereby agrees to fully indemnify, hold harmless and exonerate Indemnitee from any claims for contribution which may be brought by officers, directors or employees of the Company other than Indemnitee who may be jointly liable with Indemnitee.

 

9.                                      EXCLUSIONS.

 

Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnification, hold harmless or exoneration payment in connection with any claim made against Indemnitee:

 

(a)                                 [except as provided in Section 16.4], for which payment has actually been received by or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount actually received under any insurance policy, contract, agreement, other indemnity provision or otherwise;

 

(b)                                 for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act or similar provisions of state statutory law or common law; or

 

(c)                                  except as otherwise provided in Sections 14.5 and 14.6 hereof, prior to a Change in Control, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, hold harmless or exoneration payment, in its sole discretion, pursuant to the powers vested in the Company under applicable law.

 

10.                               ADVANCES OF EXPENSES; DEFENSE OF CLAIM.

 

10.1.                     Notwithstanding any provision of this Agreement to the contrary, and to the fullest extent not prohibited by applicable law, the Company shall pay the Expenses incurred by Indemnitee (or reasonably expected by Indemnitee to be incurred by Indemnitee within three months) in connection with any Proceeding within ten (10) days after the receipt by the Company of a statement or statements requesting such advances from time to time, prior to the final disposition of any Proceeding.  Advances shall be unsecured and interest free.  Advances shall be made without regard to Indemnitee’s ability to repay the Expenses and without regard to Indemnitee’s ultimate entitlement to be indemnified, held harmless or exonerated under the other provisions of this Agreement.  Advances shall include any and all Expenses incurred pursuing a Proceeding to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed.  To the fullest extent required by applicable law, such payments of Expenses in advance of the final disposition of the Proceeding shall be made only upon the Company’s receipt of an undertaking, by or on behalf of Indemnitee, to repay the advance to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company under the provisions of this Agreement, the Charter, the Bylaws of the Company, applicable law or otherwise.  This Section 10.1 shall not apply to any claim made by Indemnitee for which an indemnification, hold harmless or exoneration payment is excluded pursuant to Section 9.

 

6


 

10.2.                     The Company will be entitled to participate in the Proceeding at its own expense.

 

10.3.                     The Company shall not settle any action, claim or Proceeding (in whole or in part) which would impose any Expense, judgment, fine, penalty or limitation on Indemnitee without Indemnitee’s prior written consent.

 

11.                               PROCEDURE FOR NOTIFICATION AND APPLICATION FOR INDEMNIFICATION.

 

11.1.                     Indemnitee agrees to notify promptly the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification, hold harmless or exoneration rights, or advancement of Expenses covered hereunder.  The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement, or otherwise.

 

11.2.                     Indemnitee may deliver to the Company a written application to indemnify, hold harmless or exonerate Indemnitee in accordance with this Agreement.  Such application(s) may be delivered from time to time and at such time(s) as Indemnitee deems appropriate in his or her sole discretion.  Following such a written application for indemnification by Indemnitee, Indemnitee’s entitlement to indemnification shall be determined according to Section 12.1 of this Agreement.

 

12.                               PROCEDURE UPON APPLICATION FOR INDEMNIFICATION.

 

12.1.                     A determination, if required by applicable law, with respect to Indemnitee’s entitlement to indemnification shall be made in the specific case by one of the following methods, which shall be at the election of Indemnitee:  (i) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board (ii) by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee; or (iii) by vote of the stockholders.  The Company promptly will advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied.  If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination.  Indemnitee shall reasonably cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination.  Any costs or Expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

 

12.2.                     In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12.1 hereof, the Independent Counsel shall be selected as provided in this Section 12.2.  The Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected and certifying that the Independent Counsel so selected meets the requirements of “Independent Counsel” as defined in Section 2 of this Agreement.  If the Independent Counsel is selected by the Board, the Company shall give written notice to Indemnitee advising him of the identity of the Independent Counsel so selected and certifying that the Independent Counsel so selected meets the requirements of “Independent Counsel” as defined in Section 2 of this Agreement.  In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been received, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.  Absent a proper and timely objection, the person so selected shall act as Independent Counsel.  If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court of competent jurisdiction has determined that such objection is without merit.  If, within twenty (20) days after submission by

 

7


 

Indemnitee of a written request for indemnification pursuant to Section 11.2 hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Delaware Court for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Delaware Court, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 12.1 hereof.  Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14.1 of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

 

12.3.                     The Company agrees to pay the reasonable fees and expenses of Independent Counsel and to fully indemnify and hold harmless such Independent Counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

 

13.                               PRESUMPTIONS AND EFFECT OF CERTAIN PROCEEDINGS.

 

13.1.                     In making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 11.2 of this Agreement. Anyone (including the Company) seeking to overcome this presumption shall have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption.  Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.

 

13.2.                     If the person, persons or entity empowered or selected under Section 12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within thirty (30) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a final judicial determination that any or all such indemnification is expressly prohibited under applicable law; provided, however, that such 30-day period may be extended for a reasonable time, not to exceed an additional fifteen (15) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto.

 

13.3.                     The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful. Anyone seeking to overcome this presumption shall have the burden of proof.

 

13.4.                     For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the directors, officers, managers, employees, agents or representatives of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise, its Board, any committee of the Board or any director, or on information or records given or reports made to the Enterprise, its Board, any committee of the Board or any director, by an independent certified public accountant or by an appraiser or other expert selected by the Enterprise, its Board, any committee of the Board or any director.  The provisions of this Section 13.4 shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed or found to have met the applicable standard of conduct set forth in this Agreement.

 

8


 

13.5.                     The knowledge and/or actions, or failure to act, of any other director, officer, trustee, partner, managing member, fiduciary, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.

 

14.                               REMEDIES OF INDEMNITEE.

 

14.1.                     In the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 10 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 12.1 of this Agreement within thirty (30) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Sections 5, 6, 7 or the last sentence of Section 12.1 of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) a contribution payment is not made in a timely manner pursuant to Section 8 of this Agreement, (vi) payment of indemnification pursuant to Section 3 or 4 of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vii) payment to Indemnitee pursuant to any hold harmless or exoneration rights under this Agreement or otherwise is not made within ten (10) days after receipt by the Company of a written request therefor, Indemnitee shall be entitled to an adjudication by the Delaware Court to such indemnification, hold harmless, exoneration, contribution or advancement rights.  Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association.  Except as set forth herein, the provisions of Delaware law (without regard to its conflict of laws rules) shall apply to any such arbitration.  The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration.

 

14.2.                     In the event that a determination shall have been made pursuant to Section 12.1 of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 14 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination.  In any judicial proceeding or arbitration commenced pursuant to this Section 14, Indemnitee shall be presumed to be entitled to be indemnified, held harmless, exonerated to receive advances of Expenses under this Agreement and the Company shall have the burden of proving Indemnitee is not entitled to be indemnified, held harmless, exonerated and to receive advances of Expenses, as the case may be, and the Company may not refer to or introduce into evidence any determination pursuant to Section 12.1 of this Agreement adverse to Indemnitee for any purpose.  If Indemnitee commences a judicial proceeding or arbitration pursuant to this Section 14, Indemnitee shall not be required to reimburse the Company for any advances pursuant to Section 10 until a final determination is made with respect to Indemnitee’s entitlement to indemnification (as to which all rights of appeal have been exhausted or lapsed).

 

14.3.                     If a determination shall have been made pursuant to Section 12.1 of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 14, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.

 

14.4.                     The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.

 

14.5.                     The Company shall indemnify and hold harmless Indemnitee to the fullest extent permitted by law against all Expenses and, if requested by Indemnitee, shall (within ten (10) days after the Company’s receipt of such written request) pay to Indemnitee, to the fullest extent permitted by applicable law, such Expenses which are incurred by Indemnitee in connection with any judicial proceeding or arbitration brought by Indemnitee (i) to enforce his rights under, or to recover damages for breach of, this Agreement or any other indemnification, hold harmless, exoneration, advancement or contribution agreement or provision of the Charter, or the Company’s Bylaws now or hereafter in effect; or (ii) for recovery or advances under any insurance policy maintained by any person for the benefit of Indemnitee, regardless of the outcome and whether Indemnitee ultimately is determined to

 

9


 

be entitled to such indemnification, hold harmless or exoneration right, advancement, contribution or insurance recovery, as the case may be (unless such judicial proceeding or arbitration was not brought by Indemnitee in good faith).

 

14.6.                     Interest shall be paid by the Company to Indemnitee at the legal rate under Delaware law for amounts which the Company indemnifies, holds harmless or exonerates, or is obliged to indemnify, hold harmless or exonerate for the period commencing with the date on which Indemnitee requests indemnification, to be held harmless, exonerated, contribution, reimbursement or advancement of any Expenses and ending with the date on which such payment is made to Indemnitee by the Company.

 

15.                               SECURITY.

 

Notwithstanding anything herein to the contrary, to the extent requested by Indemnitee and approved by the Board, the Company may at any time and from time to time provide security to Indemnitee for the Company’s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral.  Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of Indemnitee.

 

16.                               NON-EXCLUSIVITY; SURVIVAL OF RIGHTS; INSURANCE; [PRIMACY OF INDEMNIFICATION;] SUBROGATION.

 

16.1.                     The rights of Indemnitee as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Charter, the Company’s Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise.  No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any Proceeding (regardless of when such Proceeding is first threatened, commenced or completed) arising out of, or related to, any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal.  To the extent that a change in applicable law, whether by statute or judicial decision, permits greater indemnification, hold harmless or exoneration rights or advancement of Expenses than would be afforded currently under the Charter, the Company’s Bylaws or this Agreement, then this Agreement (without any further action by the parties hereto) shall automatically be deemed to be amended to require that the Company indemnify Indemnitee to the fullest extent permitted by law.  No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.  The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.

 

16.2.                     The DGCL, the Charter and the Company’s Bylaws permit the Company to purchase and maintain insurance or furnish similar protection or make other arrangements including, but not limited to, providing a trust fund, letter of credit, or surety bond (“Indemnification Arrangements”) on behalf of Indemnitee against any liability asserted against him or incurred by or on behalf of him or in such capacity as a director, officer, employee or agent of the Company, or arising out of his status as such, whether or not the Company would have the power to indemnify him against such liability under the provisions of this Agreement or under the DGCL, as it may then be in effect.  The purchase, establishment, and maintenance of any such Indemnification Arrangement shall not in any way limit or affect the rights and obligations of the Company or of Indemnitee under this Agreement except as expressly provided herein, and the execution and delivery of this Agreement by the Company and Indemnitee shall not in any way limit or affect the rights and obligations of the Company or the other party or parties thereto under any such Indemnification Arrangement.

 

16.3.                     The Company shall, if commercially reasonable, obtain and maintain in effect during the entire period for which the Company is obligated to indemnify Indemnitee under this Agreement, one or more policies of insurance with reputable insurance companies to provide the directors and officers of the Company with coverage for losses from wrongful acts and omissions and to ensure the Company’s performance of its indemnification obligations under this Agreement. Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, trustee, partner, managing member, fiduciary, employee or agent under such policy or policies. In all such policies, Indemnitee shall be named as an insured in such a manner as to provide Indemnitee with the same rights and benefits as are accorded to the

 

10


 

most favorably insured of the Company’s directors and officers. If, at the time the Company receives notice from any source of a Proceeding as to which Indemnitee is a party or a participant (as a witness or otherwise), the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies.  The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.

 

16.4.                     [The Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and/or insurance provided by THL and certain of THL’s affiliates that, directly or indirectly, (i) are controlled by, (ii) control or (iii) are under common control with, THL (collectively, the “Fund Indemnitors”). The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Fund Indemnitors to advance Expenses or to provide indemnification for the same judgments, liabilities, fines, penalties and amounts paid in settlement incurred by Indemnitee is secondary), (ii) that it shall be required to advance the full amount of Expenses actually incurred by Indemnitee and shall be liable for the full amount of all Expenses and judgments, liabilities, fines, penalties and amounts paid in settlement as required by the terms of this Agreement and the Charter or Bylaws (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms of this Section 16.4.]

 

16.5.                     [Except as provided in Section 16.4,] in the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee [(other than against the Fund Indemnitors)], who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 

16.6.                     [Except as provided in Section 16.4,] the Company’s obligation to indemnify, hold harmless, exonerate or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, fiduciary, employee or agent of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification, hold harmless or exoneration payments or advancement of expenses from such Enterprise.  Notwithstanding any other provision of this Agreement to the contrary, (i) Indemnitee shall have no obligation to reduce, offset, allocate, pursue or apportion any indemnification, hold harmless, exoneration, advancement, contribution or insurance coverage among multiple parties possessing such duties to Indemnitee prior to the Company’s satisfaction and performance of all its obligations under this Agreement, and (ii) the Company shall perform fully its obligations under this Agreement without regard to whether Indemnitee holds, may pursue or has pursued any indemnification, advancement, hold harmless, exoneration, contribution or insurance coverage rights against any person or entity other than the Company.

 

17.                               DURATION OF AGREEMENT.

 

All agreements and obligations of the Company contained herein shall continue during the period Indemnitee serves as a director or officer of the Company or as a director, officer, trustee, partner, managing member, fiduciary, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other Enterprise which Indemnitee serves at the request of the Company and shall continue thereafter so long as Indemnitee shall be subject to any possible Proceeding (including any rights of appeal thereto and any Proceeding commenced by Indemnitee pursuant to Section 14 of this Agreement) by reason of his Corporate Status, whether or not he is acting in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement.

 

11


 

18.                               SEVERABILITY.

 

If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.

 

19.                               ENFORCEMENT AND BINDING EFFECT.

 

19.1.                     The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director, officer or key employee of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director, officer or key employee of the Company.

 

19.2.                     Without limiting any of the rights of Indemnitee under the Charter or Bylaws of the Company as they may be amended from time to time, this Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof.

 

19.3.                     The indemnification, hold harmless, exoneration and advancement of Expenses rights provided by or granted pursuant to this Agreement shall be binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or of any other Enterprise at the Company’s request, and shall inure to the benefit of Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators and other legal representatives.

 

19.4.                     The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.

 

19.5.                     The Company and Indemnitee agree herein that a monetary remedy for breach of this Agreement, at some later date, may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm.  Accordingly, the parties hereto agree that Indemnitee may enforce this Agreement by seeking, among other things, injunctive relief and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm and that by seeking injunctive relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he may be entitled.  The Company and Indemnitee further agree that Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in connection therewith.  The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by a Court of competent jurisdiction and the Company hereby waives any such requirement of such a bond or undertaking.

 

20.                               MODIFICATION AND WAIVER.

 

No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties hereto.  No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.

 

12


 

21.                               NOTICES.

 

All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (i) if delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, or (ii) mailed by certified or registered mail with postage prepaid, on the third (3rd) business day after the date on which it is so mailed:

 

(a)                                 If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide in writing to the Company.

 

(b)                                 If to the Company, to:

 

Agiliti, Inc.

6625 West 78th Street, Suite 300

Minneapolis, Minnesota 55439-2604

Attn: Thomas J. Leonard, Chief Executive Officer

 

With a copy, which shall not constitute notice, to:

 

Kirkland & Ellis LLP
300 North LaSalle
Chicago, Illinois 60654
Attn: Richard J. Campbell and Carol Anne Huff

 

or to any other address as may have been furnished to Indemnitee in writing by the Company.

 

22.                               APPLICABLE LAW AND CONSENT TO JURISDICTION.

 

This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules.  Except with respect to any arbitration commenced by Indemnitee pursuant to Section 14.1 of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally: (a) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court and not in any other state or federal court in the United States of America or any court in any other country; (b) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement; (c) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court; and (d) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum, or is subject (in whole or in part) to a jury trial.

 

23.                               IDENTICAL COUNTERPARTS.

 

This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement.  Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

 

24.                               MISCELLANEOUS.

 

Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate.  The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

 

13


 

25.                               PERIOD OF LIMITATIONS.

 

No legal action shall be brought and no cause of action shall be asserted by or in the right of the Company against Indemnitee, Indemnitee’s spouse, heirs, executors or personal or legal representatives after the expiration of two years from the date of accrual of such cause of action, and any claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such two-year period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action such shorter period shall govern.

 

26.                               ADDITIONAL ACTS.

 

If for the validation of any of the provisions in this Agreement any act, resolution, approval or other procedure is required, the Company undertakes to cause such act, resolution, approval or other procedure to be affected or adopted in a manner that will enable the Company to fulfill its obligations under this Agreement.

 

[SIGNATURE PAGE FOLLOWS]

 

14


 

IN WITNESS WHEREOF, the parties hereto have caused this Indemnity Agreement to be signed as of the day and year first above written.

 

 

AGILITI, INC.

 

 

 

 

By:

 

 

 

Name:

 

 

Title:

 

15


 

 

INDEMNITEE

 

 

 

 

 

 

 

 

Name:

 

 

Address:

 

16


EX-10.12 7 a19-2105_2ex10d12.htm EX-10.12

Exhibit 10.12

 

EXECUTION VERSION

 

Amendment to Investment Management Trust Agreement

 

This Amendment to Investment Management Trust Agreement (this “Amendment”), dated as of January 3, 2019, is by and between Federal Street Acquisition Corp., a Delaware corporation (“FSAC”) and Continental Stock Transfer & Trust Company (“Continental”).  Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Trust Agreement (as defined below).

 

WHEREAS, reference is hereby made to: (i) the Amended and Restated Agreement and Plan of Merger, dated as of December 19, 2018, by and among FSAC, Agiliti Holdco, Inc., and the other parties thereto (the “A&R Merger Agreement”), (ii) FSAC’s final prospectus as filed with the Securities and Exchange Commission (“SEC”) and declared effective on July 18, 2017 relating to FSAC’s initial public offering (the “Prospectus”), (iii) FSAC’s Definitive Proxy Statement on Schedule 14A filed with the SEC on October 10, 2018 as supplemented by FSAC’s Proxy Supplement on Schedule 14A filed with the SEC on December 20, 2018 (the “Proxy Statement”), (iv) the Underwriting Agreement, dated as of July 18, 2017, by and among Citigroup Global Markets Inc. (“Citi”), Merrill Lynch, Pierce, Fenner & Smith Incorporated (“BAML”, and together with Citi, the “Underwriters”) and FSAC (the “Underwriting Agreement”), (v) the Investment Management Trust Agreement, dated as of July 18, 2017, by and among FSAC and Continental (the “Trust Agreement”, and together with the A&R Merger Agreement, the Proxy Statement, the Prospectus, the Underwriting Agreement, the “Agreements”), (vi) the letter agreement, dated as of January 3, 2019, by and between BAML and FSAC (the “BAML Fee Acknowledgement” and the amount owed to BAML after giving effect thereto, the “BAML Revised Deferred Discount”)) and (vii) the letter agreement, dated as of January 3, 2019, by and between Citi and FSAC (the “Citi Fee Acknowledgement” and together with the BAML Fee Acknowledgement, the “Fee Acknowledgements” and the amount owed to Citi after giving effect to the Citi Fee Acknowledgment, the “Citi Revised Deferred Discount”)).

 

WHEREAS, the Trust Agreement provides, among other things, that a portion of the Property equal to $14,000,000, or $16,100,000 if the Underwriters’ over-allotment option is exercised in full, is attributable to the deferred underwriting discounts and commissions that will be payable by the Company to the Underwriters upon and concurrently with the consummation of the Business Combination;

 

WHEREAS, such portion of the Property is defined in the Trust Agreement as the “Deferred Discount”;

 

WHEREAS, pursuant to the Fee Acknowledgements , FSAC and the Underwriters agreed that, notwithstanding anything to the contrary in the Agreements and certain other agreements by and among FSAC, Citi and BAML, the Deferred Discount for all purposes of the Trust Agreement shall equal the sum of the BAML Revised Deferred Discount and the Citi Revised Deferred Discount (such sum, the “Revised Deferred Discount”);

 

WHEREAS, the Trust Agreement provides that, unless otherwise agreed between the Company and the Underwriters, the Instruction Letter shall provide that the Deferred Discount be paid directly to the account or accounts directed by the Underwriters prior to any transfer of the funds held in the Trust Account to the Company or any other person;

 

WHEREAS, pursuant to the Fee Acknowledgements, FSAC and the Underwriters agreed that the Deferred Discount shall be payable by FSAC to the extent that there are insufficient funds then existing in the Trust Account; and

 

WHEREAS, in connection with the foregoing, the parties hereto desire to amend the Trust Agreement on the terms and conditions set forth herein.

 

NOW, THEREFORE, the parties hereto hereby agree as follows:

 

1.                                      The penultimate recital set forth in the Trust Agreement is hereby deleted in its entirety and replaced with the following:

 

“WHEREAS, pursuant to the Underwriting Agreement, a portion of the Property equal to the Revised Deferred Discount is attributable to deferred underwriting discounts and commissions that will be payable by the Company to the

 


 

Underwriters upon and concurrently with the consummation of the Business Combination (as defined below) (the “Deferred Discount”).”

 

2.                                      Section 2(h) of the Trust Agreement is hereby deleted in its entirety.

 

3.                                      All terms, conditions, provisions of the Trust Agreement that are not specifically amended herein shall remain in full force and effect and shall not be altered by the provisions hereof.

 

4.                                      Continental hereby acknowledges and agrees that, pursuant to the Fee Acknowledgements, FSAC and the Underwriters have agreed that, notwithstanding anything to the contrary in the Agreements (including the Trust Agreement), the Revised Deferred Discount shall be payable by FSAC to the extent that there are insufficient funds then existing in the Trust Account.

 

5.                                      This Amendment may not be amended or waived except by an instrument in writing signed by each party hereto. This Amendment may be executed in any number of counterparts, each of which shall be an original, and all of which, when taken together, shall constitute one agreement. Delivery of an executed signature page of this Amendment by facsimile transmission or other electronic transmission (including “.pdf”, “.tiff” or similar format) shall be effective as delivery of a manually executed counterpart hereof. This Amendment shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York without regard to conflict of law principles that would result in the application of any law other than the laws of the State of New York.

 


 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first set forth above.

 

 

FSAC:

 

 

 

FEDERAL STREET ACQUISITION CORP.

 

 

 

By:

/s/ Charles P. Holden

 

Name:

Charles P. Holden

 

Title:

Chief Financial Officer

 

[Signature Page to the Amendment to Investment Management Trust Agreement]

 


 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first set forth above.

 

 

CONTINENTAL:

 

 

 

CONTINENTAL STOCK TRANSFER & TRUST COMPANY

 

 

 

By:

/s/ Francis E. Wolf Jr.

 

Name:

Francis E. Wolf

 

Title:

Vice President

 

[Signature Page to the Amendment to Investment Management Trust Agreement]

 


EX-10.13 8 a19-2105_2ex10d13.htm EX-10.13

Exhibit 10.13

 

Execution Version

 

ADVISORY SERVICES AGREEMENT

 

This ADVISORY SERVICES AGREEMENT (this “Agreement”) is entered into as of January 4, 2019 by and among (i) Agiliti, Inc., a Delaware corporation (“TopCo”), (ii) Agiliti Holdco, Inc. (f/k/a UHS Holdco, Inc.), a Delaware corporation (“Holdco”), (iii) Agiliti Health, Inc. (f/k/a Universal Hospital Services, Inc.), a Delaware corporation (“OpCo”, and, together with TopCo, and Holdco each, a “Company”, and collectively, the “Companies”), and (iv) THL Managers VIII, LLC, a Delaware limited liability company (the “Manager”).

 

RECITALS

 

WHEREAS, TopCo and Holdco are each a party to that certain Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”), dated as of December 19, 2018, by and among TopCo, Holdco, Federal Street Acquisition Corp., a Delaware corporation, Umpire SPAC Merger Sub, Inc., a Delaware corporation, Umpire Cash Merger Sub, Inc., a Delaware corporation, IPC/UHS Co-Investment Partners, L.P., a Delaware limited partnership (solely in its capacity as a Majority Stockholder (as defined in the Merger Agreement)), IPC/UHS, L.P. (solely in its capacity as a Majority Stockholder and as the Stockholders’ Representative (as defined in the Merger Agreement)) and Umpire Equity Merger Sub, Inc. (solely for purposes of Sections 1.6 and 9.12 of the Merger Agreement), pursuant to which, among other things, TopCo acquired, directly or indirectly, all of the issued and outstanding capital stock of Holdco, subject to the terms and conditions contained therein (the “Transactions”);

 

WHEREAS, the Companies desire to retain the Manager to provide certain Services (as defined below) to the Companies, and the Manager is willing to provide the Services on the terms set forth below; and

 

WHEREAS, Indemnitees (as hereinafter defined) may have certain rights to indemnification, advancement of expenses and/or insurance provided by the Manager (or its affiliates other than the Companies), which the Companies and the Manager intend to be secondary to the primary obligation of the Companies to indemnify Indemnitees as provided herein, with the Companies’ acknowledgement of and agreement to the foregoing being a material condition to Indemnitees’ willingness to provide the Services (as defined below) to the Companies.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the above premises and the representations, warranties, covenants and mutual agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

 

1.                                       Services.

 

(a)                        Services.  During the Term (as hereinafter defined) of this Agreement specified in Section 3 hereof, the Manager hereby agrees that:

 


 

(i)                            It is prepared to make available to the Companies certain of its employees or other representatives of its choosing (each, a “Consultant” and collectively, the “Consultants”), including employee, consultant, partner or individual that provides services to the Manager as part of its internal “Strategic Resources Group,” in each case, to provide management, consulting and other advisory services (excluding any services rendered by a Consultant in his or her capacity as a director or manager of any of the Companies, which services shall, for greater certainty, be rendered without remuneration and shall not be governed by the terms of this Agreement)to the Companies as requested from time to time by the board of directors or analogous governing body, as applicable, of any Company and agreed to by the Manager, including, without limitation:

 

(A)             advice in connection with the negotiation and consummation of agreements, contracts, documents and instruments necessary to provide the Companies or any of their subsidiaries with senior bank financing on terms and conditions satisfactory to the Companies;

 

(B)             financial, managerial and operational advice in connection with the Companies’ day-to-day operations, including, without limitation, advice with respect to the development and implementation of strategies for improving the operating, marketing and financial performance of the Companies and their subsidiaries; and

 

(C)             such other services (which may include financial and strategic planning and analysis, consulting services, human resources, executive recruitment services, environmental, social and corporate governance (“ESG”) initiatives and other services) as the Manager and the Companies may from time to time agree in writing ((A) — (C), collectively, the “Services”).

 

(ii)                         Its Consultants will devote such time and efforts to the performance of the Services contemplated hereby as the Manager deems reasonably necessary or appropriate; provided, however, that no minimum number of hours is or will be required to be devoted by the Consultants on a weekly, monthly, annual or other basis.  The Companies acknowledge that the Manager’s Services are not exclusive and that the Manager and the Consultants will render similar services to other persons and entities.  In providing the Services to the Companies, the Manager will act as an independent contractor and it is expressly understood and agreed that this Agreement is not intended to create, and does not create, any partnership, agency, joint venture or similar relationship and that neither the Manager, on the one hand, nor any of the Companies, on the other, has the right or ability to contract for or on behalf of each other or to effect any transaction for each other’s account.

 

(iii)                      The Services may include advice and recommendations regarding potential future events and there can be no guarantee that such future events will occur as anticipated or at all.  The Companies will be responsible for determining

 

2


 

the manner in which such advice and recommendations will be used and the Manager will not be liable in respect of any decisions made by the Companies as a result of the Manager providing the Services hereunder.  The Manager shall not have any responsibility for implementing any advice or recommendations provided under this Agreement and will not perform any management functions or make management decisions with respect to any such advice or recommendations.  Without limiting the generality of the foregoing, if any Consultant is requested by any of the Companies to represent the interests of such Company or the Companies in discussions and other interactions with third parties, such Consultant shall be acting at the instruction of and on behalf of the Companies and shall not be deemed to be acting in such Consultant’s personal capacity or on behalf of the Manager or any of its affiliates.  In no event shall the Companies and the Manager or any Consultant be deemed to have a fiduciary relationship as a result of this Agreement or the Services provided hereunder.

 

(iv)                     To the extent Services are provided by the Manager to any direct or indirect subsidiaries of TopCo (other than OpCo, which is a party to this Agreement), TopCo shall cause such subsidiary to abide by the terms of this Agreement (including, without limitation, Section 4 hereof) as if such subsidiary was a party hereto.

 

2.                                      Payment of Fees.

 

(a)                        In consideration of the Manager providing the Services, from and after the closing of the Transactions for the Term of this Agreement (as provided in Section 3 below), the Companies will jointly and severally pay to the Manager (or its designees) a non-refundable periodic retainer fee (the “Periodic Fee”) in an aggregate amount per fiscal quarter equal to the greater of (i) $375,000 or (ii) 1% of Consolidated Adjusted EBITDA (as defined below) for the immediately preceding fiscal quarter or such other amount (or formula) as may be mutually agreed between TopCo and the Manager, such fee being payable in arrears on the fifteenth day of the month immediately following the last day of each fiscal quarter of the Companies (i.e., January 15, April 15, July 15 and October 15) following the closing of the Transactions , the first such payment to be made on April 15, 2019; provided, however, that the Periodic Fee payable in respect of any fiscal quarter for which the Consolidated Adjusted EBITDA is not known or reasonably estimable on the date payment is due shall be $375,000, with the Periodic Fee payable in respect of the next fiscal quarter to include, in addition to the Periodic Fee in respect of such next fiscal quarter, an amount equal to the excess, if any, of (x) the amount payable in respect of the prior fiscal quarter as finally determined less (y) $375,000.  By way of example, if the Consolidated Adjusted EBITDA for the first quarter of fiscal year 2020 is not known or reasonably estimable on April 15, 2020 but, when finally determined, is equal to $50,000,000, and thus the Periodic Fee for such quarter would be $500,000 pursuant to this Section 2(a), the payment for the first fiscal quarter of 2020 would be $375,000 and the payment for the second fiscal quarter of 2020 would be increased by $125,000.  For purposes of this Agreement, “Consolidated Adjusted EBITDA” shall have the meaning ascribed to such term or similar term used to calculate

 

3


 

financial covenants and ratios in the Credit Agreement, dated as of January 4, 2019 between Holdco, OpCo, JPMorgan Chase Bank, N.A. as Administrative Agent and the other parties thereto (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”); provided, however, that, for purposes of determining the amount of the Periodic Fees for any fiscal year, Consolidated Adjusted EBITDA may be adjusted upward by mutual agreement of TopCo and the Manager to reflect the projected financial performance of Topco and its direct and indirect subsidiaries for such fiscal year.

 

(b)                        From and after the closing of the Transactions, for the Term of this Agreement, in consideration of the Manager advising the Companies in connection with the consummation of any financing or refinancing (equity or debt), dividend, recapitalization, acquisition, disposition and spin-off or split-off transactions involving the Companies or any of their direct or indirect subsidiaries (however structured), the Companies will jointly and severally pay to the Manager (or an affiliate of the Manager designated by it) a fee in connection with each such transaction to be agreed upon between the Manager and the Companies at the time of such transaction, such fee to be due and payable for the foregoing services at the closing of such transaction.

 

(c)                         In the case of the initial public offering following the closing of the Transactions of TopCo’s (or any of its subsidiaries’’) common stock in an offering registered under the Securities Act of 1933 (as in effect from time to time) on Form S-1 (or any successor form) (an “Initial Public Offering”), the Companies shall pay to the Manager (or its designees), in addition to the fees payable above, an amount equal to the net present value (using a discount rate equal to the then applicable yield on U.S. Treasury Securities of like maturity) of the Periodic Fees, assuming such fees were based upon the higher of the amounts set forth in Section 2(a) using Consolidated Adjusted EBITDA of the most recently completed fiscal year, that would have been payable to the Manager with respect to the period from the date of such transaction until the scheduled date of termination of this Agreement in effect immediately prior to such transaction in accordance with Section 3 below.

 

(d)                        For as long as Manager is receiving Periodic Fees pursuant to Section 2(a), the Companies will jointly and severally pay to the Manager (or an affiliate of the Manager as designated by the Manager) fees for other management, consulting and other advisory services provided by the Manager to the Companies.   The amount of any such fees payable pursuant to this Section 2(d) shall be discussed in good faith by the Companies and the Manager.

 

(e)                         Each payment made pursuant to this Section 2 will be paid by wire transfer of immediately available federal funds to the applicable accounts specified on Schedule 1 hereto or to such other account(s) as the Manager may specify to the Companies in writing prior to such payment.  The Manager may, in its sole discretion, elect to waive payment of all or any portion of any fees or other amounts due under this Section 2 (including, for the avoidance of doubt, pursuant to the last sentence of Section 3 below).  No waiver of any payment on any one occasion will

 

4


 

extend to, effect, or be construed as, a waiver of any future payment. Notwithstanding anything herein to the contrary, while all payments and obligations of the Companies hereunder are joint and several, OpCo shall have primary liability for all such payments and obligations.

 

(f)                          Notwithstanding the foregoing, payment of all or any portion of the fees described above in this Section 2 shall be deferred to the extent necessary (i) to avoid a breach of any financial covenant under, or if such payment would otherwise be prohibited by, the Credit Agreement, or (ii) if any Company’s board of directors, managers or analogous governing body determines in good faith that making a payment of all or such portion of the Periodic Fee would jeopardize such Company’s ability to continue as a going concern (including by virtue of any legal or contractual restrictions prohibiting such payment), and shall be promptly paid when payment thereof (A) would no longer result in any breach of a financial covenant under, nor be prohibited by, such financing agreements or (B) would no longer jeopardize such Company’s ability to continue as a going concern (including by virtue of such payment being no longer prohibited), as applicable; provided that, any such deferred fees shall accrue interest, on such portion that is deferred for the number of days that payment is deferred, at a rate equal to the 6-month treasury rate (initially such rate that is in effect on the first date of such deferral and adjusted on each 180th day thereafter to the rate then in effect) plus 100 basis points.

 

3.                                                              Term.  This Agreement will continue in full force and effect until January 4, 2027; provided, that, upon expiration of the term of this Agreement, this Agreement shall automatically extend for successive periods of one (1) year; and provided further, however, that (a) the Manager may cause this Agreement to terminate at any time, (b) this Agreement may be terminated by the Company by written notice to the Manager on or prior to March 31, 2019 if at a meeting of TopCo’s board of directors or committee thereof duly called to consider, among other things, this Agreement prior to such date, TopCo has not, in accordance with its policies and applicable laws, rules and regulations, ratified its execution and delivery by TopCo, HoldCo and OpCo, and (c) this Agreement will terminate automatically immediately prior to (i) an Initial Public Offering or (ii) (A) any transaction or series of related transactions that results in any person or group (within the meaning of Section 13(d)(3) of the Exchange Act) other than the Manager Funds and their affiliates or Affiliated Funds or their affiliates (or any portfolio company of  the Manager Funds, their affiliates or Affiliated Funds) acquiring, directly or indirectly (whether via a sale of equity interests, merger, consolidation, combination or other reorganization), shares of capital stock (or other equity securities of the surviving entity, as applicable) that represent more than fifty percent (50%) of the total outstanding voting power of TopCo (or the surviving entity, as applicable) or (B) a sale or disposition of all or substantially all of the assets of TopCo and its subsidiaries on a consolidated basis other than to an entity with respect to which, following such sale or other disposition, more than fifty percent (50%) of the combined outstanding voting power of the then outstanding voting securities of such entity is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities (or affiliates of such individuals and entities) who were the beneficial owners, respectively, of the capital stock immediately prior to such sale or other disposition in the same relative proportion as among them as existed immediately prior to giving effect to such transaction (each a “Change of Control”); provided that, in the case of clause (A) above, such

 

5


 

transaction shall only constitute a Change of Control if it results in the Manager Funds or Affiliated Funds ceasing to have the power (whether by ownership of voting securities, contractual right or otherwise) to designate a majority of the board of directors of TopCo, unless, in the case of an Initial Public Offering, TopCo and the Manager determine otherwise (the period on and after the date hereof through the termination hereof being referred to herein as the “Term”). In the event of a termination of this Agreement, the Companies will, jointly and severally, pay the Manager (or its designees) (i) all due and unpaid fees pursuant to Sections 2(a), 2(b) and 2(d) above, fee amounts pursuant to Section 2(c) above, as applicable, and expenses. For purposes of this Agreement: “Affiliated Fund” means, with respect to any specified Person, each investment fund or entity set up as a corporation, trust, limited liability company, general or limited partnership or other entity that is under common control with such Person or that is under the control of independent trustees or individuals serving in a similar capacity who were appointed or otherwise engaged, or can be removed and/or replaced, by such Person or an investment adviser affiliated with such Person; and “Person” means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a government or any branch, department, agency, political subdivision or official thereof.  Sections 3 through 15 shall survive any termination of this Agreement.

 

4.                                      Expenses; Indemnification.

 

(a)                        Expenses.  The Companies will jointly and severally pay on demand all expenses (including, without limitation, all air travel (by first class on a commercial airline or by charter, as determined by the Manager) and other travel-related expenses) incurred by the Manager, any of its Consultants and any funds affiliated with or advised by the Manager or its affiliates who are providing equity financing to TopCo and/or the other Companies to help effectuate the transactions contemplated by the Merger Agreement (such funds, the “Manager Funds” and, such investments, the “Manager Investments”) (or any of them) (i) in connection with this Agreement, the transactions contemplated by the Merger Agreement or any related transactions, (ii) relating to operations of, or Services provided by the Manager to, the Companies or any of their affiliates from time to time or (iii) otherwise in any way relating to the Companies or in any way relating to, or arising out of, the Manager Investments or the ownership or sale thereof by any Manager Fund.  Without limiting the generality of the foregoing, the Companies jointly and severally agree to pay on demand all expenses incurred by the Manager, any of its Consultants or the Manager Funds (or any of them) in connection with, or relating to, (x) the preparation, negotiation and execution of this Agreement and any other agreement executed in connection with, or related to, this Agreement, the Merger Agreement, the financing of the transactions contemplated by the Merger Agreement, the Manager Investments or the consummation of the transactions contemplated hereby and thereby or (y) any and all amendments, modifications, restructurings and waivers, and exercises and preservations of rights and remedies relating to any of the foregoing, and in each case will specifically include the fees and disbursements of counsel, accountants, consultants or advisors retained by the Manager, the Manager Funds or their respective consultants or advisors and any out-of-pocket expenses incurred by the Manager in connection with the provision of Services to the Companies from time to

 

6


 

time or the attendance by Consultants at any meeting of the board of directors or analogous body (or any committee thereof) of any of the Companies or any of their affiliates.  In no event shall reimbursements provided under this Agreement be subject to liquidation or exchange in a manner that violates, and the reimbursements shall be made in a manner that complies with all, requirements of Treasury Regulation Section 1.409A-3(i)(1)(iv). As additional consideration for the Services, the Companies will provide the Manager with such support facilities and space at the Companies’ facilities as may be required to enable the Manager to properly perform the Services.

 

(b)                        Indemnity and Liability.

 

(i)                            The Companies hereby jointly and severally indemnify and agree to exonerate and hold the Manager, the Manager Funds, and each of their respective past, current and future partners, shareholders, members, affiliates, directors, officers, Consultants, fiduciaries, managers, controlling persons, employees and agents and each of the past, current and future partners, shareholders, members, affiliates, directors, officers, fiduciaries, managers, controlling persons, employees and agents of each of the foregoing (collectively, the “Indemnitees”), each of whom is an intended third party beneficiary of this Agreement and may specifically enforce the Companies’ obligations hereunder, free and harmless from and against any and all actions, causes of action, suits, claims, liabilities, losses, damages and costs and expenses or any other amounts in connection therewith, including without limitation all actual out-of-pocket attorneys’ fees and expenses (collectively, the “Indemnified Liabilities”), incurred by the Indemnitees or any of them as a result of, arising out of, or in any way relating to (1) this Agreement, the transactions contemplated by the Merger Agreement, any transaction to which the Companies are a party, the Manager Investments (including but not limited to service as a Manager-designated member of the board of directors or analogous governing body of any of the Companies or any affiliate thereof) or the ownership or sale thereof by any Manager Fund or any related transactions or (2) operations of, or Services provided by the Manager to, any of the Companies or any affiliate of any of the Companies from time to time (including but not limited to any indemnification obligations assumed or incurred by any Indemnitee to or on behalf of any of the Companies or any of their accountants or other representatives, agents or affiliates) provided that no indemnification shall be available for any such Indemnified Liabilities arising from such Indemnitee’s willful misconduct or bad faith as determined by a final, non-appealable determination of a court of competent jurisdiction. If and to the extent that the foregoing undertaking may be unavailable or unenforceable for any reason (other than as a result of the proviso), each of the Companies hereby agrees to make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities that is permissible under applicable law.  For purposes of this Section 4(b), none of the circumstances described in the limitations contained in the second preceding sentence shall be deemed to apply absent a final non-appealable judgment of a court of competent jurisdiction to such effect, in which case to the extent any such limitation is so determined to

 

7


 

apply to any Indemnitee as to any previously advanced indemnity payments made by the Companies, then such payments shall be repaid by such Indemnitee to the Companies.

 

(ii)                         Any Indemnitee may, at its own expense, retain separate counsel to participate in such defense. In any action, claim, suit, investigation or proceeding in which both of one or more of the Companies, on the one hand, and an Indemnitee, on the other hand, is, or is reasonably likely to become, a party, such Indemnitee shall have the right to employ separate counsel at the expense of the Companies and to control its own defense of such action, claim, suit, investigation or proceeding if, in the reasonable opinion of counsel to such Indemnitee, a conflict or potential conflict exists between any of the Companies, on the one hand, and such Indemnitee, on the other hand, that would make such separate representation advisable.  The Companies agree that they will not, without the prior written consent of the applicable Indemnitee, settle, compromise or consent to the entry of any judgment in any pending or threatened claim, suit, investigation, action or proceeding relating to the matters contemplated hereby (if any Indemnitee is a party thereto or has been threatened to be made a party thereto) unless such settlement, compromise or consent includes an unconditional release of the applicable Indemnitee and each other Indemnitee from all liability arising or that may arise out of such claim, suit, investigation, action or proceeding.

 

(iii)                      The rights of any Indemnitee to indemnification hereunder will be in addition to any other rights any such person may have under any other agreement or instrument referenced above or any other agreement or instrument to which such Indemnitee is or becomes a party or is or otherwise becomes a beneficiary or under law or regulation.  The Companies hereby agree that they are the indemnitors of first resort (i.e., their obligations to any Indemnitee under this Agreement are primary and any obligation of the Manager (or any affiliate thereof other than the Companies) to provide advancement or indemnification for the same Indemnified Liabilities (including all interest, assessment and other charges paid or payable in connection with or in respect of such Indemnified Liabilities) incurred by Indemnitee is secondary), and if the Manager (or any affiliate thereof other than the Companies) pays or causes to be paid, for any reason, any amounts otherwise indemnifiable hereunder or under any other indemnification agreement (whether pursuant to contract, bylaws, charter or otherwise) with any Indemnitee, then (i) the Manager (or such affiliate, as the case may be) shall be fully subrogated to all rights of Indemnitee with respect to such payment and (ii) the Companies shall reimburse the Manager (or such other affiliate) for the payments actually made.  Each of the Companies hereby unconditionally and irrevocably waives, relinquishes and releases (and covenants and agrees not to exercise, and to cause each affiliate of any of the Companies not to exercise), any claims or rights that any of the Companies may now have or hereafter acquire against any Indemnitee (in any capacity) that arise from or relate to the existence, payment, performance or enforcement of one of the Companies’ obligations under this Agreement or under any indemnification obligation (whether pursuant to any

 

8


 

other contract, any organizational document or otherwise), including any right of subrogation, reimbursement, exoneration, contribution or indemnification and any right to participate in any claim or remedy of any Indemnitee against any Indemnitee, whether such claim, remedy or right arises in equity or under contract, statute, common law or otherwise, including any right to claim, take or receive from any Indemnitee, directly or indirectly, in cash or other property or by set-off or in any other manner, any payment or security or other credit support on account of such claim, remedy or right.  None of the Indemnitees will be liable to the Companies or any of their affiliates for any act or omission suffered or taken by such Indemnitee that does not constitute willful misconduct or bad faith as determined by a final, non-appealable determination of a court of competent jurisdiction.

 

5.                                      Disclaimer and Limitation of Liability; Opportunities.

 

(a)                        Disclaimer; Standard of Care.  The Manager makes no representations or warranties, express or implied, in respect of the Services provided or to be provided by it hereunder.  In no event will the Manager or any of the Indemnitees be liable to any of the Companies or any of their affiliates for any act, alleged act, omission or alleged omission that does not constitute willful misconduct or bad faith of the Manager as determined by a final, non-appealable determination of a court of competent jurisdiction. The Companies agree that any advice or recommendations (written or oral) provided by the Manager under this Agreement is solely for the use and benefit of the Companies and may not be disclosed to, or used or relied upon for any purpose by, any other person or entity without the prior written approval of the Manager.

 

(b)                        Freedom to Pursue Opportunities.  In recognition that the Manager and its affiliates currently have, and will in the future have or will consider acquiring, investments in numerous companies with respect to which the Manager, or its affiliates or Consultants, may serve as an advisor, a director or in some other capacity, and in recognition that the Manager and its affiliates and the Consultants have myriad duties to various investors and partners, and in anticipation that the Companies and the Manager (or one or more affiliates, associated investment funds or portfolio companies, or clients of the Manager) may engage in the same or similar activities or lines of business and have an interest in the same areas of corporate opportunities, and in recognition of the benefits to be derived by the Companies hereunder and in recognition of the difficulties that may confront any advisor who desires and endeavors fully to satisfy such advisor’s duties in determining the full scope of such duties in any particular situation, the provisions of this Section 5(b) are set forth to regulate, define and guide the conduct of certain affairs of the Companies as they may involve the Manager.  Except as the Manager may otherwise agree in writing after the date hereof:

 

(i)                            The Manager and its affiliates will have the right: (A) to directly or indirectly engage in any business (including, without limitation, any business activities or lines of business that are the same as or similar to those pursued by,

 

9


 

or competitive with, any of the Companies and their subsidiaries), (B) to directly or indirectly do business with any client or customer of any of the Companies and their subsidiaries, (C) to disclose the terms of this Agreement or information about the Companies to any Manager Fund or any affiliate, partner, investor, co-investor, officer, director, manager, employee or advisor of any Manager Fund, (D) to take any other action that the Manager believes in good faith is necessary or appropriate to fulfill its obligations as described in the first sentence of this Section 5(b), and (E) not to present potential transactions, matters or business opportunities to any of the Companies or any of their subsidiaries, and to pursue, directly or indirectly, any such opportunity for itself, and to direct any such opportunity to another person.

 

(ii)                         The Manager and its past, present and future officers, directors, employees, partners, members, Consultants, other clients, stockholders, affiliates and other associated entities will have no duty (contractual or otherwise) to communicate or present any corporate opportunities to the Companies or any of their affiliates or to refrain from any action specified in Section 5(b)(i), and the Companies on their own behalf and on behalf of their affiliates, hereby renounce and waive any right to require the Manager or any of its affiliates to act in a manner inconsistent with the provisions of this Section 5(b).

 

(iii)                      Neither the Manager nor any past, present, or future officer, director, employee, partner, member, Consultant, other client, stockholder, affiliate or associated entity thereof will be liable to the Companies or any of their affiliates for breach of any duty (contractual or otherwise) by reason of any activities or omissions of the types referred to in this Section 5(b) or of any such person’s participation therein.

 

(c)                         Limitation of Liability.  In no event will the Manager or any of its affiliates or any Consultant or other Indemnitee be liable to the Companies or any of their affiliates for any indirect, special, punitive, incidental or consequential damages, including, without limitation, lost profits or savings, whether or not such damages are foreseeable, or for any third party claims (whether based in contract, tort or otherwise), relating to the Services provided or to be provided by the Manager hereunder.  Additionally, in no event shall the aggregate liability of the Manager with respect to this Agreement and any Services provided hereunder exceed the fees received by the Manager pursuant to Section 2 of this Agreement.

 

6.                                       Assignment, etc.  Except as provided below, no party hereto has the right to assign this Agreement without the prior written consent of the other parties hereto.  Notwithstanding the foregoing, (a) the Manager may assign all or part of its rights and obligations hereunder to any affiliate of the Manager that provides services similar to those called for by this Agreement, in which event the Manager will be released of all of its rights and obligations hereunder, and (b) the provisions hereof for the benefit of Indemnitees other than the Manager shall also inure to the benefit of such other Indemnitees and their successors and assigns.

 

10


 

7.                                      Amendments and Waivers.  Except as otherwise provided herein (including, without limitation, the Manager’s ability to waive payments pursuant to Section 2(e) and terminate this Agreement pursuant to Section 3), no amendment or waiver of any term, provision or condition of this Agreement will be effective, unless in writing and executed by the Manager and TopCo.  No course of dealing and no delay on the part of any party hereto in exercising any right, power or remedy conferred by this Agreement shall operate as waiver thereof or otherwise prejudice such party’s rights, powers and remedies.  No single or partial exercise of any rights, powers or remedies conferred by this Agreement shall preclude any other or further exercise thereof or the exercise of any other right, power or remedy.

 

8.                                       Governing Law; Jurisdiction.

 

(a)                        Choice of Law.  This Agreement (including, without limitation, the validity, construction, effect or performance hereof and any remedies hereunder or related hereto) and all claims or causes of action of any kind (whether in contract, tort or otherwise) that may be based upon, arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement (including, without limitation, any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement or as an inducement to enter into this Agreement), shall be governed by the internal laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.

 

(b)                        Consent to Jurisdiction.  Each of the parties hereto, by its execution hereof, (i) hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts in the State of Delaware for the purposes of any claim or action arising out of or based upon this Agreement or relating to the subject matter hereof, (ii) hereby waives, to the extent not prohibited by applicable law, and agrees not to assert by way of motion, as a defense or otherwise, in any such claim or action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such proceeding brought in the above-named court is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court and (iii) hereby agrees not to commence any claim or action arising out of or based upon this Agreement or relating to the subject matter hereof other than before the above-named courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such claim or action to any court other than the above-named courts whether on the grounds of inconvenient forum or otherwise; provided, that any action to enforce a judicial award of a state or federal court in the State of Delaware pursuant to this Section 8 may be brought in any court of competent jurisdiction.  Each of the parties hereby consent to service of process in any such proceeding, and agree that service of process by registered or certified mail, return receipt requested, at its address specified pursuant to Section 10 is reasonably calculated to give actual notice.

 

11


 

(c)                         Waiver of Jury Trial.  TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW WHICH CANNOT BE WAIVED, EACH PARTY HERETO HEREBY WAIVES AND COVENANTS THAT IT WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE) ANY RIGHT TO TRIAL BY JURY IN ANY FORUM IN RESPECT OF ANY ISSUE OR ACTION, CLAIM, CAUSE OF ACTION OR SUIT (IN CONTRACT, TORT OR OTHERWISE), INQUIRY, PROCEEDING OR INVESTIGATION ARISING OUT OF OR BASED UPON THIS AGREEMENT OR THE SUBJECT MATTER HEREOF OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE TRANSACTIONS CONTEMPLATED HEREBY, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING.  EACH PARTY HERETO ACKNOWLEDGES THAT IT HAS BEEN INFORMED BY THE OTHER PARTIES HERETO THAT THIS SECTION 8(C) CONSTITUTES A MATERIAL INDUCEMENT UPON WHICH THEY ARE RELYING AND WILL RELY IN ENTERING INTO THIS AGREEMENT.  ANY PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 8(C) WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF EACH SUCH PARTY TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY.

 

9.                                       Entire Agreement.  This Agreement constitutes the entire understanding of the parties and supersedes all prior agreements and all other arrangements, understandings and communications, whether oral or written, among the parties with respect to the specific subject matter hereof.  There are no representations, agreements, arrangements, or understandings, oral or written, among the parties relating to the Services and the compensation therefor which are not fully expressed in this Agreement.

 

10.                                Notice.  All notices, requests or other communications required or permitted to be given hereunder shall be in writing (including facsimile transmission and electronic mail (via portable document format (*.pdf)  or similar electronic means), so long as a receipt of such facsimile or email is requested and received and the sender on the same day also sends a confirming copy of such notice by a recognized overnight delivery service (charges prepaid) to the physical address of such notice recipient) and shall be given to the respective addresses of the parties set forth below:

 

For notices and communications to the Companies, or any of them, to them at:

 

Agiliti, Inc.

 

6625 West 78th Street, Suite 36

 

Minneapolis, Minnesota 55439

 

Attention:

Thomas Leonard, Chief Executive Officer

Email:

tomleonard@uhs.com

 

For notices and communications to the Manager, to it at:

 

c/o Thomas H. Lee Partners, L.P.

100 Federal Street

Boston, MA 02110

 

12


 

Attention:

Josh Nelson & Shari Wolkon

Email:

jnelson@thl.com, & swolkon@thl.com

Facsimile No.:

(617) 227-3514

 

with a copy (which shall not constitute notice) to:

 

Kirkland & Ellis LLP

300 N. LaSalle Street

Chicago, Illinois 60654

Attention:

Richard J. Campbell, P.C. and Christopher R. Elder

Email:

richard.campbell@kirkland.com & christopher.elder@kirkland.com

Facsimile No.:

(312) 862-2200

 

By notice complying with the foregoing provisions of this Section 10, each party shall have the right to change the mailing address, facsimile number or email address for future notices and communications to such party.

 

11.                                Action Necessary to Effectuate the Agreement.  The parties hereto agree to take or cause to be taken all such corporate and other action as may be reasonably necessary to effect the intent and purposes of this Agreement.

 

12.                                Severability.  It is the desire and intent of the parties that the provisions of this Agreement be enforced to the fullest extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought.  Accordingly, the invalidity or unenforceability of any particular provision of this Agreement shall not affect the other provisions hereof, and this Agreement shall be construed in all respects as if the invalid or unenforceable provision were omitted.  Notwithstanding the foregoing, if such provision could be more narrowly drawn so as not to be invalid or unenforceable in such jurisdiction, it shall, as to such jurisdiction, be so more narrowly drawn, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

 

13.                             Headings.  All headings and captions in this Agreement are for purposes of reference only and shall not be construed to limit or affect the substance of this Agreement.

 

14.                             Currency.  All references to currency or dollar amounts in this Agreement refer to the lawful currency of the United States of America.

 

15.                             Counterparts.  This Agreement may be executed in two or more counterparts each of which when delivered (including via facsimile or e-mail portable document format (*.pdf) or similar electronic means) shall be deemed an original but all of which together shall constitute one and the same instrument, and all signatures need not appear on any one counterpart.

 

[The remainder of this page is intentionally left blank.  Signatures follow.]

 

13


 

IN WITNESS WHEREOF, each of the parties has duly executed this Agreement effective as of the date first above written.

 

THE COMPANIES:

 

 

AGILITI, INC.

 

 

 

By:

/s/ Tom Leonard

 

Name: Tom Leonard

 

Title: Chief Executive Officer

 

 

 

AGILITI HOLDCO, INC.

 

 

 

By:

/s/ Tom Leonard

 

Name: Tom Leonard

 

Title: Chief Executive Officer

 

 

 

AGILITI HEALTH, INC.

 

 

 

By:

/s/ Tom Leonard

 

Name: Tom Leonard

 

Title: Chief Executive Officer

 

[SIGNATURE PAGE TO ADVISORY SERVICES AGREEMENT]

 


 

THE MANAGER:

THL MANAGERS VIII, LLC

 

 

 

By:

Thomas H. Lee Partners, L.P., its managing member

 

By:

Thomas H. Lee Advisors, LLC, its general partner

 

By:

THL Holdco, LLC, its Managing Member

 

 

 

By:

/s/ Charles P. Holden

 

 

Name:

Charles P. Holden

 

 

Title:

Managing Director

 

[SIGNATURE PAGE TO ADVISORY SERVICES AGREEMENT]

 


EX-16.1 9 a19-2105_2ex16d1.htm EX-16.1

Exhibit 16.1

 

January 10, 2019

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC  20549

 

Commissioners:

 

We have read the statements made by Federal Street Acquisition Corp. under Item 4.01 of its Form 8-K dated January 4, 2019.  We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Federal Street Acquisition Corp. contained therein.

 

Very truly yours,

 

 

 

/s/ Marcum LLP

 

 

 

Marcum LLP

 

 


EX-99.1 10 a19-2105_2ex99d1.htm EX-99.1

Exhibit 99.1

 

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF AGILITI, INC.

 

Capitalized terms used herein and not otherwise defined have the meanings assigned to such terms in Agiliti, Inc.’s Definitive Proxy Statement/Prospectus (the “Proxy Statement/Prospectus”) filed with the SEC on October 10, 2018 or the Supplement to the Definitive Proxy Statement/Prospectus (the “Proxy Statement/Prospectus Supplement”) filed with the SEC on December 20, 2018.

 

These unaudited pro forma condensed combined financial statements give effect to the Business Combination on the terms contemplated by the A&R Merger Agreement.

 

The historical consolidated financial statements of Agiliti Health, Inc., a wholly owned subsidiary of Agiliti Holdco, and its subsidiaries are included in the Proxy Statement/Prospectus and Proxy Statement/Prospectus Supplement and incorporated by reference in the Current Report on Form 8-K of which this exhibit is a part, as opposed to those of Agiliti Holdco. Agiliti Holdco is a holding company without any operations or employees, and no liabilities or material assets beyond its investment in Agiliti Health, Inc. Further, prior to the Mergers, Agiliti had no material operations, assets, or liabilities.

 

The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2017 was derived from Agiliti Health, Inc.’s audited consolidated statement of operations for the year ended December 31, 2017 and FSAC’s audited statement of operations for the period from March 21, 2017 (inception) to December 31, 2017. The unaudited pro forma condensed combined balance sheet and statement of operations as of and for the nine months ended September 30, 2018 were derived from Agiliti Health, Inc.’s unaudited consolidated financial statements as of and for the nine months ended September 30, 2018 and FSAC’s unaudited condensed financial statements as of and for the nine months ended September 30, 2018.

 

The unaudited pro forma condensed combined statements of operations for the year ended December 31, 2017 and for the nine months ended September 30, 2018 give pro forma effect to the Business Combination as if it had occurred on January 1, 2017. The unaudited pro forma condensed combined balance sheet as of September 30, 2018 gives effect to the Business Combination as if it was completed on September 30, 2018.

 

This information should be read together with Agiliti Health, Inc.’s and FSAC’s respective financial statements and the related notes, “FSAC’s Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Agiliti’s Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and the other financial information included the Proxy Statement/Prospectus and Proxy Statement/Prospectus Supplement and incorporated by reference in the Current Report on Form 8-K of which this exhibit is a part.

 

The unaudited pro forma condensed combined financial statements give effect to the Business Combination in accordance with the acquisition method of accounting for business combinations, with FSAC deemed to be the accounting acquirer because, among other reasons, cash consideration was transferred from FSAC to the Selling Equityholders, and the former shareholders of FSAC as well as purchasers of FSAC common stock own approximately 99% of the outstanding common stock of Agiliti which represents a controlling interest in Agiliti.

 

Holders of FSAC public shares had the right to elect to redeem their shares for cash equal to their pro rata share of the aggregate amount on deposit in the Trust Account (as of two business days prior to the closing of the Business Combination) in accordance with FSAC’s amended and restated certificate of incorporation. Based on funds in the Trust Account of approximately $466.2 million as of September 30, 2018, the per share redemption price would have been approximately $10.14.

 

The unaudited pro forma condensed combined financial statements reflect adjustments to the historical financial information that are expected to have a continuing impact on the results of the combined company, factually supportable and directly attributable to the following:

 

·                  the Mergers;

 

·                  the payment of the merger consideration to the Selling Equityholders, including the issuance of approximately 336,000 shares in connection with the Rollover;

 

·                  the issuance of approximately 98,939,000 shares of common stock of Agiliti including the issuance of approximately 86,795,000 issued to THL Stockholder in the Private Placement and the 11,500,000 Founder Shares;

 


 

·                  the warrants to purchase common stock of FSAC becoming, in accordance with their terms, warrants to purchase common stock of Agiliti and the assumption by Agiliti of all rights and obligations under the warrant agreement governing such warrants;

 

·                  the repayment of approximately $684.4 million of outstanding indebtedness, including accrued interest, of Agiliti Health as of September 30, 2018 and the entry into the Debt Financing assuming the Business Combination had been consummated on September 30, 2018 for purposes of the balance sheet and on January 1, 2017 for purposes of the statements of operations; and

 

·                  the redemption from holders electing to redeem their public shares, in accordance with FSAC’s amended and restated certificate of incorporation.

 

The unaudited pro forma condensed combined financial information is for illustrative purposes only. The financial results may have been different had the companies always been combined. You should not rely on the unaudited pro forma condensed combined financial information as being indicative of the historical results that would have been achieved had the companies always been combined or the future results that the combined company will experience. Agiliti and FSAC have not had any historical relationship prior to the Business Combination. Accordingly, no pro forma adjustments were required to eliminate activities between the companies.

 

1. Basis of Pro Forma Presentation

 

Overview

 

The unaudited pro forma condensed combined financial statements have been prepared assuming the Business Combination is accounted for using the acquisition method of accounting with FSAC as the acquiring entity and Agiliti Health, Inc. as the acquiree. Under the acquisition method of accounting, FSAC’s assets and liabilities will retain their carrying values and assets and liabilities will be recorded at their fair values measured as of the acquisition date. The excess of the purchase price over the estimated fair values of net assets acquired will be recorded as goodwill. The pro forma adjustments have been prepared as if the Business Combination and the other related transactions had taken place on September 30, 2018 in the case of the unaudited pro forma condensed combined balance sheet and on January 1, 2017 in the case of the unaudited pro forma condensed combined statements of operations.

 

The acquisition method of accounting is based on Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) 805, Business Combinations (“ASC 805”), and uses the fair value concepts defined in FASB ASC 820, Fair Value Measurements (“ASC 820”). ASC 805 requires, among other things, that most assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date by FSAC, who was determined to be the accounting acquirer.

 

ASC 820 defines the term “fair value,” sets forth the valuation requirements for any asset or liability measured at fair value, expands related disclosure requirements and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined in ASC 820 as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” This is an exit price concept for the valuation of the asset or liability. In addition, market participants are assumed to be buyers and sellers in the principal (or the most advantageous) market for the asset or liability. Fair value measurements for an asset assume the highest and best use by these market participants. Many of these fair value measurements can be highly subjective, and it is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.

 

Under ASC 805, acquisition-related transaction costs are not included as a component of consideration transferred but are accounted for as expenses in the periods in which such costs are incurred, or if related to the issuance of debt, capitalized as debt issuance costs. Acquisition-related transaction costs expected to be incurred as part of the business combination, include estimated fees related to the issuance of long-term debt, as well as advisory, legal and accounting fees.

 

The unaudited pro forma condensed combined financial statements should be read in conjunction with (i) FSAC’s historical financial statements and related notes for the period from March 21, 2017 (date of inception) to December 31, 2017 and for the nine months ended September 30, 2018, as well as “FSAC’s Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included elsewhere in this proxy statement/prospectus, (ii) Agiliti Opco’s historical consolidated financial statements and related notes for the year ended December 31, 2017 and for the nine months ended September 30, 2018, as well as “Agiliti Health, Inc.’s Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in the Proxy Statement/Prospectus and Proxy Statement/Prospectus Supplement and incorporated by reference in the Current Report on

 

2


 

Form 8-K of which this exhibit is a part.

 

The pro forma adjustments represent management’s estimates based on information available as of the date hereof and are subject to change as additional information becomes available and additional analyses are performed. The unaudited pro forma condensed combined financial statements do not reflect possible adjustments related to restructuring or integration activities that have yet to be determined or transaction or other costs following the Business Combination that are not expected to have a continuing impact. Further, one-time transaction-related expenses anticipated to be incurred prior to, or concurrent with, closing the Business Combination and the other related transactions are not included in the unaudited pro forma condensed combined statements of operations. However, the impact of such transaction expenses is reflected in the unaudited pro forma condensed combined balance sheet as a decrease to retained earnings and a decrease to cash, unless otherwise noted.

 

2. Preliminary Allocation of Purchase Price

 

The total purchase consideration for the Business Combination has been allocated to the assets acquired, liabilities assumed, and noncontrolling interest for purposes of the unaudited pro forma condensed combined financial information based on their estimated relative fair values. The allocation of the purchase consideration herein is preliminary. The final allocation of the purchase consideration for the Business Combination will be determined after the completion of a thorough analysis to determine the fair value of all assets acquired, liabilities assumed and noncontrolling interest but in no event later than one year following the completion of the Business Combination.

 

Accordingly, the final acquisition accounting adjustments could differ materially from the preliminary amounts presented in these unaudited pro forma condensed combined financial statements. Any increase or decrease in the fair value of the assets acquired, liabilities assumed and noncontrolling interest, as compared to the information shown herein, could also change the portion of the purchase consideration allocable to goodwill and could impact the operating results of Agiliti following the Business Combination due to differences in the allocation of the purchase consideration, depreciation and amortization related to some of these assets and liabilities. The purchase consideration was preliminarily allocated as follows:

 

(In thousands)

 

 

 

Cash paid to Selling Equityholders

 

$

714,428

 

Equity consideration paid to Selling Equityholders

 

21,822

 

Tax Receivable Agreement payable due to Selling Equityholders

 

43,947

 

Total purchase price

 

$

780,197

 

Accounts receivable

 

$

97,166

 

Inventories

 

11,257

 

Prepaids and other assets

 

6,928

 

Medical equipment

 

236,610

 

Property and office equipment

 

44,084

 

Intangibles

 

407,000

 

Other

 

10,789

 

Goodwill

 

845,693

 

Current liabilities

 

(93,440

)

Deferred tax liabilities

 

(87,602

)

Long-term debt

 

(691,651

)

Other long-term liabilities

 

(6,457

)

Non-controlling interest

 

(180

)

Net assets acquired

 

$

780,197

 

 

The estimated value of the equity consideration paid to Selling Equityholders includes common stock of Agiliti with an estimated fair value of approximately $2.9 million and roll-over options with an intrinsic value of $19.0 million. Such roll-over options are fully vested and exercisable following the consummation of the Business Combination for approximately 2,976,000 shares of common stock of Agiliti with a weighted average exercise price of $2.13 per share. The estimated value of the aggregate equity consideration issued to Selling Equityholders of $21.8 million is based on the per share value of $8.50 per share as established by the A&R Merger Agreement.

 

3


 

The estimated value of $43.9 million relates to the Tax Receivable Agreement that Agiliti entered into with Agiliti Holdco and the stockholders’ representative at the closing of the Business Combination. The Tax Receivable Agreement generally provides for the payment by Agiliti Holdco to the Selling Equityholders of 85% of certain tax benefits that Agiliti and its subsidiaries (including Agiliti Holdco) actually realizes or are deemed to realize from the use of certain tax attributes in periods after the closing of the Business Combination. Agiliti and its subsidiaries (including Agiliti Holdco) will retain the tax benefit, if any, of the remaining 15% of these tax attributes.

 

Preliminary identifiable intangible assets in the unaudited pro forma condensed combined financial information consist of intangibles derived from customer relationships and certain non-compete agreements. Customer relationships were valued through application of the income approach. Under this approach, revenue, operating expenses and other costs associated with existing customers were estimated in order to derive cash flows attributable to the existing customer relationships. The resulting cash flows were then discounted to present value at a rate of 9.9% to arrive at the fair value of existing customer relationships as of the valuation date. The amortization related to the customer relationships is reflected as an unaudited pro forma adjustment to the unaudited pro forma condensed combined statement of operations using the sum of the years digits method of amortization which approximates the pattern of benefit expected from the intangible assets. Company management has determined the estimated remaining useful life of the customer relationships based on the projected economic benefits associated with these relationships. The 15-year preliminarily estimated useful life represents the approximate point in the projection period in which a majority of the asset’s cash flows are expected to be realized based on assumed attrition rates. The non-compete agreements are preliminarily estimated to have definite useful lives based on the underlying non-compete agreements of approximately five years. These assumptions have been developed based on discussions with Agiliti’s management and review of historical customer data.

 

The preliminarily estimated fair value of the debt assumed approximates its historical carrying value, which is consistent with the debt trading values as of September 30, 2018 (as applicable).

 

The amount that will ultimately be allocated to these identified intangible assets, and the related amount of amortization, may differ materially from this preliminary allocation.

 

The preliminary allocation of the purchase consideration to property and equipment was based on the fair value of such assets determined using the indirect cost method. Depreciation expense for property and equipment was preliminarily estimated based on a straight line methodology over four years, which approximates the remaining weighted useful life of such underlying assets.

 

Goodwill represents the excess of the total purchase consideration over the fair value of the underlying net assets, largely arising from the workforce and extensive efficient distribution network that has been established by Agiliti.

 

The table set forth below presents a reconciliation of the purchase consideration as determined under GAAP to the aggregate merger consideration under the Merger Agreement:

 

(in thousands)

 

 

 

Total purchase price (as determined under GAAP)

 

$

780,197

 

Less: Estimated payments to the Selling Equityholders under the Tax Receivable Agreement

 

(43,947

)

Plus: Amount of Agiliti’s long term debt repayment(a)

 

684,400

 

Plus: Capital leases assumed

 

19,350

 

Merger consideration

 

$

1,440,000

 

 


(a)         Represents the retirement of historical long-term debt held by Agiliti under its 7.625% senior secured notes and its senior secured credit facility along with the associated accrued interest.

 

3. Pro Forma Adjustments and Assumptions

 

The unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the Business Combination and other transactions described above and has been prepared for informational purposes only. The unaudited pro forma condensed combined statements of operations are not necessarily indicative of what the actual results of operations would have been had the Business Combination taken place on the date indicated, nor is it indicative of the future consolidated results of operations of the combined company. The unaudited pro forma condensed combined financial information is based upon the

 

4


 

historical consolidated financial statements of FSAC and Agiliti Health, Inc. and subsidiaries and should be read in conjunction with their historical financial statements included in the Proxy Statement/Prospectus and Proxy Statement/Prospectus Supplement and incorporated by reference in the Current Report on Form 8-K of which this exhibit is a part.

 

The historical consolidated financial statements have been adjusted in the unaudited pro forma condensed combined financial information to give effect to pro forma events that are (1) directly attributable to the Business Combination, the Private Placement and the Debt Financing, (2) factually supportable, and (3) with respect to the statements of operations, expected to have a continuing impact on the results of Agiliti.

 

There were no intercompany balances or transactions between Agiliti and FSAC as of the dates and for the periods of these unaudited pro forma combined financial statements.

 

The pro forma combined consolidated provision for income taxes does not necessarily reflect the amounts that would have resulted had the companies filed consolidated income tax returns during the periods presented.

 

The pro forma basic and diluted earnings per share amounts presented in the unaudited pro forma condensed combined statements of operations are based upon the number of Agiliti’s shares outstanding, assuming the Business Combination and Private Placement occurred on January 1, 2017.

 

5


 

Unaudited Pro Forma Condensed Combined Statement of Operations

 

For Nine Months Ended September 30, 2018

 

(in thousands, except per share data)

 

 

 

FSAC

 

Agiliti

 

Pro Forma
Adjustments

 

 

 

Pro Forma
Combined

 

Revenues

 

$

 

$

421,175

 

$

 

 

 

$

421,175

 

Cost of revenues

 

 

273,322

 

14,399

 

(a)

 

287,721

 

Gross margin

 

 

147,853

 

(14,399

)

 

 

133,454

 

Selling, general and administrative

 

11,316

 

102,138

 

28,913

 

(b)

 

142,367

 

Gain on legal settlement

 

 

(26,291

)

 

 

 

(26,291

)

Operating income

 

(11,316

)

72,006

 

(43,312

)

 

 

17,379

 

Other Income (Expense)

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(40,128

)

8,013

 

(c)

 

(32,115

)

Interest income

 

5,702

 

 

(5,702

)

(d)

 

 

Other income (expense)

 

(12

)

 

 

 

 

(12

)

Income (loss) before income taxes and noncontrolling

 

(5,626

)

31,878

 

(40,750

)

 

 

(14,749

)

Benefit (Provision) for income taxes

 

1,128

 

(767

)

10,607

 

(e)

 

10,968

 

Net Income attributable to noncontrolling interest

 

 

(241

)

 

 

 

(241

)

Net Income (Loss)

 

$

(4,498

)

$

30,870

 

$

(30,394

)

 

 

$

(4,022

)

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per Common Share

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.65

)

 

 

 

 

(f)

 

$

(0.04

)

Diluted

 

$

(0.65

)

 

 

 

 

(f)

 

$

(0.04

)

Weighted Average Common Shares Outstanding

 

 

 

 

 

 

 

 

 

 

 

Basic

 

13,245

 

 

 

 

 

 

 

98,939

 

Diluted

 

13,245

 

 

 

 

 

 

 

101,915

 

 

6


 

Unaudited Pro Forma Condensed Combined Statement of Operations

 

For Year Ended December 31, 2017

 

(in thousands, except per share data)

 

(amounts in thousands, except per share)

 

FSAC

 

Agiliti

 

Pro Forma
Adjustments

 

 

 

Pro Forma
Combined

 

Revenues

 

$

 

$

514,783

 

$

 

 

 

$

514,783

 

Cost of revenues

 

 

343,028

 

19,199

 

(a)

 

362,227

 

Gross margin

 

 

171,755

 

(19,199

)

 

 

152,556

 

Selling, general and administrative

 

485

 

125,910

 

41,975

 

(b)

 

168,370

 

Operating income

 

(485

)

45,845

 

(61,174

)

 

 

(15,814

)

Other Income (Expense)

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(53,762

)

10,844

 

(c)

 

(42,918

)

Interest income

 

2,275

 

 

(2,275

)

(d)

 

 

Other income (expense)

 

(22

)

 

 

 

 

(22

)

Income (loss) before income taxes and noncontrolling interest

 

1,768

 

(7,917

)

(52,270

)

 

 

(58,420

)

Benefit (Provision) for income taxes

 

(627

)

17,159

 

20,661

 

(e)

 

37,193

 

Net Income attributable to noncontrolling interest

 

 

(414

)

 

 

 

(414

)

Net Income (Loss)

 

$

1,141

 

$

8,828

 

$

(31,944

)

 

 

$

(21,975

)

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per Common Share

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.01

)

 

 

 

 

(f)

 

$

(0.22

)

Diluted

 

$

(0.01

)

 

 

 

 

(f)

 

$

(0.22

)

Weighted Average Common Shares Outstanding

 

 

 

 

 

 

 

 

 

 

 

Basic

 

11,861

 

 

 

 

 

 

 

98,939

 

Diluted

 

11,861

 

 

 

 

 

 

 

101,915

 

 

See accompanying notes to unaudited pro forma condensed combined financial information.

 

7


 

Pro Forma Adjustments to the Statement of Operations:

 


(a)   Represents the adjustments to depreciation of $13.7 million and $18.3 million for the nine months ended September 30, 2018 and the year ended December 31, 2017, respectively and other expenses primarily related to resetting Agiliti’s rent of $0.7 million and $0.9 million for the nine months ended September 30, 2018 and the year ended December 31, 2017, respectively within Cost of revenue, primarily reflecting the impact of the changes in fair values of Medical equipment and Property and office equipment, based on the preliminary purchase price allocation.

 

(b)   Represents the adjustments to amortization of $28.9 million and $42.0 million for the nine months ended September 30, 2018 and the year ended December 31, 2017, respectively within Selling, general and administrative reflecting the impact of the changes in fair value of intangible assets, primarily customer relationships, based on the preliminary purchase price allocation. Amortization of the acquired intangible assets will be recognized using the sum of the years digits method of amortization over the estimated useful life, which represents the projected economic benefits associated with the acquired intangible assets. Assuming the Business Combination had occurred on January 1, 2017, future annual amortization expense as of December 31, 2017 related to the acquired intangible asset is estimated as follows: $48.2 million in 2018, $44.8 million in 2019, $41.5 million in 2020, $38.2 million in 2021, $33.2 million in 2022 and $149.6 million thereafter.

 

(c)    Represents the net change to interest expense related to the repayment of historical debt of Agiliti and issuance of new debt in connection with the Business Combination. Pro forma interest expense assumes a weighted average rate of approximately 5.5% on the new senior term loan and senior secured credit facility. We drew approximately $34.0 million of borrowings on the $150.0 million senior secured credit revolving facility at the closing of the Business Combination. Each 1/8% change in the assumed rate would create a $0.8 million change in annual interest expense.

 

(d)   Represents the adjustment to eliminate the historical interest income of FSAC associated with the funds that were held in the Trust Account, which were used to fund portions of the cash consideration and debt refinancing in connection with the Business Combination.

 

(e)    Represents the adjustment to record the tax expense based on total pro forma combined income (loss) before income taxes as if FSAC had been subject to U.S federal, state and local income tax as a corporation using an estimated effective income tax rate of 26% and 39% in 2018 and 2017 respectively, inclusive of all applicable U.S. federal, state and local income taxes. Pro forma tax rates do not reflect any impact with respect to changes in the historical Agiliti valuation allowance (which was assumed to be released as part of the Business Combination such that no valuation allowance was reflected on the September 30, 2018 balance sheet and no tax benefit was reflected on the September 30, 2018 income statement). However, the historical Agiliti income tax expense of $10.2 million for September 30, 2018, and income tax benefit of $17.2 million for December 31, 2017, were calculated as if the historical Agiliti valuation allowance still exists, given that the valuation allowance release is assumed to occur on September 30, 2018. Additionally, the December 31, 2017, Agiliti tax benefit of $17.2 million includes a tax benefit for the revaluation of Agiliti’s historic net deferred tax liability as a result of the Tax Cuts and Jobs Act (the “Tax Act”) passed on December 22, 2017. Aside from the reduction in the federal tax rate, no further adjustments as a result of the Tax Act were included in either the 2018 and 2017 tax adjustments.

 

(f)     Pro forma basic earnings per share was computed by dividing pro forma net income attributable to Agiliti common shareholders by the weighted average shares of Class A Common Stock, as if such shares were issued and outstanding as of January 1, 2017. Basic shares outstanding were calculated based on the following common shares outstanding:

 

FSAC Class A common stock

 

307,593

 

FSAC Class F common stock

 

11,500,000

 

Private Placement to THL Stockholder

 

86,795,398

 

Equity consideration—shares

 

336,081

 

Total common shares outstanding

 

98,939,072

 

Equity consideration—options

 

2,975,618

 

 

 

 

 

Diluted shares outstanding

 

101,914,690

 

 

Pro forma dilutive earnings per share was computed using the “if-converted” method to determine the potential dilutive effect of its outstanding options.

 

Earnings per Common Share for FSAC exclude income attributable to common stock subject to redemption of $4.1 million and

 

8


 

$1.3 million for the nine months ended September 30, 2018 and for the period from March 21, 2017 (inception) through December 31, 2017, respectively.

 

The outstanding FSAC warrants became warrants to purchase shares of common stock of Agiliti. The warrants are not dilutive on a pro forma basis; however, the potential dilutive impact will ultimately be recognized based on the actual market price on the date of measurement.

 

9


 

Unaudited Pro Forma Balance Sheets

 

As of September 30, 2018

 

(in thousands, except per share data)

 

 

 

FSAC

 

Agiliti

 

Pro Forma
Adjustments

 

 

 

Pro Forma
Combined

 

Assets

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

3,189

 

$

 

$

 

(a)

 

$

3,189

 

Accounts receivable less allowance for doubtful accounts of $1,225 at Sept 30, 2018

 

 

97,166

 

 

 

 

97,166

 

Inventories

 

 

11,257

 

 

 

 

11,257

 

Other current assets

 

123

 

6,928

 

 

 

 

7,051

 

Total current assets

 

3,312

 

115,351

 

 

 

 

118,663

 

Investments held in trust account

 

466,238

 

 

(466,238

)

(a)

 

 

Medical equipment

 

 

666,494

 

(429,884

)

(b)

 

236,610

 

Property and office equipment

 

 

113,600

 

(69,516

)

(b)

 

44,084

 

Accumulated depreciation

 

 

(572,400

)

572,400

 

(b)

 

 

Other Intangibles, net

 

 

146,136

 

260,864

 

(c)

 

407,000

 

Deferred Tax Asset

 

1,722

 

 

(1,722

)

 

 

 

Other

 

 

10,789

 

 

 

 

10,789

 

Goodwill

 

 

346,168

 

499,525

 

(d)

 

845,693

 

Total assets

 

$

471,272

 

$

826,138

 

$

365,429

 

 

 

$

1,662,839

 

Liabilities and Equity

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

 

Current portion of long-term debt

 

$

 

$

5,766

 

$

 

 

 

$

5,766

 

Book overdrafts

 

 

1,564

 

 

 

 

1,564

 

Accounts payable

 

9,161

 

33,478

 

 

 

 

42,639

 

Accrued compensation

 

 

26,255

 

 

 

 

26,255

 

Accrued interest

 

 

6,406

 

(6,406

)

(e)

 

 

Other accrued expenses

 

526

 

19,971

 

 

 

 

20,497

 

Total current liabilities

 

9,687

 

93,440

 

(6,406

)

 

 

96,721

 

Long-Term Debt, less current portion

 

 

691,651

 

(7,442

)

(e)

 

684,209

 

Pension and other long-term liabilities

 

 

10,726

 

39,678

 

(f)

 

50,404

 

Deferred income taxes, net

 

 

35,581

 

50,299

 

(g)

 

85,880

 

Deferred underwriting fees

 

16,100

 

 

 

(5,500

)

(h)

 

10,600

 

Total Liabilities

 

25,787

 

831,398

 

70,629

 

 

 

927,814

 

Common stock subject to possible redemption

 

440,485

 

 

(440,485

)

(i)

 

 

Stockholders’ equity

 

 

 

 

 

 

 

 

 

 

 

Class A Common stock, $.0001 par value

 

 

 

9

 

(j)

 

9

 

Class F Common stock, $.0001 par value

 

1

 

 

(1

)

(i)

 

 

Accumulated other comprehensive loss

 

 

 

(6,002

)

6,002

 

(k)

 

 

Non controlling interest

 

 

180

 

 

 

 

180

 

Additional paid in capital

 

8,356

 

251,469

 

487,782

 

(l)

 

747,607

 

Retained Earnings

 

 

 

 

 

 

 

 

Accumulated deficit

 

(3,357

)

(250,907

)

241,493

 

(m)

 

(12,771

)

Total Stockholders’ equity (deficit)

 

5,000

 

(5,260

)

735,285

 

 

 

735,025

 

Total Liabilities and Stockholders’ Equity

 

$

471,272

 

$

826,138

 

$

365,429

 

 

 

$

1,662,839

 

 

See accompanying notes to unaudited pro forma condensed combined financial information.

 

10


 

Pro Forma Adjustments to the Balance Sheet:

 


(a)  Represents the net adjustment to cash associated with FSAC’s payment of cash consideration in the Business Combination:

 

Pro forma net adjustment to cash associated with purchase adjustments (in thousands):

 

FSAC cash previously held in Trust Account(1)

 

$

466,238

 

Proceeds from Private Placement(2)

 

737,763

 

Proceeds from new debt(3)

 

694,000

 

Shareholder Redemptions(4)

 

(463,111

)

Repayment of Agiliti’s long-term debt(5)

 

(684,400

)

Cash Consideration(6)

 

(714,428

)

Payment of transaction costs(7)

 

(36,062

)

Net adjustments to cash

 

$

0

 

 


(1)  Represents the adjustment related to the reclassification of the cash equivalents held in the Trust Account in form of investments to cash and cash equivalents to reflect the fact that these investments were available for use in connection with the Business Combination and the payment of a portion of the cash consideration.

 

(2)  Represents the issuance of approximately 86,795,000 shares of Class A common stock of FSAC at a price of $8.50 per share in the Private Placement which resulted in aggregate proceeds $737.8 million

 

(3)  Represents additional funds raised of $694.0 million, including approximately $660.0 under the senior secured term loan and approximately $34.0 million of borrowings on the $150.0 million senior secured revolving credit facility at the closing of the Business Combination.

 

(4)  Represents cash paid for redemptions of FSAC common shares.

 

(5)  Represents the retirement of historical long-term debt held by Agiliti under its 7.625% senior secured notes and its senior secured credit facility along with the associated accrued interest.

 

(6)  Represents the cash consideration portion of the total consideration paid to effectuate the Business Combination prior to any Selling Equityholders’ costs and amounts to be paid under the escrow agreement.

 

(7)  Reflects the impact of estimated transaction costs payable of $36.1 million, including deferred underwriting compensation attributable to FSAC’s IPO, fees and expenses attributable to the Private Placement, debt financing fees related to the new senior secured term loan and senior secured revolving credit facility, and banking, legal and accounting fees.

 

(b)      Represents the adjustments to Medical equipment and Property and office equipment to (i) reflect the adjustment to the respective fixed asset category to reflect their estimated fair values based on the preliminary purchase price allocation, and (ii) to eliminate the historical accumulated depreciation (see Note 2).

 

(c)       Represents the adjustment to intangible assets to reflect their estimated fair values on the preliminary purchase price allocation (see Note 2).

 

(d)      Represents the adjustment to goodwill based on the preliminary purchase price allocation (see Note 2).

 

(e)       Represents the adjustment related to the repayment of Agiliti’s long-term debt and accrued interested including (i) $678.0 million of principal balance, (ii) $6.4 million of accrued interest, (iii) the elimination of $4.1 million related to deferred financing costs, and (iv) the elimination of unamoritized bond premium of $4.2 million, partially offset by (v) the issuance of $694.0 million of new long-term debt in the form of a senior secured term loan of $660.0 million and drawn borrowings under our senior secured revolving credit facility of $34.0 million, and (vi) related deferred financing costs of $21.5 million. Although borrowings under the term loan will be made within 30 days of the closing of the Business Combination and Agiliti’s long-term debt will be repaid at such time, these unaudited pro forma condensed combined financial statements give effect to the incurrence of the new borrowings and the repayment of the long-term debt at the closing of the Business Combination, assuming such closing had taken

 

11


 

place on September 30, 2018. These unaudited pro forma condensed combined financial statements are presented as such to better reflect indebtedness following the Business Combination.

 

(f)        Reflects an increase to Pension and Other Long-Term Liabilities of $43.9 million for the fair value of the Tax Receivable Agreement, which represents contingent consideration in the Business Combination, less $4.2 million related to the fair value adjustment to deferred rent. The amount of expected future payments under the Tax Receivable Agreement are dependent upon a number of factors, including Agiliti’s cash tax savings rate in the years in which it utilizes tax attributes subject to the Tax Receivable Agreement. Forecasts provided by Agiliti management and current enacted tax rates were used in calculating the Tax Receivable Agreement liability. To the extent that changes in future tax law, earnings forecasts, or subsequent exchanges occur, adjustments to the Tax Receivable Agreement liability, which will be measured at fair value with changes in fair value being recorded in earnings, will be made.

 

(g)      Represents adjustments to move the presentation of FSAC’s historical deferred tax asset against Agiliti’s historical deferred tax liability and to reflect applicable deferred tax assets and liabilities associated with the purchase accounting adjustments. The deferred taxes are primarily related to the difference between the financial statement and tax basis in the investment in Agiliti Health, Inc. This basis difference primarily results from the Business Combination where Agiliti receives a step-up value adjustment on certain assets for financial accounting purposes.

 

(h)      Represents the relief of previously accrued deferred underwriting costs.

 

(i)         Represents an adjustment to reflect that at the time of issuance, certain of FSAC’s Class A common stock was subject to a possible redemption and, as such, an amount of $440.5 million was classified as redeemable equity in FSAC’s historical consolidated balance sheet as of September 30, 2018. No shares of common stock of Agiliti will be subject to redemption and all outstanding common stock has been reclassified from redeemable equity to additional paid in capital and Class A common stock, $0.0001 par value.

 

(j)         Represents an adjustment for increase in Class A common stock outstanding to 98,939,072, with a $0.0001 par value and the associated elimination of Class F common stock.

 

(k)      Represents the elimination of Agiliti’s accumulated other comprehensive loss of $6.0 million

 

(l)         Represents the pro forma adjustments to additional paid-in capital (APIC).

 

Reverse Agiliti historical APIC

 

$

(251,469

)

Conversion of redeemable shares held by FSAC’s public stockholders to APIC, net of par amount

 

462,855

 

Increase to APIC attributable to the stock issued to the Selling Equityholders

 

21,822

 

Increase to APIC attributable to the Private Placement

 

737,755

 

Pro forma adjustment to APIC assuming no redemptions

 

$

485,482

 

 

(m)  Represents the elimination of Agiliti’ accumulated deficit of $250.9 million and $7.4 million for estimated transaction costs FSAC incurred related to the merger.

 

12


EX-99.2 11 a19-2105_2ex99d2.htm EX-99.2

Exhibit 99.2

 

EXECUTIVE COMPENSATION DISCUSSION AND ANALYSIS OF AGILITI, INC.

 

Agiliti, Inc. (“Agiliti”) was formed in August 2018 in connection with the entry into the Agreement and Plan of Merger, dated as of August 13, 2018, which was amended and restated by the A&R Merger Agreement (as defined in the Current Report on Form 8-K to which this exhibit is attached). For the year 2018 and prior to the consummation of the Business Combination (as defined in the Current Report on Form 8-K to which this exhibit is attached), none of the officers or directors of Agiliti received any cash or equity compensation for services rendered to Agiliti.

 

The executive compensation discussion and analysis set forth herein reflects the executive compensation of Agiliti Holdco, Inc. (“Agiliti Holdco”) and its subsidiaries for the year ended December 31, 2018 (to the extent calculable on the date hereof). References to “we,” “our” and “us” are to Agiliti Holdco and its subsidiaries, which following the closing of the Business Combination are wholly-owned subsidiaries of Agiliti. References to “our board of directors” and “our compensation committee” are to the board of directors and compensation committee of Agiliti Holdco prior to the closing of the Business Combination.

 

Introduction

 

In this compensation discussion and analysis we discuss our compensation program, including our compensation philosophy and objectives and each component of compensation for our chief executive officer, chief financial officer, and the other individuals included in the Summary Compensation Table below (collectively, the “named executive officers”).

 

Compensation Philosophy and Objectives

 

We strive to ensure that we are able to attract and retain talented employees and reward performance. We also believe that the most effective executive compensation program is one that is designed to reward the achievement of specific annual and long-term strategic goals of our Company. Accordingly, our compensation committee (and our board, in ratifying the compensation committee’s determination) evaluates both performance and compensation to ensure both that the compensation provided to key executives is fair and reasonable, and that it remains competitive relative to the compensation paid to similarly situated executives of a group of peer companies in the same or similar industries, adjusted for our size and ownership model. To these ends, our compensation committee and board of directors have determined that our executive compensation program for our named executive officers should include base salary, annual performance-based incentive and long-term equity (stock option) compensation that rewards performance as measured against established goals, and competitive health, dental and other benefits.

 

Overview of Agiliti Holdco’s Historical Compensation Programs and Processes

 

We have structured our compensation program to motivate the named executive officers to achieve the business goals set by us, and to reward them for achieving these goals. In furtherance of this, our compensation committee conducts an annual review of our total compensation program to achieve the following goals:

 

·                  provide fair, reasonable and competitive compensation;

 

·                  link compensation with our business plans;

 

·                  reward achievement of both company and individual performance; and

 

·                  attract and retain talented executives who are critical to our success.

 

We believe that these goals reflect the importance of pay for performance by providing our named executive officers with an opportunity to earn compensation for above average performance. The compensation for each named executive officer includes (1) a base salary that we believe is competitive with salary levels for similarly

 


 

situated executives of our peer companies, adjusted for our size and ownership model, and (2) incentive compensation that is contingent upon achievement of specific corporate and individual objectives.

 

In 2017, the compensation committee considered certain elements of total compensation against a group of publicly traded companies in the same or related industries (the “Peer Group”). Our compensation committee reviewed the compensation, including base salary and incentive compensation, paid to executives in the Peer Group, and considered the performance evaluations in determining the appropriate base salary for each named executive officer for the year 2018. In approving the compensation for our named executive officers, our board of directors considered the recommendations of our compensation committee, our company’s performance and the need to attract, retain, and motivate our executives.

 

It is challenging for us to identify a group of similarly situated peer companies, because the identity of competitors varies among our three service solutions, and great variability exists in the size and scope of activities among healthcare industry businesses, including our competitors. For purposes of determining the 2018 base salary for our named executive officers, our compensation committee determined that it was appropriate to select the following companies for inclusion in the Peer Group based on the sensitivity of each Peer Group member to similar marketplace trends and industry sector:

 

·                  Stericycle, Inc., a company that outsources medical waste disposal services;

 

·                  Healthcare Services Group, Inc., a company that outsources housekeeping and dietary services to medical facilities;

 

·                  Cerner Corporation, a supplier of healthcare information technology solutions;

 

·                  HealthSouth Corporation, a provider of inpatient rehabilitative services;

 

·                  R1 RCM Inc., formerly known as Accretive Health, Inc., a provider of revenue cycle management services for the U.S. healthcare industry.

 

·                  Premier Healthcare Solutions, Inc., a national healthcare alliance delivering an integrated platform of solutions through its supply chain services and performance services segments;

 

·                  Team Health Holdings Inc., a provider of hospital-based clinical outsourcing in multiple departments including anesthesia, hospital medicine and emergency medicine;

 

·                  Surgery Partners, Inc., a leading operator of surgical facilities and ancillary services;

 

·                  Kinetic Concepts, Inc., a provider of negative pressure wound therapy devices; and

 

·                  Hill-Rom Holdings, Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry, including patient support systems, safe mobility and handling solutions, non-invasive therapeutic products for a variety of acute and chronic medical conditions, medical equipment rentals, surgical products and information technology solutions.

 

We have not yet evaluated or examined the selection of companies to comprise the Peer Group for purposes of determining 2018 incentive compensation or 2019 compensation.

 

2018 Executive Compensation Components

 

For fiscal 2018 the principal components of compensation for our named executive officers were base salary and annual performance-based incentive compensation, each of which is addressed in greater detail below. For 2018 each named executive officer also had severance and/or change of control benefits, and was eligible to participate in our long-term savings plan and the broad-based benefit and welfare plans that are available to our

 

2


 

employees in general. In addition, the named executive officers were eligible to receive stock option awards from Agiliti Holdco under its stock option plan.

 

We do not have an established formula or target for allocating between cash and non-cash compensation, or between short-term and long-term incentive compensation. Instead, our goal is to ensure that the compensation we pay is sufficient to attract and retain executive officers, and to reward them for performance that meets the goals set by our compensation committee.

 

Setting Executive Compensation

 

The compensation committee determined the total compensation for our named executive officers based on a consideration of the following factors:

 

·                  the scope of responsibility of each named executive officer;

 

·                  market data from Peer Group companies;

 

·                  an assessment of the positions of similarly situated executives within the Peer Group and internal comparisons to the compensation received by those executives;

 

·                  internal review of each named executive officer’s compensation, both individually and relative to other named executive officers;

 

·                  individual performance of each named executive officer, which is assessed based on factors such as fulfillment of job responsibilities, the financial and operating performance of the activities directed by each named executive officer, experience and potential;

 

·                  the total compensation paid to each named executive officer in past years (including long-term equity (stock option) compensation awarded by Agiliti Holdco under its stock option plan); and

 

·                  performance evaluations for each named executive officer.

 

Base Salary

 

We provide our named executive officers with a base salary to compensate them for services rendered. Salary levels are typically considered in March of each year as part of our performance review process and upon a promotion or other change in job responsibility. Merit-based increases to salaries of the named executive officers are based on the compensation committee’s assessment of the individual’s performance.

 

Base salary ranges are determined for each named executive officer based on his or her position and responsibility and utilizing our compensation committee’s knowledge and expertise regarding the market, with reference to market data regarding Peer Group compensation compiled from public sources, compensation consultants and independent analysts. Base salary ranges are designed so that salary opportunities for a given position will be targeted at the midpoint of the base salary established for each range.

 

Our goals and objectives for the overall senior management team include:

 

·                  setting the appropriate tone at the top framework for ethics, policies and business practices across the Company;

 

·                  driving growth of revenue and EBITDA;

 

·                  being present in the field across our diverse geographical footprint with our localized employee base driving culture and best practices; and

 

3


 

·                  supporting the roll out of our products to customers by helping to communicate the key customer benefits of reducing cost, improving efficiency and improving patient outcomes.

 

Each of the named executive officers is expected to participate in the above activities, with particular emphasis on their areas of expertise. Thus, Mr. Leonard has emphasis in setting the strategy and direction for us; Mr. Pekarek has emphasis areas in controls, reporting, budgeting and capital attraction; Mr. Ketzel has the emphasis areas of growth and revenue, operational excellence and customer service; Ms. Bird has the emphasis areas of market development, growth and research; and Mr. Creviston has the emphasis areas of development and retention of talent and design and administration of compensation programs.

 

Finding that the named executive officers achieved the objectives discussed above, on March 6, 2018, the compensation committee determined to increase the base salaries of Mr. Leonard from $666,250 to $685,000, Mr. Pekarek from $435,625 to $450,000, Mr. Ketzel from $446,516 to $475,000, Mr. Creviston from $307,500 to $315,188 and Ms. Bird from $307,500 to $330,000. These increases reflected the increasing complexity of our business and the increased responsibilities these executives took on to meet growth objectives. These include increased strategic partnership activity, product development, expanded geographic markets and design and delivery of more complex customer-focused service solutions.

 

On January 4, 2019, the board of directors of Agiliti approved an increase in Mr. Leonard’s annual salary from $685,000 to $750,000 effective upon consummation of the Business Combination.

 

Annual Performance-Based Incentive Compensation

 

The annual performance-based incentive compensation component is offered through the Executive Incentive Program (the “EIP”), an annual cash incentive program that provides our executive officers with an opportunity to earn annual incentive awards based on our financial performance. Under the EIP, our named executive officers can earn incentive awards that are based on a percentage of base salary, with the percentage for each officer (other than Mr. Leonard, whose percentage was specified in his employment agreement with us) set at a level the compensation committee has determined is consistent with his level of accountability and impact on our operations. In setting this percentage of base salary, the compensation committee also considers the incentive compensation paid to executives in the Peer Group. The percentage of base salary for our named executive officers (other than the chief executive officer) varies from 65% to 75% of base salary. The target award under the EIP for Mr. Leonard, our chief executive officer, was 100% of base salary, as specified in his employment agreement. The 2018 EIP targets for each of our named executive officers were as follows:

 

Senior
Manager

 

2018
Executive
Incentive Plan
Target as a
Percent
of 2018 Base
Salary

 

Thomas J. Leonard

 

100

%

James B. Pekarek

 

70

%

Kevin E. Ketzel

 

75

%

Robert L. Creviston

 

65

%

Bettyann Bird

 

70

%

 

4


 

The corporate financial performance objectives under the EIP relate to capital expenditures and Adjusted EBITDA, defined as earnings attributable to us before interest expense, income taxes, depreciation and amortization and excludes non-cash share-based compensation expense, management, board and other nonrecurring gain, expenses or loss. For fiscal 2018, the compensation committee established the capital expenditures target at $50 million and the Adjusted EBITDA target at $146 million. Adjusted EBITDA is used internally as a measure of operational performance, we disclose it externally to assist analysts, investors and lenders in their comparisons of operational performance, valuation and debt capacity across companies with differing capital, tax and legal structures. EBITDA, however, is not a measure of financial performance under GAAP and should not be considered as an alternative to, or more meaningful than, net income as a measure of operating performance or to cash flows from operating, investing or financing activities as a measure of liquidity. Because EBITDA is not a measure of GAAP and is thus susceptible to varying interpretations and calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. EBITDA does not represent an amount of funds that is available for management’s discretionary use. Adjusted EBITDA is included because certain compensation plans are based upon this measure.

 

The threshold levels for achievement of the corporate financial objective, and the formula for payment of awards under the EIP, are determined by the compensation committee. In March 2019, the threshold levels for achievement of the corporate financial objectives for 2018 EIP awards will be determined by the compensation committee of Agiliti and will be paid to our named executive officers thereafter. Our named executive officers’ eligibility to earn an incentive award is based on our achievement of those corporate financial objectives for the current year, calculated by comparing actual and target capital expenditures and Adjusted EBITDA for that fiscal year.

 

Severance and/or Change of Control Benefits

 

We have adopted an Executive Severance Pay Plan that provides for severance benefits for certain of our senior executive officers, including Mr. Ketzel, Mr. Creviston, and Ms. Bird, who are named executive officers. In addition, we have entered into employment agreements with Mr. Leonard, our chief executive officer, and Mr. Pekarek, our chief financial officer. These employment agreements provide for severance and/or change of control benefits for Mr. Leonard and Mr. Pekarek. Severance and/or change in control benefits serve several purposes and are designed to:

 

·                  aid in the attraction and retention of the executives as a competitive practice;

 

·                  keep the executives focused on running the business, impartial and objective when confronted with transactions that could result in a change of control; and

 

·                  encourage our executives to act in the best interest of our stockholder in evaluating transactions.

 

For a detailed discussion of the foregoing, please refer to the caption “Potential Payments Upon Termination or Change in Control” below.

 

Long-Term Savings Plan and Other Benefits

 

We adopted a Long-Term Savings Plan, which is a tax-qualified retirement savings plan pursuant to which all employees, including the named executive officers, are able to contribute to the plan the lesser of up to 60% of their annual salary or the limit prescribed by the IRS on a pre-tax basis. We will match 50% of up to 6% of base pay that is contributed to the Long-Term Savings Plan, subject to the limits prescribed by the IRS, excluding any catch-up contributions. Matching contributions and any earnings on the matching contributions are vested in accordance with the following schedule:

 

5


 

Years of 
Service

 

Vesting 
Percentage

 

Less than 1

 

 

1

 

33

%

2

 

66

%

3

 

100

%

 

Long-Term Equity Incentive (Stock Option) Compensation

 

The 2007 Stock Option Plan of Agiliti Holdco (“2007 Stock Option Plan”) provides for the award of stock options to our named executive officers and was designed to:

 

·                  enhance the link between the creation of stockholder value and long-term executive incentive compensation;

 

·                  provide an opportunity for increased equity ownership of Agiliti Holdco by executives; and

 

·                  maintain competitive levels of total compensation.

 

Stock option award levels vary among participants based on their positions with us. Consistent with past practice, broad-based stock option awards were granted in June of 2007, following a change of control of Agiliti Holdco. Thereafter, options were generally expected to be granted periodically throughout the year and were granted to individuals who were newly hired or who were promoted or who increased their job responsibilities. None of the executive officers received grants of options under the 2007 Stock Option Plan in 2018. Following the Business Combination, stock options outstanding under the 2007 Stock Option Plan have a weighted average exercise price of $2.13 per share. The ultimate value of an award will depend on Agiliti’s stock price.

 

Effective November 4, 2014, the compensation committee recommended, and the board of directors of Agiliti Holdco (the “Agiliti Holdco board of directors”) approved, an amendment (the “Amendment”) to the 2007 Stock Option Plan to remove the 2007 Stock Option Plan’s mandatory ten year limit on the duration of stock options. In addition, the compensation committee recommended, and the Agiliti Holdco board of directors approved, unilateral amendments to certain outstanding stock option agreements. These amendments extended the expiration date of such options to November 4, 2024 and reset the option exercise price at $0.71 per share, which was the fair market value of Agiliti Holdco’s common stock on the amendment date as determined by a third party valuation obtained by the Agiliti Holdco board of directors. The original options were granted from June 18, 2007 to May 21, 2013 with exercise prices ranging from $1.00 to $1.83. The Amendment to the 2007 Stock Option Plan and the amendments to the individual options did not change the number of options granted, the vesting commencement date, the vesting schedules or any continued service requirements.

 

On May 9, 2018, Agiliti Holdco adopted the 2018 Executive Management Stock Option Plan (the “2018 Stock Option Plan”). The 2018 Stock Option Plan contemplated the grant of non-qualified stock options. The maximum number of shares for which options could be granted was 2,500,000 under the 2018 Stock Option Plan. In the second quarter of 2018, 2,499,000 shares of Agiliti Holdco common stock were issued to certain Agiliti’s executives, including named executive officers other than the chief executive officer pursuant to the 2018 Stock Option Plan.

 

Prior to the Business Combination, options granted pursuant to the 2018 Stock Option Plan had an exercise price of $0.71 per share and could only be exercised upon a change of control (as defined in the 2018 Stock Option Plan) and only if such change of control occurred no later than March 15th of the calendar year following the calendar year in which the signing of a binding agreement for Agiliti to undergo a change of control occurs. No expense has been recorded for this plan in 2018. Additionally, all awards of options granted pursuant to the 2018 Stock Option Plan provide for a claw back in the event an award recipient voluntarily terminates his or her

 

6


 

employment with Agiliti without Good Reason or has his or her employment terminated by Agiliti for Cause (as such terms are defined in Agiliti’s Executive Severance Pay Plan) within one year following a change in control of Agiliti Holdco.

 

The 2007 Stock Option Plan and the 2018 Executive Management Stock Option Plan were assumed by Agiliti at the closing of the Business Combination.

 

Other Benefits

 

Our named executive officers are eligible to participate in the same broad-based benefit and welfare plans that are made available to our employees in general.

 

Pay Ratio

 

The ratio of the annual total compensation of our Chief Executive Officer to the annual total compensation of our median employee (other than the Chief Executive Officer) for 2018 is not calculable as of the date hereof because the amount of non-equity incentive compensation payable to our Chief Executive Officer for 2018 is not calculable at this time. The annual total compensation of our Chief Executive Officer for 2018 is expected to be determined in March 2019.

 

Tax and Accounting Implications

 

Deductibility of Executive Compensation

 

The compensation committee reviews and considers our deductibility of executive compensation. We believe that compensation paid under our EIP is generally deductible for federal income tax purposes. Section 280G of the IRS Code provides that we may not deduct compensation paid in connection with a change of control that is treated as an excess parachute payment. In certain circumstances, the compensation committee may elect to approve compensation that is not fully deductible to ensure competitive levels of compensation for our executive officers. The Tax Cuts and Jobs Act limited our deductibility to $1 million for named executive officers beginning after January 1, 2018.

 

Accounting for Share-Based Compensation

 

Beginning January 1, 2006, we began accounting for our share-based compensation, namely, stock options issued under the 2007 Stock Option Plan, as required by ASC Topic 718, “Compensation—Stock Compensation.”

 

While Agiliti Holdco established the 2007 Stock Option Plan, compensation expense related to service provided by Agiliti’s employees, including the named executive officers, is recognized in Agiliti’s Statements of Operations.

 

Executive Compensation

 

The following tables and accompanying narrative disclosure should be read in conjunction with the Compensation Discussion and Analysis.

 

Summary Compensation Table

 

The table below sets forth the compensation awarded to, earned by or paid to the named executive officers for our 2018, 2017, and 2016 fiscal years as further described in the footnotes below.

 

7


 

Name and Principal
Position

 

Year

 

Salary
($)

 

Option
Awards
($)(1)

 

Stock
Awards
($)

 

Non-Equity
Incentive
Plan
Compensation
($)(2)

 

All Other
Compensation
($)(3)

 

Total
($)

 

Thomas J. Leonard

 

2018

 

$

679,952

 

$

 

$

 

 

 

$

8,100

 

 

 

Chief Executive Officer

 

2017

 

$

661,875

 

$

 

$

 

$

697,616

 

$

9,000

 

$

1,368,491

 

and Director

 

2016

 

$

650,000

 

$

(190,700

)

$

 

$

699,400

 

$

9,000

 

$

1,167,700

 

James B. Pekarek

 

2018

 

$

446,130

 

$

 

$

 

 

 

$

9,180

 

 

 

Executive Vice President

 

2017

 

$

432,765

 

$

 

$

 

$

350,000

 

$

9,555

 

$

792,320

 

and Chief Financial Officer

 

2016

 

$

417,361

 

$

167,150

 

$

 

$

330,000

 

$

9,067

 

$

923,578

 

Kevin E. Ketzel

 

2018

 

$

467,331

 

$

 

$

 

 

 

$

8,100

 

 

 

President

 

2017

 

$

443,584

 

$

 

$

 

$

400,000

 

$

8,872

 

$

852,456

 

 

 

2016

 

$

432,765

 

$

167,150

 

$

 

$

360,000

 

$

6,492

 

$

966,407

 

Robert L. Creviston

 

2018

 

$

313,118

 

$

 

$

 

 

 

$

5,427

 

 

 

Chief Human Resources

 

2017

 

$

305,481

 

$

 

$

 

$

209,285

 

$

4,079

 

$

518,845

 

Officer

 

2016

 

$

295,505

 

$

117,005

 

$

 

$

210,000

 

$

7,297

 

$

629,807

 

Bettyann Bird

 

2018

 

$

323,942

 

$

 

$

 

 

 

$

8,100

 

 

 

Senior Vice President,

 

2017

 

$

305,481

 

$

 

$

 

$

250,000

 

$

1,349

 

$

556,830

 

Marketing

 

2016

 

$

288,462

 

$

534,880

 

$

 

$

225,000

 

$

1,385

 

$

1,049,727

 

 


(1)                                 The amounts in the “Option Awards” column reflect that Mr. Pekarek, Mr. Ketzel, Mr. Creviston and Ms. Bird received grants of options in the year ended December 31, 2016. No option awards under the 2007 Stock Option Plan were granted in 2017 and 2018 to our named executive officers. On March 14, 2016, Mr. Leonard entered into an amended Stock Option Agreement with Agiliti Holdco, amending the amount of his stock option award from 15,000,000 options to 14,000,0000. Mr. Leonard agreed to relinquish 1,000,000 options in order to return them to the stock option pool to be awarded to members of management. The amounts in the “Option Awards” column reflect the grant date fair value or incremental fair value, determined in accordance with ASC Topic 718, of awards granted pursuant to the 2007 Stock Option Plan. Assumptions used in the calculation of these amounts are included in Item 15, Note 11, Share-Based Compensation to our audited consolidated financial statements for the fiscal year ended December 31, 2017 included our Annual Report on Form 10-K for such year. See the table below “2018 Grants of Plan-Based Awards” for information relating to the number of options granted in 2018 under the 2018 Stock Option Plan. Following the closing of the Business Combination, pursuant to the A&R Merger Agreement, a percentage of outstanding options were assumed by Agiliti and are now options to purchase shares of Agiliti common stock.

 

(2)                                 The amounts in the “Non-Equity Incentive Plan Compensation” column reflect the cash awards to the named executive officers under the EIP, which is discussed in detail under the caption “Annual

 

8


 

Performance—Based Incentive Compensation.” The amounts payable for 2018 are not calculable as of the date hereof and are expected to be determined in March 2019.

 

(3)                                 The amounts in the “All Other Compensation” column reflect our contributions for all of the named executive officers to the Long-Term Savings Plan, discussed in detail under the caption “Long-Term Savings Plan and Other Benefits” and credit to the healthcare premium.

 

2018 Grants of Plan-Based Awards

 

 

 

 

 

Estimated Future Payouts
Under Non-Equity Incentive
Plan Awards(1)

 

All Other
Option
Awards:
Number of
Securities
Underlying

 

Exercise
or Base
Price of
Option

 

Grant
Date
Fair
Value
of 
Option

 

Name

 

Grant
Date

 

Threshold
($)

 

Target
($)

 

Maximum
($)

 

Options
(#)(3)

 

Awards
($/sh)(4)

 

Awards
($)(2)

 

Thomas J. Leonard

 

2018

 

$

0

 

$

680,000

 

$

1,360,000

 

 

$

 

$

 

James B. Pekarek

 

2018

 

$

0

 

$

312,300

 

$

624,000

 

600,000

 

$

0.71

 

$

 

Kevin E. Ketzel

 

2018

 

$

0

 

$

350,500

 

$

701,000

 

600,000

 

$

0.71

 

$

 

Robert L. Creviston

 

2018

 

$

0

 

$

203,500

 

$

407,000

 

233,000

 

$

0.71

 

$

 

Bettyann Bird

 

2018

 

$

0

 

$

226,800

 

$

453,600

 

600,000

 

$

0.71

 

$

 

 


(1)                                 The amounts shown under “Estimated Future Payouts Under Non-Equity Incentive Plan Awards” reflect the threshold, target and maximum payment levels, respectively, under our EIP. These amounts are based on the named executive officer’s base salary and position for the year ending and as of December 31, 2018. The 2018 EIP payout is not calculable as of the date hereof and are expected to be determined in March 2019.

 

(2)                                 The amounts in the “Grant Date Fair Value of Option Awards” column reflect the grant date fair value, determined in accordance with ASC Topic 718, of awards pursuant to the 2018 Stock Option Plan. Because options granted under the 2018 Stock Option Plan could only be exercised upon a change of control (as defined in the 2018 Stock Option Plan), no expense was recorded for this plan in 2018.

 

(3)                                 Stock options were granted to the named executive officers during 2018 under the 2018 Stock Option Plan. Following the closing of the Business Combination, pursuant to the A&R Merger Agreement, a percentage of these options were assumed by Agiliti and are now options to purchase shares of Agiliti common stock.

 

(4)                                 Following the closing of the Business Combination, pursuant to the A&R Merger Agreement, outstanding options have a weighted exercise price of $2.13 per share.

 

9


 

Outstanding Equity Awards at December 31, 2018

 

 

 

Option Awards(1)

 

Stock Awards(2)

 

Name

 

Grant
Date

 

Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable

 

Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable

 

Option
Exercise
Price ($)

 

Option
Expiration
Date

 

Grant
Date

 

Number of
Securities
Underlying
Restricted
Stock Unit

 

Thomas J. Leonard

 

5/8/2015

 

8,999,998

 

5,000,002

 

$

0.71

 

11/4/2024

 

4/13/2015

 

7,042,254

 

James B. Pekarek

 

5/10/2018

 

 

600,000

 

$

0.71

 

(3)

 

 

 

James B. Pekarek

 

3/9/2016

 

250,000

 

250,000

 

$

1.02

 

11/4/2024

 

 

 

James B. Pekarek

 

5/21/2013

 

2,750,000

 

 

$

0.71

 

11/4/2024

 

 

 

Kevin E. Ketzel

 

5/10/2018

 

 

600,000

 

$

0.71

 

(3)

 

 

 

Kevin E. Ketzel

 

3/9/2016

 

250,000

 

250,000

 

$

1.02

 

11/4/2024

 

 

 

Kevin E. Ketzel

 

8/5/2015

 

1,833,315

 

916,685

 

$

0.71

 

11/4/2024

 

 

 

Robert L. Creviston

 

5/10/2018

 

 

233,000

 

$

0.71

 

(3)

 

 

 

Robert L. Creviston

 

3/9/2016

 

175,000

 

175,000

 

$

1.02

 

11/4/2024

 

 

 

Robert L. Creviston

 

5/21/2013

 

1,250,000

 

 

$

0.71

 

11/4/2024

 

 

 

Bettyann Bird

 

5/10/2018

 

 

600,000

 

$

0.71

 

(3)

 

 

 

Bettyann Bird

 

3/9/2016

 

800,000

 

800,000

 

$

1.02

 

11/4/2024

 

 

 

 


(1)                                 Option awards granted under Agiliti Holdco’s 2007 Stock Option Plan are discussed in detail under the caption “Long-Term Equity Incentive (Stock Option) Compensation”. As of December 31, 2018, options granted under the 2007 Stock Option Plan for our named executive officers vested over a six-year period of service with one-sixth vesting on December 31 of each year of the six-year period, with such unvested options included in the “Number of Securities Underlying Unexercised Options Unexercisable” column, except for options to Mr. Leonard vest over a five-year period with one-fifth vesting on April 13 of each year over the five-year period. Following the Business Combination, outstanding stock options are fully-vested.

 

(2)                                 In connection with the hiring of Mr. Leonard as our Chief Executive Officer in 2015, he was granted a Restricted Stock Unit Award in the amount of 7,042,254 restricted stock units of Agiliti Holdco which vested 25% on each of April 13, 2016, April 13, 2017, April 13, 2018, and April 13, 2019, provided that Mr. Leonard is employed by Agiliti on the relevant vesting date. Each restricted stock unit represented one share of common stock of Agiliti Holdco.

 

(3)                                 Options awards granted under Agiliti Holdco’s 2018 Stock Option Plan are discussed in detail under the caption “Long-Term Equity Incentive (Stock Option) Compensation”. Options granted under the 2018 Stock Option Plan for our named executive officers could only be exercised upon a change of control (as defined in the 2018 Stock Option Plan). Following the Business Combination, outstanding options are fully-vested.

 

10


 

Potential Payments Upon Termination or Change in Control

 

Potential Payments Under Employment Agreements

 

Agiliti expects that its compensation committee will approve amended and restated employment agreements for Mr. Leonard, Mr. Pekarek and Mr. Ketzel in March 2019.

 

Thomas J. Leonard—Employment Agreement

 

The following termination and change of control payments are payable under Mr. Leonard’s employment agreement, contingent upon Mr. Leonard or his representative executing and delivering a release of all claims against us and all present and former directors, officers, agents, representatives, executives, successors and assignees of us and its direct or indirect owners within 60 days of the date of termination, provided there has not been any revocation thereof by Mr. Leonard or his representative.

 

Payments Made Upon Death or Disability

 

In the event of death or disability, Mr. Leonard or his legal representative will receive, on the 10th day following termination, the following:

 

·                  100% of his base salary in effect immediately prior to executive’s termination;

 

·                  earned and unpaid bonus for the calendar year ending prior to the date of termination, if any; and

 

·                  reimbursement for expenses.

 

Additionally, Mr. Leonard will receive accrued vested benefits through any of our benefit plans, programs or arrangements at the times specified therein. “Disability” means the named executive officer becomes physically or mentally disabled, whether totally or partially, either permanently or so that the named executive officer is unable substantially and competently to perform his duties for 180 days during any 12-month period during the term of his employment agreement. Mr. Leonard will also receive a lump sum payment of $11,350, which is equivalent to the amount of the portion of Mr. Leonard’s COBRA premiums as we paid during Mr. Leonard’s employment.

 

Payments Made Upon Termination Without Cause or Resignation For Good Reason

 

If we terminate Mr. Leonard’s employment without Cause or he resigns for Good Reason, Mr. Leonard will receive, in substantially equal installments in accordance with our regular payroll practices, payments consisting of the following:

 

·                  100% of his current base salary;

 

·                  100% of his target bonus opportunity for the year of termination; and

 

·                  reimbursement for expenses.

 

We also will pay Mr. Leonard his pro rata EIP award for the calendar year in which his employment terminates, at the time we pay EIP awards to other senior executives for that same calendar year. Additionally, Mr. Leonard will receive accrued vested benefits through any of our benefit plans, programs or arrangements at the times specified therein and Company-paid COBRA continuation coverage for up to 18 months post-termination. Mr. Leonard will also receive a lump sum payment of $11,350, which is equivalent to the amount of the portion of Mr. Leonard’s COBRA premiums as we paid during Mr. Leonard’s employment.

 

11


 

“Cause” means:

 

·                  the commission by Mr. Leonard of, or the indictment for (or pleading guilty or nolo contender to) a felony or crime involving moral turpitude;

 

·                  Mr. Leonard’s repeated failure or refusal to faithfully and diligently perform the usual and customary duties of his employment or to act in accordance with any lawful direction or order of the board of directors, which failure or refusal is not cured within 30 days after written notice thereof;

 

·                  Mr. Leonard’s material breach of fiduciary duty;

 

·                  Mr. Leonard’s theft, fraud, or dishonesty with regard to us or any of its affiliates or in connection with his duties;

 

·                  Mr. Leonard’s material violation of our code of conduct or similar written policies;

 

·                  Mr. Leonard’s willful misconduct unrelated to us or any of its affiliates having, or likely to have, a material negative impact on us or any of its affiliates (economically or its reputation);

 

·                  an act of gross negligence or willful misconduct by Mr. Leonard that relates to the affairs of us or any of its affiliates; or

 

·                  material breach by Mr. Leonard of any of the provisions of his employment agreement.

 

Mr. Leonard will have “Good Reason” for termination if, other than for Cause, any of the following has occurred:

 

·                  we have materially diminished Mr. Leonard’s responsibilities, authorities or duties (provided that in the event of Mr. Leonard’s disability, our appointment of an interim Chief Executive Officer shall not constitute a diminution of Mr. Leonard’s responsibilities, authorities or duties);

 

·                  we have reduced Mr. Leonard’s base salary or EIP target percentage, other than in connection with an across-the-board reduction of base salary or EIP target percentage applicable to substantially all of our senior executives; or

 

·                  we have relocated Mr. Leonard’s place of employment by more than 50 miles.

 

Payments Made Upon Termination for Cause or Resignation Without Good Reason

 

If we terminated Mr. Leonard’s employment under his employment agreement for Cause or he resigns without Good Reason, all of Mr. Leonard’s rights to payments, other than payment for services already rendered, including any unearned annual bonus and any other benefits otherwise due, cease upon the date of termination.

 

Payments Made Upon a Change of Control

 

Mr. Leonard is not entitled to any cash payments based solely on a change of control.

 

The following table shows payments that would have been payable as of December 31, 2018 upon a termination under Mr. Leonard’s employment agreement.

 

12


 

Thomas J. Leonard
Chief Executive Officer and Director

 

Executive Benefits 
and
Payments Upon
Separation

 

Death or
Disability
on
12/31/2018

 

For Good
Reason or
Without 
Cause
Termination
on
12/31/2018

 

Change of
Control
Related
Termination
on
12/31/2018

 

Compensation:

 

 

 

 

 

 

 

Non-Equity Incentive Plan

 

$

685,000

 

$

685,000

 

$

 

Stock Options

 

 

 

953,500

 

Benefits and Perquisites:

 

 

 

 

 

 

 

Health and Welfare Benefits

 

11,350

 

11,350

 

 

Severance Payments

 

685,000

 

685,000

 

 

Total

 

$

1,381,350

 

$

1,381,350

 

$

953,500

 

 


(1)                                 The above table excludes the intrinsic value of vested stock options.

 

James B. Pekarek—Employment Arrangement

 

On November 2, 2016, Agiliti amended its employment agreement, previously entered into on April 11, 2013, with Mr. Pekarek. The terms of Mr. Pekarek’s amended employment agreement, as they relate to the possible payment upon his termination, are summarized below. The amounts shown below assume that termination of employment was effective as of December 31, 2018, include amounts earned through that date, and are estimates of the amounts which would be paid out to the named executive officers upon their termination. The actual amounts paid can only be determined at the time of each named executive officer’s separation from us.

 

The following termination and change of control payments are payable under Mr. Pekarek’s employment arrangement, contingent upon Mr. Pekarek or his representative executing and delivering a release of all claims against us and all present and former directors, officers, agents, representatives, executives, successors and assignees of us and its direct or indirect owners within 45 days of the date of termination, provided 15 days have elapsed since such execution without any revocation thereof by Mr. Pekarek or his representative.

 

Payments Made Upon Death or Disability

 

In the event of death or disability, Mr. Pekarek or his legal representative will receive, on the 61st day following termination, a lump sum payment consisting of the following:

 

·                  100% of his current base salary;

 

·                  $11,350 intended for health and welfare benefits; and

 

·                  earned and unpaid bonus for the calendar year ending prior to the date of termination, if any.

 

Additionally, Mr. Pekarek will receive accrued vested benefits through any of our benefit plans, programs or arrangements at the times specified therein. “Disability” means the named executive officer becomes physically or mentally disabled, whether totally or partially, either permanently or so that the named executive officer is unable substantially and competently to perform his duties for 180 days during any 12-month period during the term of his employment agreement.

 

13


 

Payments Made Upon Termination Without Cause or Resignation For Good Reason

 

If we terminate Mr. Pekarek’s employment without Cause or he resigns for Good Reason, Mr. Pekarek will receive, on the 61st day following termination, a lump sum payment consisting of the following:

 

·                  175% of his current base salary;

 

·                  $11,350 intended for health and welfare benefits; and

 

·                  earned and unpaid bonus for the calendar year ending prior to the date of termination, if any.

 

We also will pay Mr. Pekarek his pro rata EIP award for the calendar year in which his employment terminates, at the time we pay EIP awards to other senior executives for that same calendar year. Additionally, Mr. Pekarek will receive accrued vested benefits through any of our benefit plans, programs or arrangements at the times specified therein.

 

“Cause” means:

 

·                  the commission by the named executive officer of a felony for which he is convicted; or

 

·                  the material breach by the named executive officer of his agreements or obligations under his employment agreement described in a written notice to the named executive officer that is not capable of being cured or has not been cured within 30 days after receipt.

 

Mr. Pekarek will have “Good Reason” for termination if, other than for Cause, any of the following has occurred:

 

·                  Mr. Pekarek’s base salary or EIP target percentage has been reduced, other than in connection with an across-the-board reduction, not to exceed 5% of the then current base salary, of approximately the same percentage in executive compensation to executive employees imposed by our board of directors in response to negative financial results or other adverse circumstances affecting us;

 

·                  our board of directors establishes an unachievable and commercially unreasonable adjusted EBITDA target that we must achieve for the named executive officer to receive an EIP under his employment agreement and Mr. Pekarek provides written notice of his objection to the board of directors within ten business days;

 

·                  we have reduced or reassigned a material portion of Mr. Pekarek’s duties, have diminished his title, have required Mr. Pekarek to relocate outside the greater Minneapolis, Minnesota area, have relocated our corporate headquarters outside the greater Minneapolis area or have removed or relocated outside the greater Minneapolis area a material number of our employees or senior management, in each case without Mr. Pekarek’s written consent; or

 

·                  we have breached, in any material respect, the employment agreement of Mr. Pekarek.

 

Payments Made Upon Termination for Cause or Resignation Without Good Reason

 

If we terminated Mr. Pekarek’s employment under his employment arrangement for Cause or he resigns without Good Reason, all of Mr. Pekarek’s rights to payments, other than payment for services already rendered and any other benefits otherwise due, cease upon the date of termination.

 

Payments Made Upon a Change of Control

 

If we terminate Mr. Pekarek’s employment without Cause or Mr. Pekarek resigns for Good Reason at any time within six months before, or 24 months following, a change of control and notwithstanding and in lieu of

 

14


 

amounts provided for resignation without Cause or for resignation for Good Reason, Mr. Pekarek is entitled to receive, on the 61st day following termination, a lump sum payment consisting of the following:

 

·                  262.5% of his current base salary;

 

·                  $11,350 intended for health and welfare benefits; and

 

·                  earned and unpaid bonus for the calendar year ending prior to the date of termination, if any.

 

We also will pay Mr. Pekarek his pro rata EIP award for the calendar year in which his employment terminates, at the time we pay EIP awards to other senior executives for that same calendar year. Additionally, Mr. Pekarek will receive accrued vested benefits through any of our benefit plans, programs or arrangements at the times specified therein.

 

However, if Mr. Pekarek’s employment terminates within six months prior to a Change in Control due to termination by us without Cause or due to termination for Good Reason, then Mr. Pekarek will receive payments in accordance with the provisions noted under the heading “Payments Made Upon Termination Without Cause or Resignation For Good Reason,” and within 30 days following the Change in Control, Mr. Pekarek will receive an additional lump sum payment equal to the difference between the payment already received and the amount required under the Change in Control provisions noted above.

 

“Change of control” means (i) when any “person” (as defined in Section 13(d) and 14(d) of the Exchange Act) (other than Agiliti or its affiliates, any trustee or other fiduciary holding securities under an employee benefit plan of Agiliti or any Subsidiary, or any corporation owned, directly or indirectly, by the stockholder or stockholders, as the use may be, of Agiliti, in substantially the same proportions as their ownership of stock of Agiliti), acquires, in a single transaction or a series of transactions (whether by merger, consolidation, reorganization or otherwise), (A) “beneficial ownership” (as defined in Rule 13d-3 under the Exchange Act) of securities representing more than 50% of the combined voting power of Agiliti (or, prior to a public offering, more than 50% of Agiliti’s outstanding shares of common stock), or (B) substantially all or all of the assets of Agiliti and its Subsidiaries on a consolidated basis or (ii) a merger, consolidation, reorganization or similar transaction of Agiliti with a “person” (as defined above) if, following such transaction, the holders of a majority of Agiliti’s outstanding voting securities in the aggregate immediately prior to such transaction do not own at least a majority of the outstanding voting securities in the aggregate of the surviving corporation immediately after such transaction. “Subsidiary” means any corporation in an unbroken chain of corporations beginning with Agiliti if, at the time of a change of control, each of the corporations (other than the last corporation in the unbroken chain) owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in the chain.

 

The following table shows the payments that would have been payable as of December 31, 2018 upon a termination or change of control of us under Mr. Pekarek’s employment arrangement.

 

15


 

James B. Pekarek
Executive Vice President and Chief Financial Officer

 

Executive Benefits and
Payments Upon 
Separation(1)

 

Death or
Disability on
12/31/2018

 

For Good
Reason or
Without
Cause
Termination 
on
12/31/2018

 

Change of
Control
Related
Termination 
on
12/31/2018

 

Compensation:

 

 

 

 

 

 

 

Non-Equity Incentive Plan

 

$

315,000

 

$

315,000

 

$

315,000

 

Stock Options

 

 

 

83,575

 

Benefits and Perquisites:

 

 

 

 

 

 

 

Health and Welfare Benefits

 

11,350

 

11,350

 

11,350

 

Severance Payments

 

450,000

 

787,500

 

1,181,300

 

Total

 

$

776,350

 

$

1,135,850

 

$

1,591,225

 

 


(1)                                 The above table excludes the intrinsic value of vested stock options.

 

Potential Payments Under Our Executive Severance Pay Plan

 

On November 2, 2016, Agiliti made changes to its Executive Severance Pay Plan, previously adopted on June 1, 2007 which the compensation committee amended on December 31, 2008 to comply with Section 409A of the Code. The amended Executive Severance Pay Plan provides benefits that are economically equivalent to the benefits the covered senior executives were entitled to under the June 1, 2007 plan, with the timing of payment and certain other provisions modified to comply with Section 409A. Additionally, references to the controller were removed.

 

In March 2015, the Executive Severance Pay Plan was amended to change the definition of a covered “executive” to cover any employee possessing a title of Vice President or above, or any employee who is designated in writing as covered by the Executive Severance Pay Plan by our chief executive officer; to specify that the first six months of severance pay will be made regardless of other employment while the next six months will be reduced by the value of compensation the employee receives from any alternate employment; and to provide that we will pay the employer’s portion of any COBRA premiums rather than an upfront lump sum payment of COBRA premium equivalents.

 

In November 2016, the Executive Severance Pay Plan was amended to include changes to the severance benefits to which such persons are entitled upon an “Involuntary Termination” (as defined in the Amended Executive Severance Pay Plan) from us relating to the amount and timing of the bonus, the payments required to be made by us to such executive relating to the continued cost of healthcare insurance coverage under COBRA, and the amounts that would be payable to the executive if the executive’s “Involuntary Termination” were to occur during the “Change of Control Period” (as defined in the Amended Executive Severance Pay Plan). This disclosure is qualified in its entirety by reference to the Amended Executive Severance Pay Plan.

 

Executives covered by the Executive Severance Pay Plan include the following named executive officers: Mr. Ketzel, Mr. Creviston and Ms. Bird. The terms of the Executive Severance Pay Plan, as they related to the possible payments upon the terminations of the aforementioned named executive officers, are summarized below. The amounts shown assume that termination was effective as of December 31, 2018, include amounts earned

 

16


 

through that date and are estimates of the amounts which would be paid out to the named executive officer upon his termination. The actual amounts paid can only be determined at the time of the named executive officer’s separation from us.

 

In connection with the Business Combination, Agiliti assumed the Executive Severance Pay Plan.

 

Payments Made upon Death or Disability

 

In the event of termination of employment for Death or Disability of a named executive officer, and the named executive officer or designee signs a General Release within 45 days of the date of termination, the named executive officer or designee will receive his or her:

 

·                  current salary on a bi-weekly payment schedule for the 12-month period following termination (“Severance Period”);

 

·                  lump payment of $11,350 for COBRA benefits; and

 

·                  pro-rated bonus within 61 days following the effectiveness of the General Release.

 

The first payments will be made as soon as practicable following the effectiveness of the General Release and will include any such payment(s) that would otherwise have been made prior to the time the General Release was effective. “General Release” means a written release of all claims against us and our affiliates in the form presented by us, which includes confidentiality, non-competition, non-solicitation and no-hire provisions.

 

Payments Made Upon a Change in Control

 

In the event of termination of employment due to a Change in Control, and the named executive officer or designee signs a General Release within 45 days of the date of termination, the named executive officer will receive his or her:

 

·                  current salary on a bi-weekly payment schedule for the 12-month period following termination (“Severance Period”);

 

·                  lump payment of $11,350 for COBRA benefits; and

 

·                  100% of target bonus within 61 days following the effectiveness of the General Release.

 

Mr. Ketzel as President will receive an additional amount equal to 100% of target bonus for the then-current fiscal year.

 

“Change of control” means any event as a result of which Irving Place Capital and its affiliates collectively cease to own and control all of the economic and voting rights associated with ownership of at least 50.1% of the outstanding capital stock of or any sale or transfer of all or substantially all of our assets.

 

Notwithstanding the foregoing, a change of control will not include the sale or transfer of all or substantially all of our assets to a private equity firm, or a company owned or controlled by a private equity firm.

 

Payments Made Upon Termination for Cause, Resignation Except for Good Reason

 

In the event of termination of employment for Cause, voluntary resignation except for Good Reason, no severance benefits are payable.

 

17


 

“Cause” means:

 

·                  the executive’s continued failure, whether willful, intentional, or grossly negligent, after written notice, to perform substantially the executive’s duties (the “duties”) as determined by the executive’s immediate supervisor, or the chief executive officer, or a senior vice president of Agiliti (other than as a result of a disability);

 

·                  dishonesty or fraud in the performance of the executive’s duties or a material breach of the executive’s duty of loyalty to Agiliti or its subsidiaries;

 

·                  conviction or confession of an act or acts on the executive’s part constituting a felony under the laws of the United States or any state thereof or any misdemeanor which materially impairs such executive’s ability to perform the duties;

 

·                  any willful act or omission on the executive’s part which is materially injurious to the financial condition or business reputation of Agiliti or any of its subsidiaries; or

 

·                  any breach by the executive of any non-competition, non-solicitation, non-disclosure or confidentiality agreement applicable to the executive.

 

“Change of control” means any event as a result of which Irving Place Capital and its affiliates collectively cease to own and control all of the economic and voting rights associated with ownership of at least 50.1% of the outstanding capital stock of or any sale or transfer of all or substantially all of the assets of Agiliti.

 

Notwithstanding the foregoing, a change of control will not include the sale or transfer of all or substantially all of the assets of Agiliti to a private equity firm, or a company owned or controlled by a private equity firm.

 

“Good Reason” means that, other than for Cause, any of the events set forth in paragraphs (i)-(iii) below has occurred; within 30 days of such event, the named executive notifies Agiliti in writing of such event, and Agiliti fails to cure the event within 60 days of receiving such notice; and the named executive terminates employment no later than 90 days after providing such notice:

 

·                  We have demoted Executive, as evidenced by a material reduction or reassignment of Executive duties (per Executive job description), provided, however, that any change in Executive’s position constituting a lateral move or promotion will not be deemed to give rise to Good Reason unless Executive is required to relocate pursuant to section (iii) below;

 

·                  the executive’s base salary has been materially reduced other than in connection with an across-the-board reduction of approximately the same percentage in executive compensation to employees imposed by our board of directors in response to negative financial results or other adverse circumstances affecting us; or

 

·                  we have required the executive to relocate in excess of 50 miles from the location where the executive is currently employed.

 

Payments Made Upon Termination Without Cause or Resignation for Good Reason

 

If we terminate the named executive officer’s employment without Cause (other than death or disability) or the named executive officer resigns for Good Reason and the named executive officer signs a General Release within 45 days of the date of termination, the named executive officer will receive his or her then current salary on a bi-weekly payment schedule for the 12-month period following termination (“Severance Period”), provided the time period allowed by us for rescission of the General Release has elapsed. The first payments will be made as soon as practicable following the effectiveness of the General Release and will include any such payment(s) that would otherwise have been made prior to the time the General Release was effective. “General Release” means a written release of all claims against us and our affiliates in the form presented by us, which includes confidentiality, non-competition, non-solicitation and no-hire provisions.

 

18


 

A failure to execute a General Release within 45 days of the named executive officer’s date of termination or a subsequent rescission of such General Release within the time allowed will result in the loss of any rights to receive payments or benefits under the Executive Severance Pay Plan.

 

The named executive officer will also receive a pro rata payment under our EIP, based on days employed, for the then current calendar year in which the termination occurs, payable within 61 days of termination. The named executive officer will receive a lump payment of $11,350 for COBRA benefits.

 

The following tables show the payments that would have been payable as of December 31, 2018 to each of the named executive officers covered by our Executive Severance Pay Plan upon a termination or change of control.

 

Kevin E. Ketzel
President

 

Executive Benefits and
Payments Upon 
Separation(1)

 

Death or
Disability
on
12/31/2018

 

For Good
Reason or
Without
Cause
Termination
on
12/31/2018

 

Change of
Control
Related
Termination
on
12/31/2018

 

Compensation:

 

 

 

 

 

 

 

Non-Equity Incentive Plan

 

$

356,250

 

$

356,250

 

$

712,500

 

Stock Options

 

 

 

283,592

 

Benefits and Perquisites:

 

 

 

 

 

 

 

Health and Welfare Benefits

 

11,350

 

11,350

 

11,350

 

Severance Payments

 

475,000

 

475,000

 

475,000

 

Total

 

$

842,600

 

$

842,600

 

$

1,482,442

 

 

Robert L. Creviston
Chief Human Resources Officer

 

Executive Benefits and
Payments Upon 
Separation(1)

 

Death or
Disability
on
12/31/2018

 

For Good
Reason or
Without
Cause
Termination
on
12/31/2018

 

Change of
Control
Related
Termination
on
12/31/2018

 

Compensation:

 

 

 

 

 

 

 

Non-Equity Incentive Plan

 

$

204,872

 

$

204,872

 

$

204,872

 

Stock Options

 

 

 

58,503

 

Benefits and Perquisites:

 

 

 

 

 

 

 

Health and Welfare Benefits

 

11,350

 

11,350

 

11,350

 

Severance Payments

 

315,200

 

315,200

 

315,200

 

Total

 

$

531,422

 

$

531,422

 

$

589,925

 

 

19


 

Bettyann Bird
Senior Vice President, Marketing

 

Executive Benefits and
Payments Upon 
Separation(1)

 

Death or
Disability
on
12/31/2018

 

For Good
Reason or
Without
Cause
Termination
on
12/31/2018

 

Change of
Control
Related
Termination
on
12/31/2018

 

Compensation:

 

 

 

 

 

 

 

Non-Equity Incentive Plan

 

$

231,000

 

$

231,000

 

$

231,000

 

Stock Options

 

 

 

267,440

 

Benefits and Perquisites:

 

 

 

 

 

 

 

Health and Welfare Benefits

 

11,350

 

11,350

 

11,350

 

Severance Payments

 

330,000

 

330,000

 

330,000

 

Total

 

$

572,350

 

$

572,350

 

$

839,790

 

 


(1)                                 The above tables exclude the intrinsic value of vested stock options.

 

Director Compensation

 

Agiliti has not yet determined director compensation following the Business Combination.

 

Through December 31, 2018, we paid each of our independent directors cash compensation of $50,000 per year for their service as independent directors ($70,000 for the chair). Members of our audit committee who were independent also received an annual fee of $5,000 ($10,000 for the chair), and members of our compensation committee who our board determined were independent received an annual fee of $5,000. Directors who were not independent do not receive compensation for services on the board of directors.

 

Independent directors were eligible to receive grants of stock options under the 2007 Stock Option Plan, subject to the approval of Agiliti Holdco’s board of directors. In addition, we reimbursed our independent directors for all out-of-pocket expenses incurred in connection with their activities as members of the board, provided that they are expected to follow travel and expense guidelines established for all of our officers and directors.

 

2018 Cash Compensation

 

In 2018, each of our independent directors for 2018 (Mr. Workman, Mr. Schochet, Mr. Crane, Mr. Feiner and Mr. Grotting) received cash compensation of $50,000] for his service as an independent director. Mr. Workman, who also served as chairman of the board and chairman of the audit committee, received $20,000 annual cash compensation for his service as chairman of the board and $10,000 annual cash compensation for his service as chair of the audit committee. In addition, annual fees based on committee memberships were paid as described below.

 

·                  Mr. Workman received cash compensation of $20,000 for his service as chairman of our board and $10,000 as chairman of the audit committee. Mr. Workman received aggregate cash compensation of $80,000 during 2018.

 

20


 

·                  Mr. Schochet received cash compensation of $5,000 for his service as a member of our audit committee. Mr. Schochet received an aggregate amount of $55,000 during 2018.

 

·                  Mr. Crane received cash compensation of $5,000 for his service as a member of our compensation committee. Mr. Crane received an aggregate amount of $55,000 during 2018.

 

·                  Mr. Feiner received cash compensation of $5,000 for his service as a member of our compensation committee. Mr. Feiner received an aggregate amount of $55,000 during 2018.

 

·                  Mr. Grotting received cash compensation of $5,000 for his service as a member of our compensation committee. Mr. Grotting received an aggregate amount of $55,000 during 2018.

 

Stock Option Compensation

 

On May 4, 2016, Mr. Workman, Mr. Schochet, Mr. Crane, Mr. Feiner and Mr. Grotting each received a grant of 50,000 nonqualified stock options for the purchase of shares of common stock of Agiliti Holdco, Inc. at a price of $1.02 per share pursuant to the 2007 Stock Option Plan for his service as an independent director. These stock options vested over a two-year period of service with 50% of the grant vesting on December 31 each year.

 

On March 8, 2017, Mr. Workman, Mr. Schochet, Mr. Crane, Mr. Feiner and Mr. Grotting each received a grant of 50,000 nonqualified stock options for the purchase of shares of common stock of Agiliti Holdco, Inc. at a price of $1.19 per share pursuant to the 2007 Stock Option Plan for his service as an independent director. These stock options vested over a two-year period of service with 50% of the grant vesting on December 31 each year.

 

On March 7, 2018, Mr. Workman, Mr. Schochet, Mr. Crane, Mr. Feiner and Mr. Grotting each received a grant of 50,000 nonqualified stock options for the purchase of shares of common stock of Agiliti Holdco, Inc. at a price of $1.87 per share pursuant to the 2007 Stock Option Plan for his service as an independent director. These stock options vested over a two-year period of service with 50% of the grant vesting on December 31 each year.

 

In connection with the Business Combination a percentage of these options were assumed by Agiliti and are now options to purchase common stock of Agiliti at a weighted exercise price of $2.13 per share.

 

The 2007 Stock Option Plan is discussed in detail under the caption “2007 Stock Option Plan” above.

 

2018 Director Compensation Table

 

The table below summarized the compensation paid by us to directors for the fiscal year ended December 31, 2018:

 

Name(1)

 

Fees Earned
or Paid in 
Cash
($)(2)

 

Option
Awards
($)(3)

 

Total
($)

 

John L. Workman

 

$

80,000

 

$

9,955

 

$

89,955

 

Barry Schochet

 

55,000

 

9,955

 

64,955

 

Bret D. Bowerman

 

 

 

 

David Crane

 

55,000

 

9,955

 

64,955

 

Michael C. Feiner

 

55,000

 

9,955

 

64,955

 

Robert Juneja

 

 

 

 

John B. Grotting

 

55,000

 

9,955

 

64,955

 

Keith Zadourian

 

 

 

 

 

21


 


(1)                                 Only the members of our board of directors who are independent for compensation purposes receive compensation for their service as directors.

 

(2)                                 The amount in the “Fees Earned or Paid in Cash” column for Mr. Workman, Mr. Schochet, Mr. Crane, Mr. Feiner and Mr. Grotting represents retainer and committee fees as discussed in detail under the caption  “2018 Cash Compensation”

 

(3)                                 The amounts in the “Option Awards” column reflect the fair value, determined in accordance with ASC Topic 718, of awards granted pursuant to the 2007 Stock Option Plan. As of December 31, 2018, Mr. Workman had 324,998 options outstanding and exercisable under the 2007 Stock Option Plan. As of December 31, 2018, Mr. Schochet, Mr. Crane and Mr. Grotting, each had 425,000 options outstanding and exercisable under the 2007 Stock Option Plan. As of December 31, 2018, Mr. Feiner had 125,000 options outstanding and exercisable under the 2007 Stock Option Plan. In connection with the Business Combination a percentage of these options were assumed by Agiliti and are now options to purchase common stock of Agiliti at a weighted exercise price of $2.13 per share.

 

Compensation Committee Interlocks and Insider Participation

 

During fiscal 2018, the directors serving on the compensation committee of our board of directors were Mr. Juneja, Mr. Crane, Mr. Grotting and Mr. Feiner, none of whom has served as an officer or employee of Agiliti.

 

Our board of directors has considered the compensation policies and practices that are generally applicable to all employees, including our non-executive officers, and has concluded that such policies and practices do not create risks that are reasonably likely to have a material adverse effect on us.

 

22


EX-99.3 12 a19-2105_2ex99d3.htm EX-99.3

Exhibit 99.3

 

 

FOR IMMEDIATE RELEASE

 

FEDERAL STREET ACQUISITION CORP., THOMAS H. LEE PARTNERS, L.P.

AND AGILITI HEALTH, INC. COMPLETE BUSINESS COMBINATION

 

BOSTON and MINNEAPOLIS—January 4, 2019—Federal Street Acquisition Corp. (NASDAQ: FSACU, FSAC, FSACW) (“FSAC”), a special-purpose acquisition company sponsored by an affiliate of Thomas H. Lee Partners, L.P. (“THL”), and Agiliti Holdco, Inc., the holding company of Agiliti Health, Inc. (“Agiliti Health”), a leading, nationwide provider of healthcare technology management and service solutions and a portfolio company of Irving Place Capital Management, L.P., announced today that they have completed their business combination. The transaction had been unanimously approved by the board of directors, including a special committee of independent directors of FSAC and was approved at a Special Meeting of FSAC’s stockholders on January 3, 2019. The implied enterprise value for the combined company is approximately $1.74 billion, or 11.6x Agiliti Health’s forecasted 2018 Adjusted EBITDA of approximately $150 million and 10.2x Agiliti Health’s forecasted 2019 Adjusted EBITDA of approximately $170 million.

 

In accordance with the terms of the merger agreement, FSAC and Agiliti Holdco, Inc. have combined under a new holding company, Agiliti, Inc. (“Agiliti”). Agiliti builds on a legacy of nearly 80 years of market-leading healthcare technology and service solutions to the U.S. healthcare industry, serving approximately 7,000 national, regional and local acute care hospitals and alternate site providers across the country.

 

Upon completion of the transaction, Agiliti will be majority owned by entities affiliated with THL and management. The company will continue to be led by Thomas J. Leonard as Chief Executive Officer, along with his current management team.

 

Scott M. Sperling, Co-President of THL and Executive Chairman of the board of directors of FSAC stated, “We are extremely proud to join forces with Agiliti.  The company is well positioned to drive shareholder value by helping health systems address their most complex medical equipment challenges throughout the entire supply chain.”

 

Joshua M. Nelson, a Managing Director at THL said, “As a market-leading, growth healthcare company operating in an industry with strong fundamentals, we are excited to support Agiliti with a $750 million backstop equity financing so it may complete the business combination.  We look forward to working with Tom and the talented Agiliti team to further drive efficiencies for its health system clients, while building upon the company’s market-leading position and helping them achieve their substantial future growth prospects.”

 

Leonard added, “This transaction represents the next step in the evolution of Agiliti.  As a well-capitalized company with new, experienced strategic partners, Agiliti will remain focused on innovating our suite of offerings and providing our clients with the best-in-class service they have come to expect from us. Our nationwide service platform, coupled with our unmatched offering for Equipment Value Management has enabled a flexible and scalable model to power our growth. I look forward to our continued advancement with the support of our partners at THL.”

 

As previously announced, FSAC and Agiliti have waived the closing condition under the merger agreement that would have required Agiliti’s common stock and warrants to be listed on the NASDAQ stock exchange. The common stock and warrants of Agiliti will not be listed at closing of the transaction.

 

In connection with the transaction, Citigroup Global Markets Inc. and BofA Merrill Lynch served as financial advisors and Kirkland & Ellis LLP served as legal advisor to FSAC, and Weil, Gotshal & Manges LLP served as legal advisor to Agiliti Health.

 


 

About Agiliti, Inc.

 

Formerly known as Universal Hospital Services, Inc., Agiliti, Inc. is a leading nationwide provider of healthcare technology management and service solutions to the healthcare industry. Agiliti owns or manages more than 800,000 units of medical equipment for approximately 7,000 national, regional and local acute care hospitals and alternate site providers across the U.S. For nearly eight decades, Agiliti has delivered medical equipment management and service solutions that help clients reduce costs, increase operating efficiencies, improve caregiver satisfaction and support optimal patient outcomes. Agiliti, Inc. is the company created by the business combination of FSAC and Agiliti Health, Inc. More information is available at www.agilitihealth.com.

 

About Federal Street Acquisition Corp. and Thomas H. Lee Partners, L.P.

 

Federal Street Acquisition Corp. is a special purpose acquisition company sponsored by an affiliate of Thomas H. Lee Partners, L.P., formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase or similar business combination with one or more businesses.

 

Thomas H. Lee Partners, L.P. is a premier private equity firm investing in middle market growth companies, headquartered in North America, exclusively in four industry sectors: Healthcare, Business & Financial Services, Consumer & Retail, and Media, Information Services & Technology. Using the firm’s deep domain expertise and the internal operating capabilities of its Strategic Resource Group, THL seeks to create deal sourcing advantages, and to accelerate growth and improve operations in its portfolio companies in partnership with management teams. Since its founding in 1974, THL has raised over $25 billion of equity capital, acquired over 140 portfolio companies and completed over 360 add-on acquisitions which collectively represent a combined enterprise value at the time of acquisition of over $200 billion.

 

Forward Looking Statements

 

This press release includes forward looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Agiliti’s management’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include those described in the prospectus of Agiliti dated October 10, 2018, as supplemented. There may be additional risks that Agiliti does not presently know or that it currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Actual results, performance or achievements may differ materially and potentially adversely from any projections and forward-looking statements and the assumptions on which those forward-looking statements are based. Readers are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as such statements are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties, and other factors, many of which are beyond the control of Agiliti. All information herein speaks only as of the date hereof. Agiliti undertakes no duty to update or revise the information contained herein, publicly or otherwise.

 

Agiliti:

 

James Pekarek
Executive Vice President and Chief Financial Officer
(952) 607-3054
james.pekarek@agilitihealth.com

 

2


 

Kate Kaiser

Vice President, Corporate Communication and Investor Relations
(619) 507-9135
kate.kaiser@agilitihealth.com

 

3


GRAPHIC 13 g21051mqi001.jpg GRAPHIC begin 644 g21051mqi001.jpg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end GRAPHIC 14 g21051mqi002.jpg GRAPHIC begin 644 g21051mqi002.jpg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end